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BACKGROUND 
A first-trimester prenatal screening test for pre-eclampsia was launched in 2010. It differs 
from previously assessed prenatal screening tests.  
AIMS 
(i)  To assess the psychological benefits and consequences of providing a first trimester 
screening test for pre-eclampsia.  
(ii)  To assess the acceptability of the test amongst pregnant women and healthcare 
professionals.  
METHODS 
A mixed methods approach was taken. Five consecutive studies using primary and 
secondary data from UK pregnant women and their healthcare providers were conducted: 
(i) a systematic review, (ii) a qualitative study (pregnant women); (iii) a qualitative study 
(healthcare professionals); (iv) a case control study; (v) a discrete choice experiment. 
RESULTS 
A first trimester screening test for pre-eclampsia has the potential to positively change 
health behaviours, but could also decrease self-monitoring. The impact appears to differ 
depending on whether the woman is concerned with the potential consequences to herself or 
her fetus. Health professionals are concerned with the clinical utility of the prenatal 
screening test, and on its potential to medicalise the pregnancy pathway. However, there 
does not appear to be an association between the amount of technological monitoring and 
birthplace preference. A discrete choice experiment showed overwhelming support for the 
introduction of this test. 
CONCLUSIONS 
There is no evidence that this new prenatal screening test will cause harm to pregnant 
women. Women appear to welcome the additional information it provides. Receiving a 
positive pre-eclampsia screening test result presents potential opportunities for health-
promotion interventions. To make the most of these opportunities, it will be important for 
clinicians to understand how women perceive and respond to this screening test; the self-
regulation model provides a useful framework in which to do this. This work provides a 
framework for assessing the psychological impacts of the many emerging prenatal 
screening tests that lack a diagnostic test or risk-reduction intervention.  EXTENDED ABSTRACT 
BACKGROUND 
A first-trimester prenatal screening test for pre-eclampsia was launched in 2010. It 
differs from previous prenatal screening tests in three ways; (i) it provides a screening 
test for a health threat that impacts both mother and fetus (ii) it does not have an 
associated diagnostic test, or risk-reduction intervention (iii) it informs the mother, for 
the first time, that her pregnancy has the potential to harm her. Women found high-risk 
for pre-eclampsia receive specialist care including a 4-weekly ultrasound scan to aid 
detection of the disease at the earliest opportunity.  
AIMS 
To assess the psychological benefits and consequences of providing a first trimester 
screening test for pre-eclampsia. To assesses if pregnant women and healthcare 
professionals are accepting of its introduction.  
METHODS 
A theoretically informed, mixed methods, sequential approach to the research was 
taken. The studies were informed by a review of theoretical and empirical evidence 
regarding health screening. Five consecutive studies using primary and secondary data 
from pregnant women and their health care providers in the United Kingdom were 
conducted: 
1.  A systematic review of the literature to assess if psychological reactions to 
prenatal screening tests differ depending on whether it focuses on the mother or 
the fetus; 
2.  Semi-structured interviews with women who had experienced the pre-eclampsia 
screening test (n=15) to explore the psychological impact of the screening test. 
This study was informed by the common sense model of self-regulation 
3.  Semi-structured interviews with healthcare professionals who had cared for 
women who had had the pre-eclampsia screening test (n=20). This study was 
informed by the themes developed from study two. 
4.  A case control study (n=1100) that examined if there was an association between 
the number of ultrasounds a woman received in her pregnancy and the place of 
birth she chose.  5.  A discrete choice experiment that recruited pregnant women (n=119), women 
who had previously experienced pre-eclampsia (n=111) and healthcare 
professionals (n=76) and compared the current status-quo with a new 
biochemical screening test for pre-eclampsia on four attributes (accuracy of test, 
level of information, schedule of follow-up, and test format) in a binary choice 
format.  
RESULTS 
Pregnant women are affected by prenatal screening test differently, depending on 
whether the test focuses on the impact to the mother or the fetus. A first trimester 
screening test for pre-eclampsia does not appear to cause an unacceptable increase in 
anxiety. It has the potential to positively change health behaviours, but could also 
decrease self-monitoring behaviour. The impact differs depending on whether the 
woman is concerned with the potential consequences to herself or her fetus. Health 
professionals are concerned with the clinical utility of the prenatal screening test, and on 
its potential medicalisation of the pregnancy pathway. However, there does not appear 
to be an association with the amount of technological monitoring in pregnancy, and a 
woman’s assessment of medical risk, as measured by chosen place of birth. The discrete 
choice experiment showed overwhelming support for a biochemical screening test for 
pre-eclampsia, with accuracy and test format being the most valued attributes.  
CONCLUSIONS 
There is no evidence that the new pre-eclampsia prenatal screening test will cause harm 
to pregnant women. Women appear to welcome the additional information it provides.  
Reactions to prenatal screening tests are linked to illness representations of the health 
threat, with a perceived threat to the self resulting in a stronger sense of control, while a 
perceived threat to the fetus results in a dependence on health care providers. Receiving 
a positive pre-eclampsia screening result presents potential opportunities for health-
promotion interventions. To make the most of these opportunities, it will be important 
for clinicians to understand how women perceive and respond to this screening test; the 
self-regulation model provides a useful framework to understand these responses. This 
thesis provides a framework for assessing the psychological impacts of the many 
emerging prenatal screening tests that lack a diagnostic test or risk-reduction 
intervention.  TABLE OF CONTENTS 
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1.1  CHAPTER SUMMARY 
This chapter provides a general background to the subject of this thesis:  the 
psychological impact and acceptability of a first trimester screening test for pre-
eclampsia. The first section reviews the historical, ethical and sociological issues 
regarding screening, both generally and specific to prenatal screening. It considers 
biomedical ethics, sociological perspectives on the culture surrounding screening and 
arguments regarding the medicalisation of childbirth.  The second section reviews 
psychological research relevant to prenatal screening, such as risk perception and 
prenatal attachment. The third section considers the acceptability of prenatal screening 
tests, including the potential impact that healthcare professionals have on the uptake and 
impact of prenatal screening tests. The fourth section reviews the literature regarding 
other prenatal screening tests that may have an impact on the psychological impact and 
acceptability to pregnant women, including screening tests for gestational diabetes, HIV, 
and genetic conditions, and suggests implications from the literature for investigation of 
the psychological impact and acceptability of the pre-eclampsia screening test. The 
chapter concludes by outlining the thesis questions under investigation. 
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1.2  INTRODUCTION 
A screening programme identifies individuals who may be at increased risk of 
developing a disease or condition [1]. High risk individuals are offered information and, 
in some cases, further tests and treatments to reduce their risk of acquiring the condition 
or of complications that may arise as a result of developing the condition [2]. Pregnant 
women in the UK undergo many screening tests [3] to identify potential problems with 
their own health and that of the fetus. The purpose of the screening tests is to assess risk 
and reduce outcome uncertainty for pregnant women and their fetuses [4]. The 
psychological impacts of prenatal screening tests have been investigated in both 
quantitative and qualitative studies [5-7]. Advancements in technology have resulted in 
new screening tests that mark a shift in prenatal screening, from ‘screening-to-treat’, 
where a screening test is conducted with the aim of implementing a treatment plan (as is 
the case for screening for gestational diabetes) or reproductive choice (as is the case for 
Down’s syndrome screening), to ‘screening-to-observe’, where a screening test 
identifies individual women at higher risk but for which there is no agreed treatment 
options available to reduce the risks once they are identified, for example, as pre-
eclampsia [8], pre-term birth [9], macrosomia [10] and the haemorrhage-causing 
placenta accreta [11]. The psychological impact of these newer ‘screen-to-observe’ tests 
has been little studied. 
The impact and acceptability of prenatal screening tests are rarely considered prior to 
wide-scale introduction. For example, fetal fibronectin (fFN), a glycoprotein whose 
presence indicates an increased risk of preterm birth has been recommended for use in 
the US since 2001 [12] and in the UK since 2008 [13]. However, to date only two 
studies have explored its potential psychological effects on pregnant women [14,15]. 
Similarly, the impact of the pre-eclampsia screening test, the focus of this thesis, was 
not assessed until the body of work presented here commenced.   
Pre-eclampsia is a serious obstetric complication, affecting approximately 2% of 
pregnancies and causing over 50,000 maternal deaths worldwide each year [16]. It is the 
second largest cause of maternal deaths in the UK, after thromboembolism, accounting 
for 18% of the 107 deaths between 2006-2008 [17]. It can also affect the fetus, 
increasing the risks of preterm birth by 67%, growth-restriction by 25% and death by 
2% [18]. It has been proposed that rates of post-traumatic stress disorder (PTSD) and 
depression are higher following a traumatic pregnancy or birth [19], including those Page 18 of 316                   Chapter One: General Introduction 
affected by pre-eclampsia [20]. This may be as a result of the mother falling ill herself, 
concerns over the health of her baby, or a combination.    
Many prenatal screening tests for pre-eclampsia have been developed [21]. The UK’s 
National Screening Committee (NSC) has yet to endorse a nationwide screening 
programme for pre-eclampsia, with the most recent consultation completed in 2011 
[22]. However, one such biochemical universal first-trimester pre-eclampsia screening 
test [23] was introduced in 2009 as a routine clinical service in two maternity units in 
the UK. This test combines measurements from blood tests, ultrasound scans (USS), 
maternal characteristics and medical history to provide a risk score. Screen positive 
(high-risk) results lead to referral to a hypertension clinic, where women receive an 
increased level of monitoring, including monthly USS and blood tests measuring 
changes in pregnancy hormones. Screen negative (low-risk) women are provided with 
routine prenatal care based on National Institute of Clinical Excellence (NICE) 
guidelines [3]. The screening test was introduced as a service development and funded 
by the NHS. The services of the hypertension clinic had research elements and had 
combined NHS and research grant funding support.  
The test is conducted alongside other prenatal tests during the routine 12-week visit 
where the recommended ultrasound scan is performed [3]. Women are informed of the 
availability of the pre-eclampsia test when they book for prenatal care and are informed 
about the results (‘low-risk’ or ‘high-risk’ for developing pre-eclampsia) on the same 
day of their visit. No research has been identified that assesses the psychological impact 
of providing this information to pregnant women, nor on whether pregnant women and 
their care providers find the screening information useful.  
Prenatal screening for pre-eclampsia differs in three distinct ways from other prenatal 
tests: Firstly, until the introduction of this screening test, prenatal tests have provided 
risk information about either the pregnant woman, (diabetes screening) or about the 
fetus (Down’s syndrome screening). A positive pre-eclampsia screening test result has 
implications for fetal and maternal health. Secondly, the screening test provides risk 
information and increases surveillance, without the possibility of treatment (as occurs 
for gestational diabetes, HIV and exomphalos), or reproductive choices (as occurs for 
Down’s syndrome). Finally, the pre-eclampsia screening test informs pregnant women, 
for the first time, that there is potential that their pregnancy could provide a mortality 
risk. Traditional prenatal screening tests that impact on maternal health present either a 
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minority of cases are precursors to a diagnosis of type two diabetes) or give information 
that is not a direct consequence of the pregnancy (such as HIV screening). In view of 
these differences, empirical research is required to assess the psychological impacts and 
the acceptability of providing this information to women and their care providers. 
The remainder of this chapter reviews the literature surrounding prenatal screening and 
pre-eclampsia, including the historical contexts of prenatal screening. Page 20 of 316                   Chapter One: General Introduction 
1.3  ETHICAL, HISTORICAL AND SOCIOLOGICAL CONTEXT 
While this thesis addresses the psychological impacts and acceptability of a pre-
eclampsia screening test, these issues should be considered within the ethical, historical 
context of the introduction of prenatal screening tests.  
1.3.1    ETHICS AND SCREENING IN PRENATAL CARE 
Four key principles in biomedical ethics are acknowledged in relation to screening and 
healthcare ethics [24]: respect for autonomy (valuing an individual’s decision-making 
capabilities), non-maleficence (causing no harm), beneficence (doing good), and justice 
(treating individuals equally).  
The principle of respect for autonomy is the basis of informed consent, a legal term 
defining that consent for a test or procedure can only be given based upon a clear 
appreciation and understanding of the facts, implications, and future consequences of 
accepting that procedure. Respect for autonomy is now viewed as one of the highest 
legal and ethical principles [25]. To aid the consent process, health psychologists have 
developed evidence-based decision making tools [26-28], which are shown to increase 
satisfaction with the screening process and improve knowledge, leading to increased 
rates of autonomy.    
The principles of non-maleficence and beneficence are derived from the Hippocratic 
oath taken by medical practitioners. It has been suggested that screening programmes 
can cause divergence between these two fundamental principles, creating the “double-
effect principle” [29], potentially harming some while benefiting others. This is because 
the benefit of helping those accurately found screen positive (true-positive) or screen 
negative (true-negative) within a screening programme comes at the cost of the harm 
caused to those who are inaccurately found screen positive (false-positives) or screen 
negative (false-negatives). Costs for undergoing a screening test can include an increase 
in anxiety or worry, time, travel to testing sites as well as pain or invasiveness caused by 
the screening procedure. The majority of people experience some costs with minimal 
benefits. For example, as the majority of pregnant women are healthy, there is a high 
probability that those women undergoing a screening test will experience the discomfort 
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small chance that they will benefit by being found at risk and receiving appropriate care 
[30].  
These basic ethical principles were considered in a seminal paper published by the 
World Health Organisation in 1968 [31], which details the principles and practices of 
screening for disease.  The recommendations have informed international screening 
programme guidelines, and have been adopted by the UK’s National Screening 
Committee (NSC) [32]. A key standard within these guidelines, point 7 – “The test 
should be acceptable to the population”, is explored further below in section 1.8. 
Briefly, this principle considers both procedural concerns (such as invasiveness of the 
screening test), and the acceptability of the results and subsequent interventions offered. 
Therefore, the psychological and social impacts of a proposed screening programme 
require empirical evaluation to enable a judgment on its acceptability. 
 
1.3.2    THE DEVELOPMENT OF SCREENING IN PRENATAL CARE  
This section considers the evolution of screening tests, both in healthcare generally and 
maternity care specifically. The evolution of medical care has been explored in the work 
by Foucault [33], which outlined the change from ‘bedside medicine’ to ‘hospital 
medicine’. Bedside medicine involved viewing a clear conterminous link between 
experienced symptoms and the actual illness, so that a complaint of abdominal pain was 
the actual illness to be treated, rather than a symptom of a more fundamental 
physiological abnormality. This approach changed to ‘hospital medicine’, which 
developed with the growth of the clinical examination. This resulted in the patient’s 
description of a symptom (e.g. abdominal pain) requiring an appropriate matching to an 
observable characteristic (e.g. guarding on palpation) that the physician could detect. 
This combined clinical picture would lead to a diagnosis of a pathology, beyond the 
symptoms (e.g. appendicitis). The medical model was further developed with 
‘laboratory medicine’ [34] in which clinicians used additional sources of data to 
interpret the patient’s expressed symptoms by the use of laboratory results from tests 
such as blood tests and x-rays.  
Laboratory medicine developed into ‘surveillance medicine’ [35]. Surveillance 
medicine moves healthcare away from treating individuals that are currently ill, to those 
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healthcare professionals for regular inspection, in the hope that illness can be prevented 
or treated at the earliest opportunity [36]. This ‘problematisation of the normal’ [35] 
developed from improvements in medical technology and detection methodologies, 
such as discoveries concerning the development of illnesses and cancers and 
developments in genetic screening.  
Current medical practice assumes that identifying conditions through screening will be 
less of a burden on limited healthcare resources than treating conditions once they occur 
[30]. However, there is evidence that some screening programmes are not as cost 
effective as initially thought [37,38]. The development of surveillance medicine has led 
to a public that is more aware of health conditions and, arguably, more concerned by 
conditions that will never affect them. This has led to the term ‘the worried well’, which 
describes people who have no health problems but who have a heightened anxiety of 
developing them [39]. While some ethicists have seen this as a natural development of 
screening culture [30], others have argued that the human condition has been 
pathologised and this has led to increased and unfounded anxiety that itself now 
requires treatment [40,41].  
The detection of pre-eclampsia, (then known by the term ‘toxaemia’) was one of the 
catalysts for instigating a programme of antenatal care within the UK [42]; prior to a 
memorandum of the Department of Health in 1927 [43] formal care was only given 
during childbirth. Indeed, it was not until the 1920’s that medical textbooks referred to 
the need for clinical care during pregnancy [44]. The development of ‘a new department 
of medicine’ [45] attending to women during their pregnancy occurred at the same time 
as the development of accurate pregnancy tests [46] and the first detection of a fetal 
heart beat [43]. The schedule of care as prescribed in 1927 remains similar today.  
The introduction of screening in pregnancy in the UK began with the introduction of 
two technologies in the 1950’s: the obstetric ultrasound and amniocentesis. The use of 
USS in pregnancy was first studied by Ian Donald in Scotland in 1956 and it became 
widely used within British hospitals by 1975 [47]. The use of USS is not without 
controversy. The introduction of USS coincided with the increased use of hospitals for 
labour and delivery, with many arguing that the USS was a key cause of the 
‘medicalisation of childbirth’ [48-50].  The USS is now almost universally accepted as a 
key component of prenatal care. National guidelines within the UK recommend two 
routine USS, one in the first trimester (week 11-12) to confirm gestation and as part of 
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structural anomalies [3]. There is growing support to introduce a routine third-trimester 
USS (week 36) to detect growth-restricted fetuses [51-53]. USS are welcomed by 
service users, with a growing industry of private, non-medical, 4D scans being 
purchased [54,55].  Despite this, there is controversy over the safety of obstetric USS 
[56] and concerns over the psychological harms and benefits of its use. The 
psychological impact of ultrasound is discussed extensively in Chapter 2.  
Amniocentesis is not a screening test, but a diagnostic test. Its development, plus the 
discovery of a link between maternal age and Down syndrome births, led to a 
rudimentary screening test, whereby women over 35 were offered counselling and an 
amniocentesis to screen for Down syndrome in the fetus [57]. In 1984 it was discovered 
that reduced levels of serum alpha-fetal protein in maternal blood during the second 
trimester was associated with Down syndrome, independent of maternal age [58]. This 
led to the introduction of blood test screening of pregnant women during the second 
trimester (between 20-24 weeks). Additional tests have since been added to the 
screening program including human chorionic gonadotropin (HCG) [59] and nuchal 
fold measurement [60]. The screening tests are conducted earlier in gestation (11-12 
weeks) to enable reproductive choice. Women who are found high risk are offered a 
diagnostic test, so that those with a positive result can decide if they wish to continue 
with the pregnancy.  
Recent work has led to the discovery of free-fetal DNA, fetal DNA cells that can be 
detected within maternal blood [61]. This discovery has led to the development of a 
diagnostic test that does not carry the one-percent risk of miscarriage associated with 
amniocentesis [62].  
1.3.3    SOCIOLOGICAL CONCERNS AND PRENATAL  
SCREENING 
Sociological concerns regarding prenatal screening often focuses on prenatal diagnosis 
of fetal abnormality, termination of pregnancies and perceived eugenics [63]. These 
debates are beyond the scope of this thesis. However, some considerations against 
prenatal screening require consideration with regard to the pre-eclampsia screening test.  
The first concerns the issue of consent. Pregnancy can be viewed as a ‘special case’ 
where autonomy of the individual to consent to a screening test is subjugated in favour 
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women to choose to reject technologies approved by the medical profession [64]. This 
is because once tests are offered, to reject them may be seen as a rejection of modern 
society’s faith in science and also a rejection of modern beliefs that women should do 
everything possible for the health of the future child [65]. Women who go against 
medical advice during their pregnancy may be seen as reckless, and endangering the life 
of their unborn baby [66].   
The concept of choice is now seen as an important aspect of maternity care [67,68]. 
These are made within the context of society’s beliefs and values about medicine. It has 
been argued that the use of technology is just one way in which obstetrics medicine has 
encroached into the woman’s realm of childbirth [69]. This use of technology leads 
women away from trust in their own bodies, to being reliant on obstetrics medicine 
[70]. Some feminists have argued that western science and technology embody 
stereotypical male values of domination, control, power and objectivity [71], resulting 
in medically invasive solutions to the socially constructed images of ‘women as 
problematic’ [72]. The concern is that the new technologies will be used to construct 
women as ‘mother machines’ [73]. For example, it is claimed that the increased use of 
technology to visualise the fetus has not occurred to improve the clinical care of 
women, but rather because of the technological enthusiasm of doctors and engineers, 
and as a result of the commercialisation of healthcare [74]. Obstetric technologies such 
as routine ultrasound scanning, routine fetal electronic monitoring during childbirth, 
routine induction of labour and artificial rupture of membranes are often introduced 
without sufficient evidence [75]. These medical ‘breakthroughs’ have not resulted in a 
decrease in cerebral palsy rates, low birthweight rates, or maternal mortality rates [76].  
Despite these arguments to the contrary, most of the sociological analysis supports the 
position that the safety of mother and baby are key motivations for obstetric 
technological developments [77]. Moreover, technological developments in obstetric 
care have also been influenced by the demands of pregnant women, including improved 
accuracies [78] and safety [79] of screening tests for Down’s syndrome and the 
development of 3D ultrasound scans [80]. Indeed, a key motivator for the development 
of the prenatal screen for pre-eclampsia has been the pressure of charities such as 
Action for Pre-eclampsia (APEC) [81], who have demonstrated through membership 
surveys that women are keen for a predictive test, arguing that anticipating the onset of 
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1.3.4    SECTION SUMMARY  
This section has discussed the ethical, historical and sociological context of the 
introduction of the prenatal screening tests. It suggests that screening tests within 
women’s health can reduce women’s autonomy in favour of the improved outcomes for 
the unborn fetus, which is in contrast to other groups within society. However, it also 
suggests that technological advancements in obstetric care has often been encouraged or 
requested by pregnant women themselves. These factors need to be considered when a 
technology is introduced into prenatal care, to ensure that the desire for information 
does not hinder the discovery of any unintended consequences of that introduction.  
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1.4  THE PSYCHOLOGICAL IMPACTS OF PRENATAL SCREENING 
Informing pregnant women of an increased health risk to themselves and their fetus for 
a condition that currently has no treatment, other than expedited delivery of the fetus, 
raises the possibility of adverse psychological consequences, such as increased anxiety 
[28]. The pregnant woman identified by screening to be at high risk for pre-eclampsia 
may develop negative attitudes and/or emotions towards the pregnancy or the fetus, 
given that the pregnancy has the potential to cause serious health problems [5,82]. 
Negative emotions or attitudes have been shown to influence behaviour in a way that is 
detrimental to health, such as failing to keep appointments or to take prescribed 
medications [83]. 
On the other hand, there is also potential for benefit. For example, women can 
experience emotional and cognitive advantages from preparing for adverse events [81], 
which decrease the incidence of postnatal depression [84]. Women may also be 
motivated by the screening test results to make positive behaviour changes to improve 
their health during pregnancy, since pre-eclampsia risk can potentially be reduced 
through certain types of diet [85], regular medication [86] and increased physical 
activity [87].  
Evidence reviews of the psychological impact of prenatal screening have focused solely 
on screening tests for conditions that have health impacts for the fetus [5,88]. Studies 
have reported that receiving screen positive results is associated with short-term 
increased anxiety in women [27,89] but that certain interventions can reduce this [90].  
Research has also suggested that increased anxiety may not be undesirable, but rather an 
appropriate reaction to threatening information and illustrative of an informed decision-
making process [91]. Systematic reviews demonstrate that ultrasound screening tests do 
not affect attachment [92] or to alter health behaviours [93]. In general, women 
welcome the information that screening tests give them, and are motivated to repeat 
them in future [94]. No review can be identified that reviews the evidence base on the 
psychological impact of prenatal screening tests for conditions that affect the mother.  
The research into the emotional, cognitive and behavioural impacts of prenatal 
screening is discussed in detail in Chapter three. Three psychological consequences of 
prenatal screening that are not covered in that chapter are discussed below. 
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There is a concern that increasing a women’s perception of risk may negatively affect 
her perceptions of pregnancy and childbirth, with the label of ‘high-risk’ being shown to 
negatively affect psychosocial states [95,96]. Risk perception is an individual’s 
expectation regarding the probability of an event occurring [97]. It is well documented 
that how a person perceives the risks that they are presented by healthcare professionals 
can differ greatly from what has actually been diagnosed. How a person perceives risks 
is based on both cognitive and social biases [98]. A cognitive bias includes an 
individual’s prior assumptions about their risk status, their general emotional outlook 
and their sense of locus of control [99].  
As discussed above, healthcare professionals have an understanding of risk based on 
their specialised knowledge and training and rely on epidemiological assumptions 
[100]; conversely, women’s understanding of risk relates to their experiences and their 
social context [95]. Therefore, a woman’s assessment of her risk may be at odds with 
those of her care providers [101], and this may affect her willingness to follow a 
prescribed health regimen [102].  
How a woman perceives the risk of the information being presented to her may have a 
direct impact on how she prioritises appointments and pays attention to care regimes. 
This is especially pertinent if the risk presented is novel so that the woman has no social 
context in which to think about the risk information she has been given. The perception 
of risk for a condition that has no definitive diagnostic test or treatment may affect 
women differently than for conditions where a positive screening result is followed by a 
definitive diagnostic test, as is the case with an amniocentesis following Down’s 
Syndrome serum screening. 
1.4.2  PRENATAL ATTACHMENT AND SCREENING 
Salient aspects of the mother-child relationship may begin before birth  [103]. Pregnant 
women develop varying degrees of connectedness to their unborn child, their pregnancy 
and their anticipated role as a mother; the term ‘maternal-fetal attachment’ (MFA) 
describes this process [104]. Feelings of attachment begin early in the pregnancy and 
increase over time [105], with peak levels reported in the second trimester [106]. 
Attachment has been found to correlate with adherence to prenatal care regimes [107] 
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Three reviews suggest that prenatal screening has minimal impact on MFA [109-111]. 
Although the decision to undergo amniocentesis has been found to delay attachment, 
once the health of the fetus is confirmed it increases to the level of those not having 
diagnostic testing [112]. MFA has not been found to be associated with being found 
high risk for a condition during pregnancy [107,113-116]. 
The evidence presented thus far in this thesis suggests that a prenatal screening test for 
pre-eclampsia would not affect MFA. However, as argued above, screening for pre-
eclampsia is different from other prenatal screening tests in many ways. As pre-
eclampsia presents a mortality risk to the mother, as a direct consequence of the 
pregnancy, it may affect the relationship in a different way to other conditions and 
research is needed. 
1.4.3  POST TRAUMATIC STRESS DISORDER AND SCREENING 
There is evidence to suggest that the more predictable a stressful event is, the less likely 
it is to lead to development of pathology [117]. It appears that when the onset of the 
stressful event is unexpected, contextual stimuli are more likely to be treated as 
predictors of adverse events in the future, creating an increase in general fear [118]. 
However, when an element of control over the adverse event is introduced, this 
generalisation of the contextual stimuli does not occur. These findings are based on 
animal studies, but have been extended to human studies [119,120]. Several 
psychological theories also make a link between an individual’s assessment of their 
ability to manage events and their subsequent behavioural and affective responses to 
situations (for example, Social Cognitive Theory [121], the theory of planned behaviour 
[122], the common sense model of self regulation [123]). It has been argued that there is 
a ‘benefit in knowing’ that an adverse event such as developing pre-eclampsia is likely 
to occur during pregnancy, because it can act as a protective factor against developing 
postnatal psychological trauma such as post-traumatic stress disorder (PTSD). This 
argument is considered below.   
The criteria for a diagnosis of PTSD includes ‘persistent negative trauma-related 
emotions, such as fear, horror, anger and guilt [124]. PTSD (as defined by the 
Diagnostic and Statistical Manual of Mental Disorders V) [124] following childbirth 
receives less attention than postnatal depression (PND). A UK study [84] found 3 per 
cent of postnatal women displayed all the signs consistent with PTSD, with 24.2% of 
women showing partial signs. The authors did not explore potential causes or Page 29 of 316                   Chapter One: General Introduction 
differences in their sample. The effects of unidentified or untreated PTSD may be life-
limiting and chronic, leading, for example, to increased physical and psychiatric 
morbidity [125].  The authors of a recent systematic review, which examined a range of 
pregnancy and childbirth complications, suggested that there is a potential relationship 
between severe maternal morbidity and PTSD. This included four studies that assessed 
the association between pre-eclampsia in pregnancy and a subsequent diagnosis of 
PTSD. These studies suggest that the prevalence of PTSD following a pregnancy 
affected by pre-eclampsia is significantly higher than those unaffected by pre-
eclampsia. The authors found that women who had less control over their birth 
experience were more likely to display PTSD/ PTSD symptoms. However, the 
heterogeneity, small samples and cross-sectional survey designs limit the validity and 
generalisability of the findings and further research is required [126].  
It has been suggested that one of the causes of psychological trauma following 
pregnancy is of ‘shattered expectations’ [127], that is that the natural progress of the 
pregnancy is affected by an unexpected event. It may be that a screening test presented 
in early pregnancy that predicts the onset of pre-eclampsia would alter the expectation 
of a normal, low risk pregnancy, and therefore reduce the threat of PTSD. This 
suggestion is supported by the consumer group ‘Action for Pre-Eclampsia’ who argue 
that while a screening test for pre-eclampsia may increase anxiety prenatally, this is 
preferable to the shock and fear associated with a sudden onset of pre-eclampsia when it 
was not expected [81]. A first-trimester screening test for pre-eclampsia may increase 
the sense of control that women have over the condition, either because of behaviour 
changes that they instigate, or as a result of the prediction itself.  
1.4.4  SECTION SUMMARY  
The current evidence suggests that prenatal screening does not adversely affect 
perceptions of pregnancy risk, or maternal-fetal attachment. However, all current 
literature reviews focus on the impact of prenatal screening tests that have an associated 
diagnostic test. Women found screen-positive for pre-eclampsia would have an 
unconfirmed high-risk status from twelve weeks gestation until either the disease 
develops, or the fetus is born without complications. It is unknown what affect this 
extended period of uncertainty will have on perception of pregnancy risk or maternal-
fetal attachment, or if anticipating a disease will act as a protective factor against PTSD. 
 Page 30 of 316                   Chapter One: General Introduction 
 
1.5 THE ACCEPTABILITY OF A NEW PRENATAL SCREENING TEST 
This section considers the acceptability of screening tests. It commences by introducing 
the concept of ‘acceptability’, and discusses its value. It then considers how 
acceptability is tested when considering screening tests. Finally it considers the 
influence of healthcare professionals on the acceptability of a screening test. 
1.5.1  THE CONCEPT OF ACCEPTABILITY 
The concept of ‘acceptability’ when considering screening tests can be defined as the 
test being welcomed by those who undergo it, offer it, and wider society[128]. The term 
derives from a seminal paper published in 1968, which details the principles and 
practices of screening for disease [31]. This paper points out that a test, or series of 
tests, must be acceptable to the population to which it is offered. It points out that 
screening tests could be considered acceptable to some and not others. When 
considering prenatal screening, for example, screening for Down’s syndrome may be 
deemed unacceptable to individuals opposed to termination of pregnancy. This does not 
stop it being deemed acceptable to other individuals. The recommendations have 
informed international screening programme guidelines, and have been adopted by the 
UK’s National Screening Committee (NSC) [129].  
Prenatal screening for a variety of conditions has become routine, and all pregnant 
women are offered tests for conditions in the fetus and themselves during pregnancy. 
Prenatal screening tests are often rated highly acceptable [5]. However, neither their 
routine use nor general acceptance should prevent assessment of the acceptability of any 
new prenatal screening programme. The literature on prenatal screening suggests that 
acceptability of screening has an impact on uptake, [130,131] and the effect of 
inaccurate results may extend over a considerable time period [132,133]. Although the 
views and motivations of pregnant women and healthcare professionals have been 
sought and studied, such views are seldom sought before the technology is introduced 
[5,134].  
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There appears no consistent approach to assessing the acceptability of a screening test in 
the UK. The UK’s Health Technology Assessment (HTA) organisation funds research 
that evaluates health interventions, that either provides new knowledge, or 
systematically evaluates existing knowledge on the benefits, costs, acceptability and 
wider impacts of interventions intended to improve the health of the public and reduce 
inequalities in health. A variety of methodologies have been used within the HTA’s 
database of assessments of screening tests that aim to assess acceptability. This included 
no assessment of the views of stakeholders (where high test-performance is taken as a 
proxy for an assessment of acceptability) [135,136]; qualitative methodologies 
including semi-structured interviews [137,138] and focus groups [139,140]; quantitative 
methodologies including cross-sectional surveys [141,142] and discrete choice 
experiments [143,144]; and finally mixed methods approaches using a combination of 
qualitative and quantitative methodologies [145,146].  
1.5.3  THE INFLUENCE OF HEALTHCARE PROFESSIONALS  
A healthcare professional can influence the value a woman places on the offer of a 
screening test and the interpretation of the results received. Many factors may influence 
healthcare professionals when discussing prenatal screening tests, including personal 
opinions and attitudes [147], knowledge levels [148], and workplace and social context 
influences [149]. It has shown that a healthcare professional’s attitude towards the 
conduct of prenatal screening have the potential to affect their practice, and that they 
can exert a great influence on the people they care for [150,151]. 
It has been shown that women and healthcare professionals focus on different elements 
of prenatal screening tests. Healthcare professionals tend to value the accuracy and 
gestation that tests are conducted [79,152]. Pregnant women, however, value the safety 
elements of a screening test more [79,152]. These differences may effect discussions on 
screening tests, as healthcare professionals tend to direct the flow of consultations.  
1.5.4  SECTION SUMMARY 
The acceptability of a screening test influences both uptake and satisfaction with it. 
However, there appears no approved approach to assessing the acceptability of a 
prenatal screening tests. No research into the acceptability of a pre-eclampsia screening 
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When considering the acceptability of the pre-eclampsia screening test, it has been 
argued that acceptability would be determined either by the procedure involved [153], 
or by whether or not any benefits of the screening test would outweigh any negatives 
[154]. Contrary to this, the author of this work feels that acceptability should be 
ascertained in a systematic way. While the procedure of the test is important, for 
stakeholders to consider whether or not to undertake the pre-eclampsia screening test 
they need to be aware of all of its benefits and limitations. It should be made explicit 
that there are no approved treatment options or risk reduction interventions for pre-
eclampsia. They should consider any potential benefits and harms that the screening test 
could present, compare this with what is currently offered, and make an informed 
decision on whether or not the test is right for them. It is hoped that the work within this 
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1.6  TESTS COMPARABLE WITH PRE-ECLAMPSIA SCREENING 
As identified above, pre-eclampsia screening differs from previously studied prenatal 
screening tests in three key ways: the condition represents a health risk to mother and 
fetus, the screening test informs the mother for the first time that her pregnancy may 
harm her, and the test provides risk information without any risk reduction 
interventions. In this section we examine these three points, to help identify literature 
that may suggest hypotheses regarding a pregnant women’s reaction to the new pre-
eclampsia screening test. Table 1.1 identifies three potential screening tests that may be 
comparable to the pre-eclampsia screening test with respect to the repercussions for 
both the individual and the fetus or other family members, severe repercussions to the 
person screened and having no associated treatment or risk reduction interventions. The 
literature on the impact of screening for these conditions is then discussed in more 
detail. 
TABLE 1.1 – SCREENING TESTS COMPARABLE TO PRE-ECLAMPSIA 
Screening test  Repercussions 
for individual 
and fetus/family 
members 
No associated 
treatment / 
harm reduction 
interventions 
Routinely 
screened in 
pregnancy? 
HIV screening   Yes
1  
 
No  Yes 
Gestational Diabetes 
screening 
Yes
2  No  Yes 
Genetic Screening (inherited 
diseases and cancer 
screening) 
Yes  Condition 
dependent 
No 
1.6.1  GESTATIONAL DIABETES SCREENING 
Gestational diabetes is the development of high blood glucose levels during pregnancy, 
where no previous diabetes has been noted. Treatment consists primarily of behaviour 
changes in the form of dietary changes and an increase in physical activity [155]. 
Insulin treatments are rarely required [156]. There is a threat of a diabetic induced coma 
to the mother [157] if glucose levels remain uncontrolled. Between 25-50% of women 
diagnosed with gestational diabetes will go on to develop type-II diabetes within 10 
                                                 
1 Repercussions to fetus unlikely if the condition is identified and treated 
2 It is anticipated that the index patient (the person currently being treated for the 
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years of the pregnancy [158].  Prenatal screening for gestational diabetes does not 
appear to cause changes in anxiety, worry or depression scores ([159-161], see chapter 3 
for further discussion). One study suggested that positive dietary changes may occur 
after a diagnosis of gestational diabetes [159]. Two studies indicated that being found 
high-risk for gestational diabetes negatively affected how women perceive their health-
related quality of life when compared to women without gestational diabetes [160,161] 
(p < 0.05). 
In contrast to pre-eclampsia screening, pregnant women found at high risk for 
gestational diabetes will undergo a confirmatory test, generally an oral glucose 
tolerance test (OGTT). Those with a confirmed diagnosis commence on a risk reduction 
program of amended diet, blood-glucose monitoring, possible pharmacological 
treatment alongside increased monitoring of maternal and fetal well-being [3]. Those 
with a false-positive screening result (found high risk on the screening test, but negative 
following the OGTT) resume the normal low-risk care pathway. 
1.6.2  HIV SCREENING 
Human immunodeficiency virus (HIV) is a virus that leads to the development of 
acquired immunodeficiency syndrome (AIDS). It affects the immune system to such an 
extent that otherwise minor opportunistic infections can be fatal. Mother-to-child 
transmission of HIV is possible in the prenatal period (if an injury or clinical event 
causes maternal and fetal blood systems to mix) [162], during labour [163], and 
postnatally through breast milk [164]. The World Health Organisation (WHO) 
recommend treatment programmes to reduce the vertical transmission of HIV from 
mother to child, and a key factor in implementing these recommendations is to identify 
the pregnant women with HIV [165]. The demonstrated reduction in vertical 
transmission from screening and subsequent treatment [166] has led many countries to 
develop an opt-out rather than opt-in screening process for HIV in pregnancy [167-170]. 
Such policies have not been without critique [171,172], as discussed above (section 
1.3.2) Prenatal screening for HIV does not appear to cause changes in anxiety or worry 
scores ([173-175]; see chapter 3 for further discussion). One study suggested that 
positive sexual health behaviours may occur after screening for HIV [176]. Being found 
positive for HIV does not affect a woman’s perception of health [177].  
In contrast to pre-eclampsia screening, an HIV screening test is essentially a diagnostic 
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result, there is a very small period of time when the woman would be waiting a 
confirmatory diagnosis. Moreover, although the diagnosis may occur because of 
antenatal screening, HIV is not caused by the pregnancy, nor does the pregnancy 
exacerbate the condition [114]. Clear, internationally recommended care pathways [117] 
are followed following a diagnosis of HIV in a pregnant woman. Counselling, drug 
treatments and care plans are initiated to minimise the risk to the fetus following a 
diagnosis [114-116], and care plans instigated for the newborn following delivery [178], 
which is also in stark contrast to what occurs after a positive pre-eclampsia screening 
result, for which there is no treatment and unclear benefit of increased monitoring. 
1.6.3  GENETIC SCREENING - INHERITED CONDITIONS AND 
CANCER SCREENING 
 An alternative screening test comparison outside of the field of obstetrics is illustrated 
with genetic screening. When undergoing genetic screening tests, an individual receives 
information about their own risk of developing a condition and this information may 
affect their family [179]. Similar to pre-eclampsia screening, many genetic screening 
tests provide information about an increased or decreased potential for developing 
particular condition, but for many of the conditions, there is no option of confirmatory 
diagnostic test [180]. A positive result can lead to increased surveillance [181], and 
there is unclear advice on what risk-reduction behaviours are most beneficial [182]. 
Examples of this in women’s health are the screening tests for genetic mutations for 
breast and ovarian cancers. A body of literature exists that explores how women 
perceive their risks following a confirmation of the BRCA 1 or BRCA 2 gene. The 
impacts on women generally occur in three domains: emotional, behavioural and 
cognitive. 
EMOTIONAL IMPACTS 
Multiple studies have found no increase in general distress (measured via measurement 
such as the hospital anxiety and depression scale (HADS), the general health 
questionnaire-28 or the Hopkins symptom check list-25) [183-185], or cancer-specific 
distress (measured via the impact of events scale) [186-188] pre- or post- screening, for 
carriers or non-carriers of genetic mutations. One study of 63 women undergoing 
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opted for increased monitoring (n=12) demonstrated less general distress than those 
women who opted for profolactic surgery (n=14) [184]. 
Anxiety levels (measured by the State-Trait Anxiety Inventory) and depression scores 
(measured by the epidemiologic studies depression scale or HADS) do not tend to 
increase with screening for BRCA1/BRCA2 genetic mutations [189-191].   
BEHAVIOURAL IMPACTS 
Multiple studies have shown that being found screen positive for a genetic mutation 
significantly increases a woman’s monitoring behaviours, including both self-
examination [192-194] and attending for clinical monitoring such as mammography 
[188,195]. Screening also encourages women to adopt positive health behaviour 
changes such as amending diet and stopping smoking [196].  
COGNITIVE IMPACTS 
Multiple studies have shown that the perception of risk of those found screen positive 
for breast or colon cancer genetic mutations decreases over time [187,197-199]. While 
some show an initial increase in perception of risk in the first month after testing 
[197,199], nearly all studies have found that perceived risk falls to below pretesting 
levels within 12-months of screening [187,197-199]. This is consistent with other health 
screening tests, with the assumption being that the risk factor is normalised over time 
[200]. 
Screening for inherited genetic conditions such as breast or ovarian cancer does not 
appear to have a negative emotional or cognitive impact, and may have a positive 
impact on health behaviours. It is unknown if these findings would extend to prenatal 
pre-eclampsia screening. There are also key differences between a genetic screen and a 
screen for pre-eclampsia. Pre-eclampsia is a transient condition. Moreover, it can be 
assumed that women would react differently to a health threat presented for themselves 
and a fetus developing inside them, than to a health threat presented for themselves and 
a child (or other relative). 
1.6.4  SECTION SUMMARY  
Existing prenatal screening tests, such as those for HIV and diabetes or genetic 
screening tests such as BRCA1 may have similar and different impacts on pregnant 
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tests show that undergoing them has little or no emotional consequences, positive 
behavioural consequences and variable cognitive consequences. As the pre-eclampsia 
screening test differs from them in some ways, research is urgently needed to assess the 
potential consequences of providing the screening information to pregnant women. 
1.7  CONCLUSIONS AND RESEARCH QUESTIONS 
The pre-eclampsia screening test differs from other prenatal screening tests in three 
ways. Firstly, until the introduction of this screening test, prenatal tests have provided 
risk information about either the pregnant woman, (diabetes screening) or about the 
fetus (Down’s syndrome screening). A positive pre-eclampsia test result has 
implications for both fetal and maternal health. Secondly, the screening test provides 
risk information and increases surveillance, without a recommended treatment (as 
occurs for gestational diabetes, HIV and exomphalos), or reproductive choices (as 
occurs for Down’s syndrome). Finally, the pre-eclampsia screening test informs 
pregnant women, for the first time, that there is potential that their pregnancy could 
seriously harm them. 
This chapter has reviewed the literature relevant to this thesis. It has discussed the 
historical context of the introduction of the prenatal screening test for pre-eclampsia. It 
reviewed literature that illustrated that screening tests within women’s health can 
compromise the autonomy in favour of the perceived rights of the unborn fetus. 
However, it also showed that technological advancements in obstetric care have often 
been encouraged or requested by pregnant women themselves. A key consideration 
when introducing a screening test is whether or not the intended population view it as 
acceptable. This has yet to be tested for pre-eclampsia screening.  
The current evidence suggests that prenatal screening does not adversely effect 
perceptions of pregnancy risk, or maternal-fetal attachment. However, all current 
literature reviews the impact of prenatal screening tests that have an associated 
diagnostic test. Women found screen-positive for pre-eclampsia would have an 
unconfirmed high-risk status from twelve weeks gestation until either the disease 
develops, or the fetus is born without complications. It is unknown what effect this 
extended period of uncertainty will have on perception of pregnancy risk or maternal-
fetal attachment.  Page 38 of 316                   Chapter One: General Introduction 
Healthcare professionals and women tend to have different opinions regarding parental 
screening tests, with healthcare professionals valuing accuracy while pregnant women 
value safety elements of the screening test. Despite this, healthcare professionals are 
able to influence the uptake of prenatal screening tests. No research has been identified 
that assesses healthcare professionals’ views on pre-eclampsia screening.  
Pre-eclamspia is a heterogeneous condition, which is not yet fully understood. Current 
screening involves reviewing maternal risk characteristics only. This results in low 
sensitivity and specificity. Therefore large investments into developing a biochemical 
screening test has been made. It is felt that these screening tests will improve outcomes 
through increased detection, increased ease for conducting research and in preventing 
postnatal psychological trauma. However, these suggestions have yet to be 
demonstrated.  
There are some methodological concerns regarding the specific pre-eclampsia  
screening test that is the focus for this thesis. This includes questions regarding 
generalisability, sample sizes, confounding variables and application of the algorithm.  
Three pre-existing prenatal screening tests may have similar impacts on pregnant 
women as the pre-eclampsia screening test. These are HIV, diabetes and genetic 
screening tests. The literature regarding these screening tests show that undergoing them 
has little or no emotional consequences, positive behavioural consequences and variable 
cognitive consequences. As the pre-eclampsia screening test differs from them in some 
ways, it is unclear if these findings can be extrapolated to this screening test. 
1.7.1  RESEARCH QUESTIONS 
This thesis addresses the following research questions: 
1.  What are the psychological effects for pregnant women of screening tests for 
conditions that affect their health, compared to those that affect the health of the 
fetus? (Chapter three – methodology: systematic review) 
2.  What are the potential psychological effects and acceptability of a prenatal 
screening test for pre-eclampsia to pregnant women? (Chapter four – 
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3.  What are the barriers and facilitators to offering a universal screening test for 
pre-eclampsia as perceived by midwives and obstetricians? (Chapter five – 
methodology: qualitative interview study) 
4.  Does increased monitoring affect the birth choices of pregnant women? 
(Chapter six – methodology: case control study) 
5.  Do pregnant women and healthcare professionals find a biochemical screening 
test for pre-eclampsia acceptable? (Chapter seven – methodology: discrete 
choice experiment) 
The results of these studies will then be triangulated to answer the following questions – 
‘What are the psychological impacts of pre-eclampsia screening’ (addressed via the 
qualitative studies, the systematic review and the case control study) and ‘Is the 
screening test acceptable to the intended population?’ (addressed via the qualitative 
studies and the discrete choice experiment). 
As far as we are aware, this is the first time that the psychological impact and 
acceptability of prenatal screening tests for pre-eclampsia have been tested. The work 
conducted within this thesis will contribute to the debate on whether these tests should 
be introduced nationwide, by filling the current gap in the literature. Understanding the 
positive and negative psychological impacts of the screening test will enable clinicians 
to anticipate problems experienced by women, and adjust delivery accordingly. The 
results from this thesis will directly inform clinical practice, policy and research 
programmes. Page 40 of 316    Chapter 1: General Introduction 
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  2.1  CHAPTER SUMMARY 
This chapter focuses on pre-eclampsia. It will consider its aetiology, the current advice 
regarding its identification during prenatal care, explores the research that assesses 
potential risk reduction interventions, the case for introducing a biochemical screening 
test to aid its detection, and the current research into discovering such a test. Finally it 
provides an in-depth critique of the screening test in question. 
2.2  PRE-ECLAMPSIA 
The female body usually adapts well to pregnancy. For example, cardiac output 
generally increases by around 40% during the first trimester, but blood pressure remains 
stable [1]. A fall in blood pressure by around 5-10 millimetres of mercury (mmHg) is 
expected during the second trimester, returning to pre-pregnancy levels at term [2]. The 
renal system also alters during pregnancy, with kidneys increasing in volume due to 
increased renal blood flow and vascular volume. This results in an increased glomerular 
filtration rate. This increased filtration rate can result in reduced efficiency in the renal 
systems ability to reabsorb useful minerals, such as glucose and protein. Small amounts 
of protein or glucosurea are therefore considered benign [3].  
Historically pre-eclampsia has been called toxaemia, PET (pre-eclampsia/toxaemia) and 
EPH gestosis (edema, proteinuria hypertension). Pre-eclampsia is now the recognised 
international term, although spellings vary with preeclampsia and PE used 
interchangeably. Reported incidences of pre-eclampsia vary from 2-8% [4]. Humans are 
the only animals that develop pre-eclampsia [5]. The pathogenesis of the condition is 
not fully understood, although studies demonstrate that the placenta has a central role in 
its development, as demonstrated by the presence of pre-eclampsia in molar 
pregnancies, which lack a fetus [6] and in extra-utero abdominal pregnancies [7]. 
Placental development in a normal pregnancy requires certain cells to acquire “tumor 
like properties” [8] to invade the mother’s uterine wall.  This process involves replacing 
the maternal endothelial lining and bridging into the muscular layer. This bridging 
process involves adapting the majority of intrauterine arteries to create a system that 
diverts uterine blood flow to the floating villi, thus increasing blood flow to the 
placenta.  Page 55 of 316    Chapter 2: Pre-eclampsia 
Pre-eclampsia is a pathology of pregnancy and is considered one of a cluster of 
hypertensive disorders of pregnancy. Pregnancy-induced hypertension (PIH) is defined 
by a systolic blood pressure of at least 140 mmHg and/or a diastolic of at least 90 
mmHg; for pre-eclampsia to be diagnosed, the hypertension must present alongside 
proteinuria measuring at least 300 mg of protein in a 24 hour urine collection or a 1+ on 
a urine dipstick if a single mid-stream urine is tested [9]. Both PIH and pre-eclampsia, 
which generally occur after the first trimester [10], are considered a different disease 
than chronic hypertension, a state of high blood pressure that is known about prior to 
the pregnancy, although pre-eclampsia superimposed onto chronic hypertension is 
common [11]. Previously the presence of oedema (generalised swelling caused by fluid 
retention) was included in the differential diagnosis of pre-eclampsia. However, oedema 
does not predict poor outcome and is a subjective measure, therefore, it has now been 
excluded from the pre-eclampsia diagnosis [10].    
It is proposed that in women who develop pre-eclampsia, there is inadequate attachment 
of the placenta to the uterus (placentation). Alternatively, the placentation may be 
normal, but if the placenta is large, for example in the case of a multiple pregnancy, then 
normal uterine blood flow may be inadequate to perfuse the organ. The consequence of 
inadequate blood supply appears to affect the maternal biological response to the 
placentation, resulting in a dysfunction of endothelial cells as well as an imbalance in 
growth receptors and other hormones [8]. The combined effect of these events results in 
vasospasm and increased blood pressure, abnormal coagulation and increased 
permeability of the endothelium. The increase in blood pressure alongside the increased 
permeability of the endothelium can disrupt renal function, as the increased pressure 
results in larger molecules, such as protein, being forced through and into urine. No 
definitive causation has yet been demonstrated and research continues into this ‘disease 
of theories’ [11]. It is suggested pre-eclampsia is a heterogeneous disease and a 
heterogeneous approach to its prediction, prevention and treatment will be required 
[12]. 
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2.3  CURRENT ADVICE FOR THE IDENTIFICATION OF 
PREGNANCIES AT RISK OF PRE-ECLAMPSIA 
The UK schedule of antenatal care is designed to detect pre-eclampsia at the earliest 
opportunity[13]. The latest UK guidelines for antenatal care were issued by the National 
Institute of Clinical Excellence in 2008, with a review in 2011 that recommended no 
updates. This guideline advises that a blood pressure measurement and urinalysis check 
for proteinurea be conducted at 12, 16, 25, 28, 31, 34, 36, 38 and 40 weeks gestation. It 
also outlines nine factors that increase a woman’s risk for developing pre-eclampsia. 
These are: nulliparity (first pregnancy); age 40 years or more; a body mass index (BMI) 
of 30kg/m
2 or above; a pregnancy interval of more than 10 years; a family history of 
pre-eclampsia; previous personal history of pre-eclampsia; pre-existing vascular disease 
such as hypertension; pre-existing renal disease; and a multiple pregnancy.  More 
frequent blood pressure measurements “should be considered for pregnant women who 
have any of the predefined risk factors” [14], although no advice is given as to what 
constitutes ‘more frequent’ blood pressure measurements.  
A large percentage of pregnant women within the UK will fall into these risk categories. 
The Office of National Statistics calculated that 40.7% of births in 2010 (156,307 of the 
384,375 live births) were to nulliparous women aged less than 40 years, and a further 
4.1% (29,350 of the 723,913 live births and 236 of the 3,811 stillbirths) of the 
pregnancies in 2011 were to women 40 years or more [15]. Around 5% of pregnant 
women have a BMI of over 35 [16]. Therefore as many as half of pregnancies could 
meet the first three risk factors outlined above. It is therefore surprising that clearer 
guidelines are not given to healthcare professionals as to the number and gestation of 
additional blood pressure measurements for women who meet these criteria. As pre-
eclampsia has a documented incidence rate of around 2% of pregnancies [4] it has been 
suggested that a more accurate screening test be used to identify those at risk [17], so as 
to avoid unnecessary increased surveillance and focus care on those most likely to 
develop the disorder. These hypotheses remain untested. It is unknown if the prediction 
of pre-eclampsia would reduce the rates of pregnancy and birth-related physiological or 
psychological trauma.  
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Although there is no effective treatment for pre-eclampsia other than delivery of the 
baby and placenta, several potential therapeutic agents have been studied over the years, 
which are summarised below. 
2.4.1  LOW-DOSE ASPIRIN 
The effectiveness of low-dose aspirin in preventing pre-eclampsia has been studied 
extensively. The rationale for its use is that Aspirin inhibits synthesis of an enzyme that 
impacts placentation, without affecting prostacyclin production, potentially preventing 
the development of pre-eclampsia [18]. 
Initial studies using aspirin in the 1980s examined small numbers of very high- risk 
women (women with pre-eclampsia in a previous pregnancy) and reported significant 
reductions in incidence of pre-eclampsia [19]. However, these initial results were not 
fully replicable; a subsequent larger study, including 1100 women at medium and high 
risk failed to show any significant benefit of aspirin therapy in preventing pre-eclampsia 
or other adverse pregnancy outcomes [20]. Several other studies have shown a small 
and non-significant benefit of aspirin use in preventing pre-eclampsia. Two systematic 
meta-analyses in recent years have pooled data from these and other studies. Examining 
59 [21] and 31 [22] randomised trials respectively, a modest but consistent benefit was 
seen with aspirin in risk of pre-eclampsia (RR 0.90, 95% CI 0.84 to 0.97), and of 
serious pregnancy outcomes (RR 0.90 95% CI 0.85 to 0.96) [22]. Results were similar 
regardless of dose of aspirin used and gestation at initiation of therapy. Subgroup 
analysis failed to demonstrate exactly which groups of women were most likely to 
benefit. 
Further studies have therefore attempted to elucidate exactly which groups of “at risk” 
women benefit from aspirin use. Nulliparity, or having a first baby, is one of the most 
important risk factors for pre-eclampsia, and is the most common. A study which 
randomised over 3000 healthy nulliparous women to low dose aspirin or placebo 
reported a relative risk of 0.7 for pre-eclampsia in the aspirin group (95% CI 0.6 to 1.0) 
[23]. The reduction in risk, however, was highest in women with an initial blood 
pressure in the upper end of the normal range, which may have confounded results. 
Further, there was a small but significant excess of placental abruption, the most 
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Despite these data, the UK’s National Institute for Health and Clinical Excellence 
(NICE) recommend aspirin prophylaxis from 12 weeks’ gestation in high-risk women, 
who are in turn defined as those with chronic hypertension, diabetes, chronic kidney 
disease and those with autoimmune conditions such as systemic lupus 
erythematosis[24]. Aspirin prophylaxis is also recommended in women with 2 or more 
“moderate” risk factors (nulliparity, age >40 years, BMI >35 kg/m2, family history of 
pre-eclampsia and twin pregnancies). As yet this advice does not extend to women who 
have been found screen-positive for pre-eclampsia without any of these risk factors.  
Aspirin is safe in the second and third trimesters of pregnancy [25] but its safety in the 
first trimester remains unknown. Given that the underlying pathophysiological 
mechanisms begin early in the first trimester, further research examining the safety of 
aspirin in the first few weeks of pregnancy is required. 
2.4.2  DIETARY CHANGES AND SUPPLEMENTATION 
Several reports have suggested that calcium supplementation can reduce the incidence 
of pre-eclampsia [26]; the rationale for this comes from a 1952 study that showed that 
Ethiopian women, who had a high dietary intake of calcium, had a low prevalence of 
pre-eclampsia [27]. Its use is not recommended in the healthy pregnant population [26], 
but whether calcium supplementation is beneficial in selected high-risk groups of 
pregnant women remains uncertain. A Cochrane database systematic review considered 
12 studies including over 15,000 pregnant women, comparing calcium supplementation 
of 1g with placebo [28]. The authors reported an overall relative risk in the calcium 
supplement group of pre-eclampsia of 0.48 (95% CI 0.33 to 0.69). In high-risk women 
the relative risk was 0.38 (95% CI 0.21 to 0.68). However, the results of this meta-
analysis could be caused by the inclusion of several small trials with a high proportion 
of women with low dietary calcium intake. A further systematic review by the US Food 
and Drug Administration concluded that a relationship between calcium 
supplementation and gestational hypertension or pre-eclampsia was unlikely [29]. 
A number of studies have assessed the relationship of vitamins C and E with incidence 
of pre-eclampsia. In an initial study, high-risk women were randomised to either 1g of 
Vitamin C and 400 iu of Vitamin E per day, or placebo, from 16-22 weeks’ gestation 
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compared with 8% in the treatment group [30]. However, subsequent larger multicentre 
study study showed no impact on pre-eclampsia rates [31-33].  
The relatively low incidence of pre-eclampsia in populations with a fish-based diet such 
as inhabitants of Greenland and the Faroe Islands have led to several studies examining 
the potential role of fish oil supplements in preventing pre-eclampsia [34]. Fish oils are 
rich in long-chain polyunsaturated fatty acids, and have been shown to modulate 
vascular and inflammatory effects of early pregnancy [34]. The Fish Oil Trials In 
Pregnancy (FOTIP) study randomised 386 pregnant women with a history of 
hypertension in a previous pregnancy to either fish oils or olive oil at gestational week 
20. No effect was seen on either incidence or development of hypertension [35]. A 
Cochrane database meta-analysis of 6 trials of 2755 women similarly found no 
beneficial effects of fish oil supplementation [34]. 
2.4.3  LIFESTYLE CHANGES 
It has been suggested that regular exercise in pregnancy, alongside helping to reduce 
obesity, can reduce the risk of pre-eclampsia. Exercise is well known to reduce risk of 
hypertension in non-pregnant subjects. A study reported in 2003 retrospectively 
examined 201 women with pre-eclampsia and 383 women with normotensive 
pregnancies [36]. Self-report assessments of type, duration, frequency and intensity of 
exercise both during pregnancy, and in the year preceding the pregnancy were taken. 
The authors reported an overall 35% reduced risk (95% CI 0.43 to 0.99) of pre-
eclampsia in women who took regular exercise in the first 20 weeks of pregnancy, 
compared to inactive women [36]. This risk reduction remained significant when 
adjusted for age, BMI, parity, smoking and race. The risk of pre-eclampsia was 
inversely related to the frequency and intensity of exercise. However, there have been 
difficulties in replicating these findings. A prospective Scandinavian study, using a 
questionnaire at 14-22 weeks gestation, reported an overall reduction in risk of pre-
eclampsia with exercise of 21% (95% CI 0.65-0.96). This effect was most marked in 
women with a BMI within the normal range, with no benefit of exercise seen with 
pregnancy in those with a BMI>30 kg/m2, implying that the beneficial effects of 
exercise in pregnancy only applied to the non-obese population [37]. A further 
prospective study reported that women with more intensive exercise (more than 270 
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review of the literature in this field led to American College of Obstetrics and 
Gynaecology recommendations that in the absence of medical or obstetric 
complications pregnant women partake in 30 minutes of moderate exercise daily [39]. 
Similarly, NICE guidelines recommend that “beginning or continuing a moderate course 
of exercise is not associated with adverse outcomes.” [40]. Further large-scale 
prospective studies looking at both fetal and maternal outcomes are required before 
clinicians can give definitive guidance about optimal exercise duration and type during 
pregnancy. 
Conversely to exercise, rest has also been suggested as a risk-reduction for pre-
eclampsia.  A Cochrane review of two trials featuring 106 women showed a significant 
reduction in risk for developing pre-eclampsia with 30 minutes bed rest per day (RR 
0.13, 95% CI 0.03 to 0.51) [41]. As the sample sizes are small, definitive guidance 
cannot be made.  
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2.5  CURRENT PRE-ECLAMPSIA SCREENING RESEARCH AND 
NATIONAL POLICY 
There have been many screening tests evaluated in the literature over the years for 
predicting pre-eclampsia [11,12,42]; these screening tests differ in design (single versus 
multiple factor), target population (whole population versus pre-identified high-risk) 
and gestation of application (first versus second trimester screening). Single factor 
screening tests that calculate a risk score based on one factor. This includes screening 
tests such as  uterine artery dopplers
3, pulse-wave analysis
4, and biomarkers including 
pregnancy-associated plasma protein A (PAPP-A)
5 and inhibin A
6. Multi-factorial 
screening tests combine single-factors to improve the accuracy of the screening test.  
A systematic review conducted in 2008 [11] identified 28 different single-factor 
prenatal screening test for pre-eclampsia, while a further review in 2010 [42] reviewed 
71 multi-factor screening tests. Sensitivity of the screening tests ranged from 5.9% to 
100%, with specificity ranges of 47% to 100%, with multi-factor tests tending to 
demonstrate increased sensitivity and specificity rates. 
The Meads et al systematic review and meta-analysis on the prediction and prevention 
of pre-eclampsia [11] is a Health Technology Assessment (HTA) publication. The HTA 
is part of the National Institute for Health Research (NIHR), and produces independent 
research about the effectiveness and acceptability of different healthcare treatments and 
tests for those who use, manage and provide care in the NHS. The published reports 
directly influence decision-making bodies such as the National Institute for Health and 
Clinical Excellence (NICE) and the National Screening Committee (NSC). This report 
was used by both of these organisations in recent consultations on prenatal screening for 
pre-eclampsia [43]. Due to its influence on national policy, consideration and critique of 
its approach is warranted. The review used a 16-term search string to search four health 
databases – PubMED, EMBASE, DARE (the Cochrane Library) and MEDION 
                                                 
3 Where the spiral arteries leading from the maternal uterine vessels are assessed, with impaired flow 
being indicative of both a high-risk for pre-eclampsia and potential fetal growth restriction 
4 An assessment of maternal vasoconstriction, where increased vascular resistance is indicative of a high-
risk for pre-eclampsia 
5 A protein released by the developing fetus that is also used to predict the risk of Down’s syndrome. 
Lower than expected levels has been demonstrated to lead to an increased risk of pre-eclampsia 
6 A glycoprotein released by the placenta. Elevated levels are linked to increased likelihood of pre-
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(Methodological studies on systematic reviews of diagnostic and genetic tests), 
alongside contact with experts and forward and backward searches of reference lists. All 
study designs were included. No language restrictions were made. A pre-identified list 
of 11 ‘index tests’ were used for inclusion purposes. These index tests were selected 
following consultation with experts, and were prioritised on the basis of clinical 
relevance. Independent duplicate selection and extraction was undertaken to ensure 
accuracy. Quality assessment information were collected at the extraction stage. The 
electronic searches resulted in the review of 1210 full-text papers, and a further 40 were 
reviewed via reference list investigations. Of these, 1103 papers were excluded, leaving 
147 papers in the review. The review concludes that the quality of the studies, and the 
accuracy of the reviewed screening tests were generally poor. Only a few tests reached a 
pooled specificity above 90%, and it was noted that further investigation was required 
to support introduction of the test.  
The authors note some limitations of their review. This included that the selection of the 
tests for review was based largely on the 11 identified index tests, which reflected the 
opinion of the review team, and a small external group. No validity process (such as a 
Delphi survey [44]) was undertaken to strengthen this selection process, and the authors 
note this may have been appropriate. While a Delphi survey could have strengthened 
the validity of the index tests selected, it remains unclear why the list of index tests was 
used to begin with. The aim of the review was to ‘determine, among women in early 
pregnancy, the accuracy of various tests for predicting the later development of pre-
eclampsia and related complications’ [11]; no justification was given as to why this 
review subsequently restricted its search to the identified index tests. Restrictions are 
always required when conducting systematic reviews to avoid unworkable datasets [45], 
however, this approach could have excluded not only the single markers that were not 
considered of value by the expert panel, but also the many published papers assessing 
combination pre-eclampsia screening tests. The authors of the report do not mention 
combination tests, and the reason for exclusion, which appears to go against the stated 
aim of the review, is not justified.  
This extensive meta-analysis of single factor screening tests for pre-eclampsia has 
influenced UK national policy on whether screening should be introduced, with the 
National Screening Committee citing it as evidence that a lack of proven clinical utility 
remains [43]. Despite the exclusion of combination screening tests, this review 
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extensive research interest that the screening test has attracted, and the difficulties in 
finding one of clinical benefit.  
An alternative approach taken by the Gigu￨re et al team was to assess screening tests 
that combined biochemical and ultrasound combination markers for predicting pre-
eclampsia [42]. They used a 371 word search string in their review of two bibliographic 
databases, resulting in 37 articles, incorporating 71 different combinations of test, being 
included in the review. The screening tests included within this review appear to have 
greater accuracy than those within the Meads et al review, with higher performing tests 
demonstrating 93% sensitivity and 95% specificity. When comparing the accuracy 
results of the combined biomarkers tests versus the single factor screening tests, it 
seems that as pre-eclampsia is so heterogeneous in nature, a combination of two or more 
independent biomarkers could potentially increase test accuracy, as each would reflect a 
differing pathophysiological process. It remains unknown if this heterogeneity would 
require a variety of treatment options, or risk reduction interventions, individualised to 
the specific causes of each disease.  
Both a 2011 consultation by the NSC and the 2010 NICE guideline for antenatal care 
have concluded that there are currently no predictive tests for pre-eclampsia with 
satisfactory sensitivity and specificity rates. Therefore, currently, their use is not 
recommended by either organisation. 
2.6  THE SCREENING TEST IN QUESTION 
This thesis assesses the psychological impact and acceptability of a pre-eclampsia 
screening test that was introduced in two London hospitals in 2009. This screening test 
is based on a screening algorithm designed by Poon and colleagues [46]. As this 
screening test is central to this thesis, an extensive summary and critique of the key 
study is given below.   
2.6.1  STUDY SUMMARY 
The study used a prospective screening cohort design to derive specific algorithms for 
the calculation of patient-specific risks for early pre-eclampsia (developing prior to 34 
weeks), late pre-eclampsia (developing after 34 weeks) and gestational hypertension. 
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Exclusions were because of missing outcome data (n=417), a diagnosis of fetal anomaly 
(n=93), pregnancy loss prior to 24 weeks (147) or for cases where one or more episode 
of hypertension occurred during the pregnancy, but missing data meant that it was 
impossible to determine if this was caused by pre-eclampsia (n=27). All participants 
gave written informed consent. No mention is made of any women declining to take 
part. Outcome measures were recorded as early pre-eclampsia (pre-eclampsia 
developing prior to 34 weeks, 0.44% (n=34) of the 7797 base-cohort population), late 
pre-eclampsia (pre-eclampsia developing after 34 weeks gestation, 1.58%, n=123), 
gestational hypertension (1.74%, n=136), and controls (pregnancies that developed no 
complications and resulted in a live birth, 96.24%, n=7504).  
Additional data included history, blood pressure, pregnancy-associated plasma protein-
A (PAPP-A, a pregnancy hormone), and uterine artery pulsatility index (PI, a 
measurement of the variability of blood velocity in the uterine artery, measured via 
ultrasound scan) measurements. The history questionnaire gathered information on 
ethnicity, cigarette smoking, conception method, medical history, current medication, 
parity, obstetric history, family history of pre-eclampsia and current BMI. Maternal 
serum placental growth factor (PIGF, a pregnancy hormone) was also measured in a 
sub-sample of 627 women. All measurements were standardised.  
The researchers focused on early pre-eclampsia as this ‘is associated with increased risk 
of perinatal mortality and morbidity, and both short-term and long-term maternal 
complications’ ([46] p. 817). Various algorithms were developed to calculate a patient-
specific risk of early pre-eclampsia, late pre-eclampsia and gestational hypertension, 
using logarithmic transformation, multiple regression and calculation of multiples of the 
median (MoM). The detection and false-positive rates of these algorithms were then 
calculated. The selected algorithm would have detected 32 (93.1% of the 34) of the 
pregnancies that were subsequently affected by early pre-eclampsia, 44 (35.7% of the 
123) of those that developed late pre-eclampsia and 25 (18.3% of the 136) of those that 
developed gestational hypertension. An additional 375 (5% of the 7504) pregnancies 
that would not have developed a hypertensive disorder would have been found high risk 
by the algorithm, a five per cent false-positive rate. Therefore, of the 476 women that 
would be found screen positive by this screening algorithm, 101 (21.2%) would develop 
a hypertensive disorder. Of the 7321 women who would have been found screen 
negative, 192 would have developed a hypertensive disorder of pregnancy, giving a 
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population as high-risk, and 65.5% of them in the low-risk population, although 93% of 
those at the highest risk (those that develop early pre-eclampsia) are identified.   
2.6.2  STUDY CRITIQUE  
When published in ‘Hypertension’, the article was accompanied by an editorial 
commentary. This editorial was subtitled ‘A possibility at last!’ and commended the 
study methodology and findings. They conclude that “Poon et al are to be congratulated 
for developing a predictive model with the likelihood ratios for positive and negative 
tests needed for a clinically useful approach to predict early pre-eclampsia” [47] p. 748. 
The findings have been replicated using similar methodologies and sample groups, with 
the same or improved findings [48,49]. The many strengths of the study include its large 
total sample size, and its clear, replicable analysis techniques.  
The current best-practice tool for the reporting of cohort studies is the STROBE 
statement [50]. The statement provides best-practice guidance on how to report research 
well, rather than how to conduct research well. However, it is often assumed that if key 
elements of the study are not reported, then validity and generalisability can be 
questioned [51]. Appendix 4 provides the strobe statement checklist for cohort studies, 
along with an assessment of this study. Completion of the STROBE checklist identified 
some methodological concerns with this study. These are detailed below. 
GENERALISABILITY 
The location of the data collection is not discussed; it is unclear if participants were 
recruited from multiple or single centres. It has been pointed out [47] that the model 
requires testing within other populations to provide confidence that the results can be 
applied to other populations.  
The paper implies that data were taken from all eligible women who attended an 11 to 
13 week ultrasound scan, stating that all women attended for this appointment, and were 
enrolled into the study. No mention is made of any individuals that declined to 
participate, or who did not attend the appointment. Missing data are common in 
observational research [51].  It is surprising that during a 17-month recruitment period, 
no individuals declined a first-trimester ultrasound scan with the main purpose being to 
screen for Down syndrome. Uptake rates within the UK for the combined test for 
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[53]. Moreover, it is also surprising that every individual who attended for a first-
trimester ultrasound scan was agreeable to have a blood draw, which were linked to 
demographic details and medical history information, frozen and stored for research 
purposes. Comparable studies using stored biobank data have reported an uptake rate of 
76.4% [54]. The failure to report any missing data makes an assessment of the reported 
findings difficult. While missing data may not affect the analysis of the findings that the 
paper presents, its presence may introduce bias or affect generalisability of results [51]. 
The failure to report them makes an assessment of the complete data set difficult.  
SAMPLE SIZES 
While the cohort study consisted of a large sample, the PIGF measurement (a key 
measurement in the selected predictive algorithm) was taken from a sub-sample of 8% 
of the cohort. This sub-sample selection ‘was simply based on availability’ ([46], p. 
813). The 209 hypertensive patients were matched to the 418 controls by the date the 
sample was taken, rather than by matching for demographic data. The researchers 
asserted that the length of storage of the blood sample would have a greater predictive 
influence on developing pre-eclampsia than ethnicity, smoking status or BMI, despite 
identifying these as key risk factors in their introduction. There were significant 
differences in these demographic factors between the cohort and sub-samples, which 
introduced a risk of selection bias.  
The algorithm created in this study was based on the data from women who went on to 
develop early pre-eclampsia. The justification for this is that these are the pregnancies 
that suffer the greatest morbidity and mortality associated with the disease. This study 
consisted of 34 pregnancies that developed early pre-eclampsia, 29 of which had a PIGF 
measurement. An a priori power calculation was not feasible, as this was the first time 
this methodology was used, and therefore there was no basis for an expected sensitivity. 
The ratio of controls to cases was 229:1. 
POTENTIAL CONFOUNDING VARIABLES 
While the researchers identified many potential confounders for the development of pre-
eclampsia, there was a focus on medical factors such as, current medications, medical 
history, and method of conception. Limited assessment was made of the social aspects 
of the sample. Diet [28], exercise [55] and stress [56] have been shown to affect the 
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This cohort study recruited a sample that included women with a recognised risk factor 
for pre-eclampsia, such as a history of pre-eclampsia or pre-existing medical conditions. 
These women would be detected as high-risk by current NICE guidelines. Two recent 
studies have suggested that that their inclusion within the data set may have contributed 
to the higher sensitivity and specificity rates found [57,58].  
OTHER CONSIDERATIONS 
Other than the aforementioned missing data, the statistical analysis is sound and 
complete. Considering the total sample size, the investigators could have split the 
sample into one exploratory and confirmatory analysis; however, the team have 
conducted confirmatory analyses in subsequent studies [48,59-62] refining the 
algorithm after each study.   
The discussion includes a cautious interpretation of the results, considering other 
research. Unfortunately the authors fail to highlight any limitations of the study, 
although the authors stress then need for further, prospective, research to test the 
algorithms.  
The Fetal Medicine Foundation, a private organisation that generates income through 
prenatal screening, funded the research. While this does not impact the validity of the 
results presented, it is important to note that the authors, who of which are members of 
the foundation, may a vested interest in developing novel prenatal screening tests. 
 CRITIQUES OUTSIDE THE STROBE REMIT 
THE CLINICAL UTILITY OF THE ALGORITHM  
Alongside the methodological critique of the study, it is important to consider the 
clinical utility of the algorithm presented in the study. As noted, the detection of early 
pre-eclampsia provides a potential advantage due to its associated morbidity and 
mortality. An extension of this point is that the development of late pre-eclampsia or 
gestational hypertension rarely causes severe morbidity or mortality. This is because 
when pre-eclampsia develops after 34 weeks (which is after the development of the fetal 
lungs), delivery can be expedited with lower negative consequences [63]. Gestational 
hypertension that does not develop into pre-eclampsia is unlikely to affect the health of 
the mother or fetus during the pregnancy itself [14]. Therefore, there are further 
questions over the cost-benefit analysis of identifying these groups. This could be 
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finding, but that finding would not cause the woman or pregnancy any harms, and 
therefore the negative aspects of being found screen positive may outweigh the positive 
aspects. This algorithm would have detected 93.1% of those who had the largest 
potential benefit to being screened (i.e. 32 of the 34 early pre-eclampsia pregnancies). 
The algorithm identified four-times more unaffected pregnancies (n=476) than would 
have been affected by a hypertensive disorder of pregnancy (n=101), and 17-times more 
pregnancies (n=545) who would have a questionable benefit from being found screen 
positive than those that developed early pre-eclampsia (n=32).  
The clinical utility of these screening test remains untested, as no RCT has been 
conducted to compare outcomes such as maternal and/or fetal wellbeing. In 2014 an 
RCT commenced (the ‘ASPRE’ trial, ISRCTN 13633058) that will use the pre-
eclampsia screening test to identify women at increased risk of pre-eclampsia. Crucially, 
the primary aim of the ASPRE trial is to test the effectiveness of giving low-dose aspirin 
to those identified at high-risk, so that high-risk women will be randomised to aspirin or 
placebo arms. This differs from the way that the test was applied within the study site 
for this thesis. If low-dose aspirin is shown to have benefits for reducing pre-eclampsia, 
with no negative effects, then the most cost effective and safe intervention may be to 
provide aspirin to all pregnant women without prior testing [11]. This would be similar 
to taking folic acid to prevent fetal anomalies – a drug with no known side effects is 
taken in the hope that it will improve the health of a pregnancy, even when a risk has 
not been identified. Screening would result in both additional costs, alongside false-
negative pregnancies missing treatment. There may be advantages to providing 
screening tests for pre-eclampsia. For example, any subsequent increase in monitoring 
may prove beneficial, or may prompt positive changes in health behaviours. However, 
the clinical utility of the screening test cannot be tested without a randomised control 
trial. 
SUBSEQUENT RESEARCH 
Following its publication, attempts have been made to replicate the findings, both by 
others [57,58] and the same team [48,59-62]. Two studies by different research teams 
attempted to address the clinical utility issue highlighted above [57,58]. These studies 
used the same predictive algorithm, but restricted their sample to nulliparous women  
(not given birth, i.e. first-time pregnancies) without known pre-eclampsia risk factors. 
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previous pregnancy is associated with a very high negative predictive value. It was 
argued that biomarker prediction should target first-pregnancy women as the burden of 
disease is greater, and prediction using clinical risk parameters is not sufficiently 
accurate. Both studies concluded that the algorithm, performance for low risk 
nulliparous women was not sufficient to warrant introduction as a clinical screening 
test. 
 
SUMMARY OF CRITIQUE 
This critique of this particular pre-eclampsia screening test raises both strengths and 
limitations of the screening algorithm that was implemented in the two London trusts. 
Despite the identified limitations, this study remains a well conducted investigation, 
with a large sample size. The development of this screening test has the potential to 
greatly improve the outcome of many pregnancies.   
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2.7  CHAPTER SUMMARY  
Pre-eclamspia is a heterogeneous condition, which is not yet fully understood. Current 
screening involves reviewing maternal risk characteristics only. This results in low 
sensitivity and specificity. Therefore large investments into developing a biochemical 
screening test has been made. It is felt that these screening tests will improve outcomes 
through increased detection, increased ease for conducting research and in preventing 
postnatal psychological trauma. However, these outcomes have yet to be demonstrated. 
While extensive research has taken place to discover risk-reduction interventions for 
pre-eclampsia, and to assess the accuracy and utility of screening tests for pre-
eclampsia, their benefits and harms remain unproven. There are some concerns 
regarding the specific pre-eclampsia screening test that is the focus for this thesis. This 
includes methodological concerns regarding generalisability, sample sizes and 
confounding variables, alongside the clinical utility of the screening test.  
The combined annual birth rate of the hospitals that have introduced this screening test 
is around 11,000. That equates to a large number of women who were offered a clinical 
screening test based on the results of one study. An assessment of the clinical utility of 
the screening test is beyond the scope of this thesis. Instead, its introduction provided a 
first opportunity to make an assessment of the potential psychological impacts and 
acceptability of the screening test. Research interest in screening tests for pre-eclampsia 
remains high, with over 40 articles published on the topic in 2012. This interest suggests 
that more women will be exposed to this screening information in the future, and 
therefore the research within this thesis is urgently needed to allow women and 
healthcare professionals to make an informed decision on whether or not it is an 
appropriate screening test for them. 
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3.1  INTRODUCTION 
This thesis will be addressed using an exploratory sequential mixed-methods approach, 
embedded within the pragmatist research paradigm (see descriptions below). A 
theoretically informed approach to research enquiry and analysis is taken throughout the 
thesis. This chapter outlines the philosophical, theoretical and methodological choices 
taken within this thesis. 
The aim of this thesis is to explore the potential consequences and acceptability of a 
new first-trimester prenatal screening test. This screening test differs from previously 
studied screening tests for three reasons: 
1.  Screen-to-observe: There is no definitive diagnosis of the screening test once a 
high-risk result is identified, resulting in uncertainty until either the pregnancy 
ends, or the condition develops; 
2.  Risk to both: Pre-eclampsia provides a morbidity and mortality risk to both 
mother and fetus – until now prenatal screening tests provide risk information 
for either mother or fetus; 
3.  Severe personal consequences: This is the first prenatal screening test that 
informs a woman that her pregnancy could have fatal consequences. While 
previous assessments have been made of the consequences of screening tests 
that have severe personal consequences (e.g. for breast cancer, Huntington’s 
disease), these are not related to pregnancy. 
The novelty of this screening test as compared to those previously studied requires an 
exploratory assessment of potential consequences and acceptability to women, to inform 
future research into psychological consequences such as anxiety or prenatal attachment.  
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3.2  PHILOSOPHICAL FRAMEWORK FOR THE THESIS 
Philosophical positions are framed in various ways, generally in opposing viewpoints, 
contrasting research paradigms or comparing methodological approaches. These 
arguments stem from beliefs regarding what constitutes knowledge, and the best way to 
investigate scientific phenomena. These issues are discussed briefly below. 
3.2.1  EXPLORING RESEARCH PARADIGMS 
A research paradigm provides a framework from which a researcher approaches the 
development of knowledge [1]. They provide patterns and practices that regulate 
inquiry within a discipline [2]. Here, four research paradigms that have been used 
within action health research are considered. Positivism is a research paradigm that 
believes that knowledge has an absolute existence that can be measured, and is reliant 
on control and the removal of bias [3]. The positivist approach aims to control and 
explain the phenomena in question, in an objective, measurable and generalisable way 
[4]. The researcher is seen as an expert, independent of the study. Positivists believe that 
it is possible to transfer the assumptions and methods of natural sciences to the study of 
social objectives [5]. An alternative view to positivism is presented by post-positivism. 
Post-positivists feel that human knowledge is based on conjectures, and that therefore 
there is not an absolute truth that positivism suggests, but rather an ‘objective truth’ that 
can be sought through replication [6]. They feel that the researcher can influence what 
they are attempting to study or observe [7]. The interpretivist approach focuses on 
understanding the meaning that individuals ascribe to their actions, and the reactions of 
others [8]. The critical social theory approach focuses on the study of social institutions 
and issues of power [9].  
Each of these four paradigms has contributed greatly to the scientific advancement of 
health research. The existence of the many differing paradigms, relating to the many 
types of ontologies and epistemologies, is evidence in itself that they represent 
subjective constructs, rather than objectively ‘true’ concepts [10]. Paradigms, therefore, 
represent a way of doing research, rather than a way of defining philosophical positions. 
It can be argued that adherence to a particular paradigm places the methodology central 
to research decisions, rather than accurate assessment of the research question [11].  An 
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plurality’ [12]. This approach enables the knowledge developed from one paradigm to 
complement what has been developed within another [13]. It has been suggested that 
within any discipline that studies human beings, it is perhaps not feasible that only one 
paradigm could explain, describe, predict and change all the discipline’s phenomena 
[14]. The mixed method approach proposed by the pragmatist paradigm is defined as 
‘research in which the investigator collects and analyses data, integrates the findings, 
and draws inferences using both qualitative and quantitative approaches or methods in a 
single study or a program of inquiry [15]. It is felt to have three key advantages over a 
unitary approach [16]; (i) triangulation (using different methods to get at the same 
underlying truth, by seeking corroboration between methods) (ii) understanding (to 
elaborate and explain results) and (iii) development (the results from one research 
method can be used to guide research questions in subsequent studies, so that a 
qualitative interview study can identify what issues require larger scale quantitative 
investigation).  
3.2.2    CRITIQUE OF THE PRAGMATIC PARADIGM 
As outlined above, Pragmatism abandons the traditional perception that ontology and 
epistemology are foundations upon which social scientific inquiry should be based [17]. 
Critique of the pragmatist paradigm suggest that its proponents tend not to consider the 
philosophical issues of research design, and that therefore the research lack 
argumentative coherence and validity [18]. It is also argued that the focus on the 
research question results in a lack of reflexivity in the research process, and therefore 
methodological flaws are not addressed [8]. It is also suggested that pragmatist, mixed 
methods designs favour quantitative data over qualitative work, with the qualitative 
research being exploratory introduction to the ‘more important’ quantitative research 
that follows [8]. Some suggest that mixing quantitative and qualitative methods results 
in a lack of ‘purity’ and expert application, that subsequently affects interpretation of 
data [8] and that rigor can be compromised [18].   
The majority of the critiques aimed at pragmatism and mixed methods research are 
targeted at researchers who do not consider the philosophical implications of using 
pragmatism [18], and who lack rigour in their application of methodologies [19]. It is 
clear that a researcher cannot pick and choose a methodology without appreciating the 
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how to rigorously apply it. Indeed, a mixed methods researcher is required to have 
sufficient knowledge of all the methodologies they use, and an openness to learn more 
as the research question demands. However, when armed with this training, mixed-
methods research, grounded in pragmatism, bring elements of the various research 
paradigms together to produce research evidence that is grounded in best practice.   
3.2.3  PHILOSOPHICAL POSITION OF THIS THESIS 
A midwifery researcher completed this PhD thesis. It has been supervised by a 
Psychologist, a Nurse and a Midwife. Further methodological support has been gained 
from Medics, Sociologists and Statisticians.  From the outset, exploration of the 
potential research questions presented by the pre-eclampsia screening test illustrated 
that that a cross-discipline, mixed methods approach would be required. 
The author of this thesis feels that rather than being directed by a philosophical position, 
the approach to research should be guided by the identified research question. 
Therefore, this thesis and the work conducted within it, comes from a pragmatist 
position. While the importance of the various philosophical debates are recognised, the 
diverse perspectives both between and within the various ontological and 
epistemological perspectives can create a barrier to developing the evidence base. There 
is a value in selecting the most appropriate research methods to address specific 
research questions, and this is given greater importance than a sense of philosophical 
coherence.  
In view of this, the thesis takes a mixed-methods approach within the Pragmatic 
paradigm. It uses a combination of systematic review, qualitative, case-control and 
survey methodologies to address the research questions. An ‘exploratory design’ mixed 
method approach was selected [20]. The studies were designed in a sequential manner, 
with each one being used to identify further topics of investigation. This is illustrated in 
Figure 3.1. No methodology was chosen because of its ‘fit’ within a philosophical 
framework, but rather because it appeared the best way to answer the identified 
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3.3  THEORETICAL FRAMEWORK FOR THE THESIS  
The empirical work in this thesis was guided by psychological theory. The Common 
Sense Model of Self-Regulation (CSM) [21] is the overarching theory for this thesis. 
Other theories were incorporated to guide specific studies within the thesis and these are 
discussed in greater detail within the relevant chapters. The CSM is discussed in detail 
below.  
3.3.1    THE COMMON SENSE MODEL OF SELF-REGULATION 
Women’s reactions to a pre-eclampsia screening test are likely to be influenced by their 
perception of their risk, in other words, their expectation regarding the probability of the 
condition occurring [22]. A woman’s assessment of her risk for pre-eclampsia may be at 
odds with her medically determined risk [23], which may influence her willingness to 
follow health advice [24,25].  The attribution of a ‘high-risk’ label in pregnancy has 
been shown to negatively influence psychosocial states [26]. Conversely, there is a 
potential protective benefit to anticipating the development of pre-eclampsia, since the 
unexpected occurrence of the condition has been found to lead to increased cases of 
psychological distress post-delivery [27,28]. Alongside the potential harms or benefits 
of receiving such risk information, there are potential consequences of the increased 
monitoring that is likely to occur following a high-risk result, such as influencing the 
place of birth women choose [29] or satisfaction with increased continuity of care and 
carer [30].   
A well supported psychological theory that explains individual reactions to screening 
information is the Common-Sense Model of Self-Regulation (CSM) [21]. This is a 
parallel processing model explaining how people react to, evaluate and cope with 
threatening health information
7. The parallel processes for dealing with a given health 
threat involve managing the danger (the behavioural pathway) and the fear (the 
emotional pathway) generated by the screening information. According to this model, 
                                                 
7 Although presented here in relation to health threatening information, the CSM is also 
applied to actual illness, whereby the illness representations and coping strategies are 
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an individual compares new risk information, such as that provided by a screening test 
result, with their prior sense of risk developed from their own experience and more 
general understanding. This leads to an ‘illness representation’, consisting of six key 
dimensions: identity (the distinctive label and symptoms that an individual associates 
with the threat), causes (e.g. genetics versus luck versus behaviour), control/cure (how 
the threat can be managed, reduced or cease e.g. medicine, exercise, time) consequences 
(e.g. how much it will disrupt daily activity), coherence (how the person makes sense of 
the condition) and timeline (e.g. when the condition is likely to develop, and how long it 
will last for). Following this evaluation, coping mechanisms are initiated to relieve 
emotional (fear responses) or cognitive (danger responses) reactions to the threat. 
Coping mechanisms include avoidance [31] (internal rationalisation to aid ignoring or 
denying the threat), cognitive reappraisal [32] (thinking about the threat differently, but 
acknowledging its existence), information seeking [33] (seeking further information 
about the threat to aid understanding), social support [34] (seeking emotional support 
from others) and problem-focused coping [35] (behavioral changes aimed at reducing 
risk, such as medication adherence or increased exercise). A meta-analysis of 45 
empirical studies using the CSM [36] has shown that perceived controllability is related 
to active coping and cognitive reappraisal. The ‘consequences’ illness representation is 
associated with avoidance/denial, and expressing emotions, in that the more serious the 
consequences are perceived to be, the greater the avoidance or denial and the less 
emotion are expressed. This suggests that perceiving oneself to have more control over 
pre-eclampsia will result in less distress, and greater initiation of problem-solving or 
self-care behaviours (such as changing diet).  
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3.4  METHODOLOGICAL CONSIDERATIONS FOR THE THESIS 
To conduct the qualitative aspect of this research, Framework Analysis was chosen over 
other analytical approaches [1]. Alongside Framework Analysis, two alternative 
methodologies were considered – grounded theory (GT), and interpretive 
phemenological analysis (IPA). This section explains why the Pragmatist Deductive 
approach that directed this thesis resulted in the selection of Framework Analysis. 
There are numerous methodological approaches to qualitative research, with different 
methods appropriate for answering different questions, in much the same way as 
different statistical tests are used for different types of questions and data sets. The 
choice of method therefore, is dependent on the question being asked, and to an extent 
the philosophical standpoint of the investigators [37]. Just as the selection of an 
inappropriate statistical test would make data analysis invalid in a quantitative study, it 
is imperative that an appropriate qualitative methodology is used to ensure the findings 
address the research aims [38].  
GT, originally devised by Glaser and Strauss in 1967 [39] is a popular qualitative 
methodology. It is used to develop theory - or a model - from the data to explain the 
phenomena being explored. It utilises purposive sampling that is informed by the data 
being collected, so the responses from an interview would dictate the type of respondent 
selected for a subsequent one, in order to provide support or contradict the developing 
model. The technique recommends no pre-research literature reviews or use of a 
theoretical framework in which to base the study as this will create pre-conceptions that 
may colour the data being analysed [40]. Data are collected until saturated [41], that is, 
until no new themes or ideas develop after conducting further interviews.  
IPA also uses a thematic approach to data analysis, looking for commonalities and 
contradictions within transcripts. It is concerned with the lived experience of the 
individual on the phenomena in question, rather than generating an overarching model 
of the phenomena. As such, it aims to have small, homogenous samples, including use 
of single case studies. Proponents of IPA recommend that ‘theoretical constructs should 
not shape questions used within the interviews, or indeed search for traditional concepts 
during the process of analysis” [42], page 136. Instead, theory is used to explain the 
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It is accepted that highly inductive qualitative research designs involving the use of 
emergent conceptual frameworks contribute a great deal to the field of health research 
[43]. However, there are disadvantages to this approach. It has been argued that 
orienting concepts derived from theory can sensitise researchers to relevant issues, 
processes, and interpretations that they might not have identified themselves using an 
inductive method [44]. Framework Analysis was selected due to its accommodation of 
using pre-existing theoretical literature to shape the design, implementation and analysis 
of the data. Alongside the noted strength of theory-driven research [45], it was felt that 
the novelty of the pre-eclampsia screening test required guidance from previous 
literature and theory to strengthen the study. A theoretically-led approach also provided 
greater structure and guidance for a novice researcher.  
In view of these factors, Framework Analysis was selected as an appropriate 
methodology. It lends itself to all epistemological and ontological approaches, as well as 
providing a clear structure for identifying themes, categories and sub-themes with a 
systematic process for summarising and synthesising the data. Alongside these factors, 
the in-built auditability of the method would facilitate data management and handling 
through all the key stages. The actual process of the Framework methodology, and its 
facilitation of thematic analysis [46] is discussed in greater detail in Chapter 4.  
It is felt important to note that the selection of Framework Analysis over other 
methodologies is not to be taken as a value judgement on the effectiveness of other 
methodologies, but rather that it was deemed the most appropriate for the aims of the 
study.   
3.5  CHAPTER SUMMARY 
This chapter has outlined the philosophical, theoretical and methodological approaches 
used to investigate the research questions addressed in this thesis. A sequential mixed 
methods approach embedded within the pragmatic research paradigm was taken. The 
research was informed by various theoretical approaches, with the largest influence 
being the CSM. Framework Analysis was chosen to conduct the qualitative work within 
this thesis, as it provided the best fit for its philosophical and theoretical underpinnings. 
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CHAPTER 4: ASSESSING THE PSYCHOLOGICAL EFFECTS 
OF PRENATAL SCREENING TESTS FOR MATERNAL AND 
FETAL HEALTH CONDITIONS: A SYSTEMATIC REVIEW.  
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Harris JM, Franck L, Michie S. Assessing the psychological effects of prenatal 
screening tests for maternal and foetal conditions: a systematic review. Journal of 
Reproductive and Infant Psychology 2012;30:222–46. 
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4.1  ABSTRACT  
Background: Fetal medicine advancements have increased the variety of prenatal 
screening tests that can be offered to women. Prenatal screening tests may have positive 
or negative effects to women. This systematic review aims to review the published 
literature to determine the psychological effects of prenatal screening tests for 
conditions that affect the mother, as compared to screening tests for conditions that 
affect the fetus.  
Method: Seven electronic databases were searched for research reports on the 
emotional, behavioural and cognitive effects of prenatal screening tests published in the 
English language before December 1, 2011. Studies of diagnosed conditions, rather than 
screening tests, were excluded. 
Results: 18 studies investigated screening tests with maternal health implications and 
33 studies and 4 reviews investigated tests with fetal health implications. While tests 
with fetal health implications were associated with increases in maternal anxiety, tests 
with maternal health implications were not. Neither were associated with behavioural 
outcomes. Both types of test were associated with cognitive outcomes such as increased 
maternal responsibility and negative perceptions of health.   
Conclusions: This review found that women experienced greater anxiety following 
prenatal screening tests that had an impact on fetal health compared with those that had 
an impact on maternal health. However, this is based on relatively few studies and there 
is a need to evaluate the impact of such screening tests before they are clinically 
introduced on a large scale.  
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4.2  INTRODUCTION 
A key aim of this thesis is to assess the psychological impact of a first-trimester 
screening test for pre-eclampsia. Chapter one explored some of the literature 
investigating the psychological consequences of prenatal screening. However, 
traditionally, prenatal screening tests have provided risk information about either the 
health of the fetus, as in the case of Down’s syndrome screening, or about the health of 
the pregnant woman, as in the case of diabetes screening. The intended outcomes of 
screening tests are to provide reproductive choices (e.g., whether to terminate or 
continue the pregnancy)[1] or to minimise harm to the mother or fetus during the 
remainder of the pregnancy (as occurs for gestational diabetes, HIV and 
exomphalos)[2]. The impact of pre-eclampsia screening may differ because pre-
eclampsia affects both the mother and the fetus, and currently has no associated risk 
reduction intervention.  
As a starting point for this investigation, a systematic review of the literature was 
conducted and  the impacts of screening tests that focus on the fetus with screening tests 
that focus on the mother were compared. Knowledge gained from this SR informed the 
subsequent exploratory studies on  potential benefits and consequences of pre-eclampsia 
screening. 
Pregnancy is an uncomplicated life event for the majority of women. It is also a time 
when women are faced with screening tests, the purpose of which is to assess risk of 
serious health problems. The UK’s National Screening Committee endorses screening 
tests where the benefits outweigh any physical and psychological harm[3]. Previous 
systematic reviews of the psychological effects of prenatal screening have concentrated 
on disease-specific screening tests, focusing primarily on those with implications for 
fetal health[4-7]. No systematic literature reviews have been identified of studies that 
investigate the psychological effects of screening tests for conditions that affect 
maternal health.  
Informing a pregnant woman that they may have a condition such as HIV or gestational 
diabetes may have a different psychological impact than informing them of an increased 
risk of a fetal condition such as Down’s syndrome or exomplalos. Evidence of 
psychological impact can inform policy and clinical practice to optimise support given 
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The aim of this systematic review is to identify and evaluate the published research 
literature on the psychological effects for pregnant women of screening tests for 
conditions that affect their health, compared to those that affect the health of the fetus. It 
reviews the behavioural, emotional and cognitive effects of prenatal screening for 
conditions that have health implications for (a) the mother and (b) the fetus in three 
different contexts: Prior to results being given, following receipt of a positive (high risk) 
screening test result and following the receipt of a negative (low risk) screening test 
result. 
4.3  METHODS 
4.3.1  APPROACH 
Several different approaches can be taken when undertaking a systematic review. 
Although all systematic reviews use formal, explicit methods to describe and synthesise 
evidence, they vary considerably in the types of questions they aim to answer[8]. The 
approach chosen depends on the research question. Due to the anticipated heterogeneity 
of the data set, this review followed the approach outlined by the Centre for Reviews 
and Dissemination[9], which provides detailed guidance on narrative synthesis that is 
useful when synthesizing a broad literature with a range of study designs.  
4.3.2  SOURCES 
Seven electronic databases (PsycINFO , MEDLINE, EMBASE, CINAHL, Cochrane, 
BNI and MIDIRS) were searched, with strategies informed by those used in reviews 
conducted by the National Institute of Clinical Excellence[10], the Cochrane 
Database[11] and the Health Technology Assessment programme [12,13].  The search 
strategy of 197 terms was adapted to each database according to the advice of an 
information scientist.  Experts in midwifery, obstetrics, genetic counselling and health 
psychology were asked to identify relevant studies to validate the strategy. All databases 
were searched from January 1965 through November 2011. The references of the 
included articles were hand searched to identify further studies. The review protocol is 
available in Appendix 5, while the search strategies can be seen in Appendix 6. Page 93 of 316    Chapter 4: Systematic Review  
4.3.3  STUDY SELECTION 
All records were imported into a bibliographic referencing software programme 
(ENDNOTE version X4 Thomson, Philadelphia, PA, USA). Duplicate references were 
deleted. The thesis author (JH) examined the titles, abstracts and full-text articles to 
screen for relevant studies. A second researcher independently examined 10% of the 
titles, abstracts and full texts to allow assessment of inter-rater reliability.  Discrepancies 
were resolved through discussion. Percentage agreement scores were 93% at the title 
stage, 95% at the abstract stage and 94% for the full text stage. The second researcher 
was a health psychologist.  
Inclusion criteria were structured using the PICO process[14]: Population: Pregnant 
women in early or late pregnancy undergoing screening; Interventions: prenatal 
screening with maternal health implications; Comparator: prenatal screening with fetal 
health implications; Outcomes: psychological effects including emotions, health-related 
behaviours and cognitions. All study designs were included. Excluded studies were 
those investigating hypothetical tests, consent and confidentiality, uptake rate, 
knowledge of the condition, or that assessed the effects of a confirmed diagnosis rather 
than a positive screening test result.  
4.3.4  DATA EXTRACTION, QUALITY ASSESSMENT AND SYNTHESIS 
A data extraction form was designed for the review to capture both qualitative and 
quantitative data. This form captured 28 items of information about the studies and can 
be seen in Appendix 7.  
Methodological assessment for bias was completed using NICE methods (National 
Institute for Health and Clinical Excellence, 2009). This approach uses a checklist 
approach to look at selected quality factors depending on the study design. The quality 
assessment templates can be found here: http://publications.nice.org.uk/the-guidelines-
manual-appendices-bi-pmg6b. 
Due to the heterogeneity of the data set, a meta-analyisis was not possible. Therefore a 
narrative synthesis is provided, following the guidance of the Centre for Reviews and 
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4.4  RESULTS 
FIGURE 4.1 PRISMA 2009 FLOW DIAGRAM 
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4.4.1  OVERVIEW OF INCLUDED STUDIES 
Figure 4.1 illustrates the PRISMA flow-chart of the search strategy. The reasons for 
exclusion are listed in Appendix 8.  In total 23,093 potentially relevant studies were 
identified from the searches, of which 283 were selected for full assessment.  Fifty-five 
articles identified by the electronic searches met the inclusion criteria. Hand-searching, 
reference list searching and contacting experts did not identify additional articles.  
Eighteen studies and no reviews were found on prenatal screening tests with a maternal 
health impact; 33 studies and 4 reviews were found on prenatal screening tests with a 
fetal health impact.  
The 18 empirical studies of prenatal screening with a maternal health impact were 
conducted in nine countries (Table 4.1). Six were from the UK, three from Canada, two 
each from Australia and South Africa and one each from Ghana, Hong Kong, India, 
Ivory Coast and Zambia. Three studies investigated screening tests for gestational 
diabetes and 15 for HIV. Two studies investigated behavioural effects, 11 emotional 
effects and 12 cognitive effects of prenatal screening. Thirteen studies were cohort 
studies, five used qualitative methods and one used a mixed methods approach. Two 
studies were explicitly informed by theory.  
There were four reviews on screening tests with fetal health impact. Three reviews 
focused on ultrasound screening[5,7,15] and one on fetal anomaly screening[4] (Table 
4.2). Thirty-three empirical studies were identified that were not included within the 
review studies, which were from 11 countries: eight were from Sweden, seven from the 
USA, four each from Taiwan and Australia, three from the UK, two each from Germany 
and the Netherlands and one each from Canada, Egypt, Singapore, and Turkey. Two 
studies investigated screening tests for group-B streptococcus, two for haematological 
disorders, 15 for ultrasound screening and 18 for serum screening for fetal anomalies, 
including for Down’s syndrome and spina bifida. Four studies examined the behavioural 
impact, 30 the emotional impact and 20 the cognitive impact of the screening tests. 
Twenty-four studies used a quantitative approach, with two Randomised Control Trials 
(RCTs) and 22 cohort studies, and eight used qualitative methods. Two of the studies 
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The assessments for bias for prenatal screening tests with a maternal health impact are 
shown in Figure 4.2 for qualitative studies and Figure 4.3 for cohort and cross-sectional 
studies. The assessments for bias for prenatal screening tests with a fetal health impact 
are shown in 4.4 for qualitative studies, 4.5 for cohort and cross-sectional studies, 4.6 
for systematic reviews and 4.7 for RCT’s. Although generally acceptable across all 
study designs, the potential for bias was greater in studies concerning screening tests 
with a maternal health impact.  
The potential for bias was greater in studies concerning screening tests with a maternal 
health impact.  Four of the five qualitative studies (80%) investigating maternal health 
impacts demonstrated potential for analysis and design biases, and nine of the 14 (64%) 
cohort studies demonstrated potential for selection bias. These problems were much less 
frequent in studies focusing on fetal health impacts. Of the qualitative studies, 22% 
were unclear regarding the analytical approach while 32% of cohort studies had unclear 
or high risks for selection bias.  
4.4.2  BEHAVIOURAL IMPACT - HEALTH IMPLICATIONS FOR THE 
MOTHER 
Two studies (n=813) found a behavioural impact from screening tests with a maternal 
health impact. A cross-sectional study found evidence that receiving positive screening 
test results for gestational diabetes can have a beneficial effect on the diet of pregnant 
women, with 68% of the women found to be at-risk for gestational diabetes reporting 
that they had improved healthy eating behaviours 1 year after the pregnancy[16].  It is 
unclear if the change in behaviour was an outcome of receiving the screening test result 
alone, or of the subsequent treatment for the gestational diabetes. Another cross-
sectional study found that safe sex practices were improved by the offer of prenatal HIV 
screening, with 34% more women (McNemar test P < 0.01) discussing safe-sex 
practices and increasing condom use when offered a prenatal screening test, even if they 
declined to be screened[17] (Table 4.3). The cross-sectional designs make it impossible 
to assess if it is the screening test itself, or other factors that were responsible for the 
observed or reported changes in behaviour. Based on these few studies, there is 
insufficient evidence to suggest that prenatal screening for conditions with maternal 
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4.4.3  BEHAVIOURAL IMPACT – HEALTH IMPLICATIONS FOR THE 
FETUS 
Three of the systematic reviews on screening tests with a fetal health impact looked at 
the effect the test had on mothers’ health behaviours. Nabhan’s review of high-feedback 
ultrasound screening tests[7] versus standard feedback discussed one study of 129 
participants showed a decrease in smoking (RR 2.93; 95% confidence interval (CI) 1.25 
to 6.86) and alcohol (RR 2.96; 95% CI 1.15 to 7.60) consumptions when in the higher 
feedback group. However, both the Bricker[6]  and Baillie[5] reviews examined 
smoking rates of pregnant women before and after routine ultrasound screening tests 
and found no evidence that the screening tests influenced women’s health behaviours. 
Alcohol consumption was not discussed in these reviews. 
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TABLE 4.1 - STUDIES WITH MATERNAL HEALTH IMPLICATIONS 
 
Screening 
test  Reference  Number of 
Participants  Research Aims 
Design, 
Method and  
Theoretical 
Basis 
Measures  
1  Diabetes   (Griffiths, 
Rodgers, & 
Moses, 1993)  
Australia 
103  
54 GDM 
49 Controls 
Compare attitudes towards 
screening of ♀ with and 
without GDM 
Cross sectional 
Survey 
Likert scale 
2  Diabetes   (Kerbel, 
Glazier, & 
Holzapfel, 
1997) 
Canada 
813  
89 false 
pos 
496 neg 
228 not 
tested 
What are the adverse effects of 
a false-positive screen for 
gestational diabetes 
Longitudinal 
Survey 
Anxiety – STAI, 
CESDS, perceived 
health and 
concerns about 
newborn 
3  Diabetes   (Rumbold & 
Crowther, 
2002) 
Australia 
212  
150 neg 
37 false 
pos 
25 true pos 
Does screening for GDM 
reduce perception of health? 
Longitudinal 
Survey 
Anxiety – STAI, 
Depression - 
EPDS and SF-36. 
Further questions 
on perception of 
health, concerns 
for newborn, and 
screen process. 
4  HIV   (Stevens, 
Victor, Sherr 
et al., 1989)  
UK 
155  Testing acceptability of 
screening 
Cross sectional 
survey 
Questionnaire 
responses 
5  HIV   (Sherr, 
Jefferies, 
Victor et al., 
1996) 
UK 
76  Assessing the psychological 
impact of HIV testing 
Cross sectional 
survey 
Questionnaire 
responses 
6  HIV   (Sherr, 
Bergenstrom, 
Bell et al., 
1998)  
UK 
697  Exploring ethnic minority 
differences in antenatal HIV-
testing 
Cross sectional 
Survey 
Questionnaire 
responses 
7  HIV   (Baxter & 
Bennett, 
2000),  
UK 
137 
surveyed 
12 
interviews 
What do pregnant women think 
about antenatal HIV testing? 
Qualitative & 
Cross 
Sectional 
Survey 
Interview 
responses and 
survey results 
8  HIV   (Katz, 2001)  
Canada 
32  
21 
screened,  
11 declined 
Describe how pregnant women 
experience prenatal HIV 
screening 
Qualitative   Interview 
responses 
9  HIV   (Sherr, 
Bergenstrom, 
Bell et al., 
2001)  
UK 
154  Provide insight into the nature 
of HIV screening discussions 
within antenatal care 
Field 
observation 
Assessment of 
worry -recorded as 
high, raised or no 
effect 
10  HIV   (Sherr, 
Hackman, 
Mfenyana et 
al., 2003)  
South Africa 
23  Establishing the attitudes of 
women to HIV testing and 
counseling as a routine 
service.  
Qualitative  Interview 
responses 
11  HIV   (Yin, Shing, 
& Hung, 
2003) 
1519  Maternal acceptance of HIV 
screening 
Cross sectional 
survey 
Questionnaire 
responses 
12  HIV   (Rogers, 
Meundi, 
Amma et al., 
2006)  
India 
202  HIV related knowledge, 
attitudes benefits and risks of 
HIV-testing 
Cross sectional 
Survey 
Questionnaire 
responses 
13  HIV   (Thierman, 
Chi, Levy et 
al., 2006) 
1060  Predictors for HIV testing  Cross sectional 
survey 
Questionnaire 
responses 
14  HIV   (Dorval, 
Ritchie, & 
Gruslin, 
2007) 
Canada 
231 
188 
screened 
43 declined 
How does knowledge and 
attitude influence screening 
rates? 
Cross sectional 
Survey 
Questionnaire 
responses  Page 99 of 316    Chapter 4: Systematic Review  
 
Screening 
test  Reference  Number of 
Participants  Research Aims 
Design, 
Method and  
Theoretical 
Basis 
Measures  
15  HIV   (de Zulueta 
& Boulton, 
2007), UK 
32 
26 
screened,  
6 declined 
Explores pregnant women’s 
responses to routine HIV 
testing 
Qualitative 
Prospect 
theory 
Interview 
responses 
16  HIV   (Dube & 
Nkosi, 2008) 
South Africa 
40  To determine factors relating 
to acceptability of HIV testing 
by pregnant women 
Cross sectional 
Survey  
Health Belief 
Model 
Questionnaire 
responses, 5 point 
scale 
17  HIV   (Moyer, 
Ekpo, 
Calhoun et 
al., 2008)  
Ghana 
101  Explore optimism/ pessimism, 
knowledge of HIV and 
attitudes towards screening 
Cross sectional 
Survey 
LOT-R, SF-12 
18  HIV   (Desgrees-
Du-Lou, 
Brou, Djohan 
et al., 2009),  
Ivory Coast 
710  What are the beneficial effects 
of offering prenatal HIV 
counselling and testing? 
Cross sectional 
Survey 
Questionnaire 
responses 
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TABLE 4.2 - STUDIES WITH FETAL HEALTH IMPLICATIONS 
 
Screening 
test  Reference 
Number of 
Participant
s 
Research Aims 
Design, 
Method and  
Theoretical 
Basis 
Measures 
19  Anomaly 
screening 
 (Berne-
Fromell & 
Kjessler, 
1984)  
Sweden 
938 
699 
screened 
239 
controls 
Does screening increase 
anxiety? 
Longitudinal 
Survey 
Anxiety – VAS 
20  Anomaly 
screening 
 (Robinson, 
Hibbard, & 
Laurence, 
1984)  
UK 
312 
176 screen 
pos 
136 screen 
neg 
Assessing anxiety in mothers 
undergoing screening for fetal 
neural tube defects. 
Longitudinal 
Survey 
Anxiety - STAI 
21  Anomaly 
screening 
 (Burton, 
Dillard, & 
Clark, 1985) 
USA 
356 
112 false 
pos 
52 amnio 
192 
controls 
Assess the psychological 
impact of screening on 
pregnant women with false 
positive elevations of maternal 
serum alpha-fetoprotein  
Longitudinal 
Survey 
Anxiety – STAI 
and depression 
22  Anomaly 
screening 
 (Earley, 
Blanco, 
Prien et al., 
1991)  
USA 
92 
46 false 
pos  
46 true neg 
Investigating attitudes toward 
screening from those receiving 
false-positive or true-negative 
results.  
Cross sectional 
survey 
Anixety – LIKERT 
scale. 
Desire to repeat 
screening 
23  Anomaly 
screening 
 (Green, 
Hewison, 
Bekker et 
al., 2004)  
UK 
78 studies 
included 
To address questions 
concerned with knowledge, 
anxiety, factors associated 
with participation/non-
participation in screening 
programmes. 
Systematic 
review 
Narrative 
Synthesis 
 
24  Anomaly 
screening 
 (Ng, Lai & 
Yeo, 2004) 
Singapore 
109 
 
To assess anxiety levels in 
mothers with low-risk 
pregnancies before and after 
offering routine serum 
screening. 
 
Longitudinal 
Survey 
Anxiety –STAI 
25  Anomaly 
screening 
 (Öhman, 
Saltvedt, 
Grunewald et 
al, 2004)  
Sweden 
2026 
1030 
screened 
996 
controls 
Evaluate the effect of 
screening on anxiety 
RCT  Anxiety  - STAI, 
Worry - CWS  
(Cambridge worry 
scale) and 
Depression - 
EPDS 
26  Anomaly 
screening 
 (Lobel, 
Dias, & 
Meyer, 2005) 
USA 
87  Identify factors associated 
with emotional distress for 
pregnant women undergoing 
screening   
Cross sectional 
survey 
STIP  (Spielberger 
State-Trait 
Personality 
Inventory) 
27  Anomaly 
screening 
 (Williams et 
al., 2005)  
UK 
14  Exploring experiences of first 
trimester screening 
Qualitative   Interview 
responses 
28  Anomaly 
screening 
 (Lawson & 
Turriff-
Jonasson, 
2006)  
Canada 
70 
32 
screened 
38 controls 
Examine whether screening is 
associated with lower maternal 
attachment to pregnancy.  
 
Cross sectional 
survey 
Maternal prenatal 
attachment using 
the Prenatal 
Attachment 
Inventory  (PAI) 
29  Anomaly 
screening 
 (Öhman, 
Saltvedt, & 
Waldenstrom
, 2006)  
Sweden 
24  Explore women’s reactions to 
false-positive results 
Qualitative 
Longitudinal 
Study 
Interview 
responses 
30  Anomaly 
screening 
 (Chiang, 
Chao, & Yuh, 
2007) Taiwan 
27  Exploring how the maternal 
self is affected by abnormal 
results of prenatal screening.  
Qualitative  Interview 
responses 
31  Anomaly 
screening 
 (Chueh, 
Cheng, Shaw 
et al., 2007)  
Taiwan 
352 
172 screen 
pos  
180 screen 
neg 
Assess pre- and post-
procedural maternal anxiety 
about nuchal translucency 
thickness screening, and the 
psychological impact of 
positive screening results.  
Longitudinal 
Survey 
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Screening 
test  Reference 
Number of 
Participant
s 
Research Aims 
Design, 
Method and  
Theoretical 
Basis 
Measures 
32  Anomaly 
screening 
 (Cheng, Wu, 
Shaw et al., 
2008)  
Taiwan 
2782 
1422 fast 
report  
1360 
controls  
Does fast reporting of serum 
results via text message affect 
anxiety scores? 
Longitudinal 
Survey 
Anxiety - STAI 
33  Anomaly 
screening 
 (van den 
Berg et al., 
2008) 
Netherlands 
1666  Aiming to enhance 
understanding of prenatal 
screening decisions using a 
decision model  
Cross sectional 
survey  
Decision 
Theory 
Anxiety - child-
related, perceived 
probabilities  
34  Anomaly 
screening 
 (Öhman, 
Grunewald, 
&  
Waldenstrom
, 2009)  
Sweden 
796  Explore whether the actual risk 
and the woman’s perception of 
risk was associated with worry 
or depressive symptoms during 
and after pregnancy.  
Longitudinal 
survey 
Worry - The 
Cambridge Worry 
Scale; depression 
– EPDS  
35  Anomaly 
screening 
 (Hawthorne 
& Ahern, 
2009) 
Australia 
20  Investigating women’s 
experience of nuchal 
translucency screening 
Qualitative  Interview response 
36  Anomaly 
screening 
 (Rowe, 
Fisher, & 
Quinlivan, 
2009)  
Australia 
68  Compare maternal-fetal 
attachment in informed and 
uninformed women 
Longitudinal 
Survey 
Anxiety and 
Depression- 
Hospital Anxiety 
and Depression 
Scale  (HADS) 
Attachment – 
Antenatal 
Attachment 
Questionnaire  
(AAQ) 
37  Blood 
disorders 
 (Koelewijn, 
Vrijkotte, de 
Haas, van 
der Schoot et 
al., 2008) 
Netherlands 
213 
73 controls 
21 false 
pos 
74 benign 
result 
45 true pos 
What are women’s attitudes 
towards screening for red 
blood cell antibodies? 
Longitudinal 
Survey 
Anxiety - STAI, 
depression, locus 
of control 
38  Blood 
disorders 
 (Reed, 
2009)  
UK 
22  Exploring gendered nature of 
genetic responsibility 
Qualitative 
Feminist 
Interview 
responses 
39  GBS   (Darbyshire, 
Collins, 
McDonald et 
al., 2003) 
Australia 
35  
9 focus 
groups 
♀ experience and perceptions 
of risk for GBS 
Qualitative  Transcribed 
interviews 
40  GBS   (Cheng, 
Shaw, Lin, et 
al., 2006)  
Taiwan 
183 
71 screen 
pos 
112 
controls 
Assess maternal anxiety and  
impact of GBS screening 
Longitudinal 
Survey 
Anxiety - STAI 
and LIKERT 
scales 
41  USS   (Baillie, 
Hewison, & 
Mason, 
1999)  
UK 
35 studies 
included 
Should ultrasound in 
pregnancy be routine? 
Literature 
Review 
 (not described 
as systematic) 
Narrative 
Synthesis 
42  USS   (Bricker, 
Garcia, 
Henderson, 
& al, 2001) 
 (Garcia, 
Bricker, 
Henderson et 
al., 2002)    
(same data)  
UK 
74 papers  A review of women’s views of 
ultrasound.  
 
 
Systematic 
Review 
Narrative 
Synthesis 
43  USS   (Brisch, 
Munz, 
Bemmerer-
Mayer et al., 
2002)  
Germany 
664 
497 high 
risk 
167 low 
risk 
Longitudinal comparison of 
various risk groups having 
screening 
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Screening 
test  Reference 
Number of 
Participant
s 
Research Aims 
Design, 
Method and  
Theoretical 
Basis 
Measures 
44  USS   (Ekelin, 
Crang-
Svalenius, & 
Dykes, 2004)  
Sweden 
22  
 (+22 
fathers) 
Conceptualise thoughts and 
feelings before, during and 
after the routine ultrasound 
examination.  
Qualitative  Interview response 
45  USS   (Brisch, 
Munz, 
Kachele et 
al., 2005)  
Germany 
674 
506 high 
risk 
168 low 
risk 
Analyse the development of 
anxiety before and after 
ultrasound 
Longitudinal 
Survey 
Anxiety – STAI 
46  USS   (Ji, 
Pretorius, 
Newton et 
al., 2005)  
USA 
100 
50 2D USS 
50 3D USS 
Evaluate the effect of two-
dimensional  (2DUS) compared 
to three-dimensional 
ultrasound  (3DUS) imaging on 
the maternal- fetal bonding 
process. 
Cross sectional 
survey 
Attachment 
47  USS   (Boukydis, 
Treadwell, 
Delaney-
Black et al., 
2006) USA 
52 
24 standard  
28 
extended 
consultatio
n  
Evaluate the impact of prenatal 
ultrasound consultation on 
maternal-fetal attachment and 
anxiety in pregnant women  
RCT  Anxiety – STAI, 
depression, 
attachment, views 
on screen 
48  USS   (Lee, Shim, 
Won et al., 
2007) USA 
798  Quantify maternal anxiety 
associated with the detection 
of isolated ultrasound markers 
Cross sectional 
survey 
Anxiety - STAI 
49  USS   (Åhman, 
Runestam 
and Sarkadi, 
2009) 
11  Explore women’s experiences 
when isolated soft markers 
were discovered during the 
routine ultrasound screening. 
Qualitative  Responses to 
interview 
questions 
50  USS   (Api, Demir, 
Api et al., 
2009) Turkey 
100 
60 high 
risk 
40 low risk 
Comparing anxiety levels 
among women with high risk 
and low risk for fetal 
anomalies 
Cross sectional 
Survey  
Anxiety – STAI 
51  USS   (Carolan & 
Hodnett, 
2009) 
Australia 
10  Explore women’s experiences 
of referral on the basis of 
uncertain ultrasound findings.  
Qualitative  Responses to 
interview 
questions 
52  USS   (Ekelin, 
Svalenius, 
Larsson et 
al., 2009)  
Sweden 
2183  To investigate parents' 
expectations, experiences and 
reactions, sense of coherence 
and anxiety before and after a 
second-trimester routine 
ultrasound examination, with 
normal findings.  
Cross sectional 
survey 
Anxiety - STAI,  
PEER-U state of 
mind index 
53  USS   (Larsson, 
Svalenius, 
Marsal et al., 
2009)  
Sweden 
2049  Compare parents' worry and 
sense of coherence before and 
after a routine second-
trimester ultrasound 
examination 
Cross sectional 
survey 
Parents' 
Expectations, 
Experiences, and 
Reactions to 
Ultrasound 
[PEER-U] State of 
Mind Index 
54  USS   (Nabhan & 
Faris, 2010)  
Egypt 
4 studies 
included 
To compare high feedback 
versus low feedback during 
prenatal ultrasound for 
reducing maternal anxiety and 
improving maternal health 
behaviour. 
Systematic 
review  
Meta analysis 
55  USS; 
Anomaly 
screening 
 (Hoskovec, 
Mastrobattist
a, Johnston 
et al., 2008)  
USA 
215 
124 
maternal 
age 
55 screen 
pos 
36 soft-
markers 
Is there a difference in anxiety 
levels in women referred for 
increased maternal age, soft 
ultrasound findings, and 
abnormal serum marker 
screens. 
Cross sectional 
survey 
Anxiety – STAI 
 
 
   Page 103 of 316    Chapter 4: Systematic Review  
FIGURE 4.2 - ASSESSMENT FOR BIAS - QUALITATIVE STUDIES - IMPACT ON MATERNAL 
HEALTH 
  
FIGURE 4.3 ASSESSMENT FOR BIAS - COHORT STUDIES - IMPACT ON MATERNAL HEALTH 
  
FIGURE 4.4 - ASSESSMENT FOR BIAS - QUALITATIVE STUDIES - IMPACT ON FETAL HEALTH 
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FIGURE 4.5 - ASSESSMENT FOR BIAS - COHORT STUDIES - IMPACT ON FETAL HEALTH 
 
FIGURE 4.6 - ASSESSMENT FOR BIAS - SYSTEMATIC REVIEWS - IMPACT ON FETAL HEALTH 
 
FIGURE 4.7 - ASSESSMENT FOR BIAS - RANDOMISED CONTROL TRIALS - IMPACT ON FETAL 
HEALTH 
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4.4.4  EMOTIONAL IMPACT – HEALTH IMPLICATIONS FOR THE 
MOTHER 
Of the studies of screening tests with a maternal health impact, four studies 
demonstrated that screening tests had no impact on emotions, such as anxiety, 
depression or worry[18-20] (Table 4.4). Two of these studies[18,19] used the State-Trait 
Anxiety Index (STAI) but at different time points, therefore the results cannot be pooled 
for analysis. Two studies [21,22] suggested an increase in anxiety in pregnant women 
while awaiting HIV screening test results. However these studies did not use a validated 
anxiety measure. A study investigating HIV screening using a non-validated 
questionnaire measures of anxiety found that screening test related anxiety was 
alleviated with support from partners[23].  
There is little evidence of any emotional impact of screening tests for conditions that 
affect maternal health. Further research is needed to answer the question because of the 
many limitations of the study methods. 
4.4.5  EMOTIONAL IMPACT – HEALTH IMPLICATIONS FOR THE 
FETUS 
Studies of screening tests with a fetal health implication have shown that pregnant 
women have a significant increase in anxiety while awaiting screening test results 
compared to anxiety measured following a negative screening test result[4,24-33]. This 
is the case for those previously identified as high risk (for example, increased maternal 
age), and for those with no risk factors. However, anxiety levels are significantly higher 
in women if a risk factor has previously been identified [4,24-33]. Anxiety levels also 
were increased significantly following a positive screening test result. A previous 
review pointed out the barriers to statistical integration of the anxiety data from the 
studies in the review[4] due to the use of different measures and study designs. This 
problem remains within this review. Although 15 studies used the STAI, summary 
statistics are not possible due to variation in sampling, experimental groups and 
measurement time-points.  Six studies (n = 3516) found that pregnant women’s STAI 
scores increased significantly after receiving information that the screening test 
indicated their infant was at high risk for a health condition (n = 733) compared to pre-Page 106 of 316    Chapter 4: Systematic Review  
screening levels. Women’s anxiety levels decreased significantly after receiving 
information that the screening test indicated their infant was not at risk  (n = 3310). The 
duration of the increase in anxiety levels after a positive screening test is unclear, with 
one study suggesting returns to pre-test levels immediately following the results of a 
negative diagnostic test[27] , another by 22 weeks gestation[28]. A third study found 
that although anxiety levels decreased over time, they remained slightly elevated 
throughout the pregnancy[4]. Four studies suggested that a negative ultrasound 
screening test reduces anxiety [5,6,26,34]  in relation to pre-screening anxiety levels 
measured just prior to the test, which may be heightened in anticipation of the screening 
test taking place[4].  
Worry (a psychological construct separate from anxiety) was found to be increased both 
prior to receiving results[35] and following a positive screening test result [34,36] 
whereas a negative result was associated with a reduction in worry to lower than pre-
test levels [35,37]. Prenatal screening tests with a fetal health implication were found to 
have no effect on depression[6,27,38,39].  
There is evidence that prenatal screening tests for conditions that affect fetal health are 
associated with anxiety and worry. Both anxiety and worry appear to increase in women 
while they await results following a positive screening test result, but decrease 
following a negative screening test result.  Page 107 of 316    Chapter 4: Systematic Review  
 
 
TABLE 4.3 - BEHAVIOURAL EFFECTS 
  Maternal Health Impact  Fetal Health Impact 
Diabetes  HIV  Hematology  Ultrasound   Fetal Anomaly Serum 
screening 
Group-B Streptococcus 
Health 
Behaviour 
Screen Positive  Healthy eating 
increased  (1) 
Condom use and safe 
sex discussion 
increased  (18) 
    Screening not 
predictive of diagnostic 
or termination 
intentions  (20) 
 
Screen Negative     Condom use and safe 
sex discussion 
increased  (18) 
*also increased if 
screening declined 
  No impact on health 
behaviours  (53,54) 
No impact on parenting 
behaviours  (53) 
High feedback more 
likely to avoid alcohol 
and stop smoking  (54) 
   
 
   Page 108 of 316    Chapter 4: Systematic Review  
 
TABLE 4.4 - EMOTIONAL EFFECTS 
  Maternal Health Impact  Fetal Health Impact 
Diabetes  HIV  Hematology  Ultrasound   Fetal Anomaly Serum 
screening 
Group-B Streptococcus 
Anxiety  Screen Positive  No impact  (2,3)     Increase in anxiety 
after screen results. 
Returns to baseline 
with increased 
monitoring or by two 
weeks after birth  (37) 
Increase in anxiety  
(43,48,49,55) 
Impact decreases over 
time  (27) 
Increase in anxiety  
(20,21,23,29,31,32,33) 
No impact  (19) 
Increase in anxiety 
after screening test, no 
difference 1 week PN  
(40) 
Screen Negative   No impact  (2;3)      Anxiety decreased 
(41,42,48,52) 
High feedback- no 
impact  (42) 
High feedback- lower 
anxiety  (54) 
Small group had 
increasing anxiety 
overtime  (43) 
Anxiety decreased 
compared to non-
screened  (42) 
No impact  (25) 
No impact  (40) 
Awaiting results    Anxiety increased 
while awaiting results  
(4,12) 
Anxiety is decreased 
with information and 
support  (7) 
  Anxiety increased 
while awaiting results  
(43,45) 
Anxiety increased 
while awaiting results  
(20,30) 
 
Prior to 
screening 
  No impact  (8,9) 
HIV screening 
increases anxiety more 
than other antenatal 
screens  (N/S)  (11) 
Women feel screening 
can decrease anxiety  
(16) 
  Increase in anxiety  
(41,43) 
   
Depression  Screen Positive  No impact  (3)      No impact  (43,52)  No impact  (32)   
Screen Negative   No impact  (3)      No impact  (43)  No impact  (20,32)   
Worry  Screen Positive      Increase in worry  (22)  No impact  (52) 
Impact  (53) 
Increase in worry  (25)   
Screen Negative         Worry decreased  
(53,54) 
   
Awaiting results  Increase in worry  (2)  Majority no impact  (5)    Increase in worry  (44)     
Prior to 
screening 
  Worry affected by 
perceived risk  (5) 
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TABLE 4.5 - COGNITIVE EFFECTS 
  Maternal Health Impact  Fetal Health Impact 
Diabetes  HIV  Hematology  Ultrasound   Fetal Anomaly Serum 
screening 
Group-B Streptococcus 
 
Desire to 
repeat 
screening 
Screen 
Positive 
Desire to repeat 
screening  (1) 
  Desire to repeat 
screening  (37) 
Preference for extended 
screen  (54) 
 
Desire to repeat 
screening  (25) 
A minority regret 
having screening  
(23,24) 
Positive reaction to 
screening  (30) 
Desire to repeat 
screening  (40) 
Screen 
Negative  
Desire to repeat 
screening  (1) 
  Desire to repeat 
screening  (37) 
Women enjoyed 
screening  (43,47,51) 
Women enjoyed 
screening  (27) 
 
Maternal 
responsibility 
Screen 
Positive 
    Positive impact  (38)       
Screen 
Negative  
    Positive impact  (38)       
Prior to 
screening 
  Sense of maternal 
responsibility 
influences those who 
accept and decline 
screening  (8,15,16) 
Screening perceived as 
a maternal 
responsibility  (38) 
  Screening perceived as 
a maternal 
responsibility  (23,35) 
Screening perceived as 
a maternal 
responsibility  (39) 
Change view 
of own health 
Screen 
Positive 
Negative impact on 
personal health 
perceptions  (2,3) 
      Positive screen results 
in feeling that body 
doesn't work  (32) 
 
Screen 
Negative  
No impact  (2,3)           
Prior to 
screening 
  Health-related quality 
of life scores not 
impacted by screening 
intention  (12) 
       
Changed 
view of fetus 
Screen 
Positive 
No impact on 
perceptions of fetus’ 
health  (2,3) 
         
Screen 
Negative  
      Positive attitudinal 
changes post screen  
(47) 
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4.4.6  COGNITIVE IMPACT – HEALTH IMPLICATIONS FOR THE 
MOTHER 
One study demonstrated that women had positive attitudes about a gestational diabetes 
screening process[16] and three studies looking at HIV screening tests found that 
women felt the screening gave them a sense of maternal responsibility[40-42] . Two 
studies indicated that being found high-risk for gestational diabetes negatively affected 
how women perceive their health-related quality of life [18,19] (p<0.05), however it did 
not affect how that woman viewed her fetus[18,19] (Table 4.5). No studies were found 
that reported on the impact of prenatal screening tests on a woman’s prenatal attachment 
or risk perception.  
4.4.7  COGNITIVE IMPACT – HEALTH IMPLICATIONS FOR THE FETUS 
Women undergoing screening tests with a fetal health implication also had a positive 
view of ultrasound[5,6,39], anomaly screening[28,43], group-B streptococcus[32] and 
blood-disorder [44] screening tests. Anomaly screening[4,45], blood disorders[36], and 
group-B streptococcus[46] screening tests gave an increased sense of maternal 
responsibility. A qualitative study of 27 women reported that some women had a 
negative view of their own health following a positive screening test result for their 
fetus[47]. Two studies found that a minority of women regretted having the screening 
test following a false-positive result[4,48]. Seven studies found that attachment 
decreased following an initial positive fetal anomaly screening[49], and remained lower 
after the women underwent subsequent amniocentesis, until the health of the fetus was 
confirmed[50,51]. In contrast, studies on ultrasound screening tests showed no 
impact[5,6], or an increase in attachment following a negative screening test 
result[35,52]. 
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4.5  DISCUSSION 
This review of 51 studies and 4 systematic reviews found that women experienced 
greater anxiety following prenatal screening tests that had an impact on fetal health 
compared with those that had an impact on maternal health. However, this is based on 
relatively few studies and there is a need to evaluate the impact of such screening tests 
before they are clinically introduced on a large scale. There are fewer, and less rigorous, 
studies of the impact of prenatal screening tests for conditions that affect maternal 
health than there are for conditions that affect fetal health.  
Increased anxiety and worry may be appropriate responses to a health threat, and to the 
potential challenges posed by informed decision-making[53]. It should not, therefore, 
necessarily be seen as detrimental that prenatal screening increases anxiety to some 
extent. The data presented here suggests that pregnant women have increased anxiety 
following a high-risk result regarding their fetus’ health but not if they receive a high-
risk result regarding their own health.  One explanation for this difference may be 
differences in the severity of the conditions screened for. For example, gestational 
diabetes is in many cases a temporary condition for the pregnant woman[54], so 
screening for the condition is unlikely to have the same effect as a lifelong diagnosis for 
the fetus such as Down’s syndrome. Although HIV screening does assess the risk for a 
serious and non-transient maternal condition, a lack of consistency in the methods, such 
as outcome measures used, makes it difficult to compare the effects with studies of fetal 
screening tests.  
An alternative explanation for experiencing less anxiety for conditions that affect the 
mother may be that a threat to oneself is viewed as more ‘controllable’ than a threat to 
the fetus. Individuals who have a greater sense of control over a health threat have been 
found to experience less anxiety towards those threats[55].  
The evidence regarding the cognitive impact of prenatal screening tests shows that 
women liked the information that screening tests gave them, and would repeat screening 
in subsequent pregnancies.   
As health promotion is a key aim of prenatal care[56], the studies that illustrated a 
potential for positive changes in dietary and safer sex health behaviours [17,41] 
highlight a potential benefit in providing prenatal screening tests. Providing information Page 112 of 316    Chapter 4: Systematic Review  
on the consequences of behaviour is a recognised behaviour change technique[57] and 
screening for diabetes and HIV present  an opportunity to provide information that has 
the potential to change behaviour and improve health. However, there were few studies 
of the impact of prenatal screening on pregnant women’s health behaviours, so no 
conclusions can be drawn.  
Since a high-risk result from prenatal screening tests generally leads to increased 
surveillance [10], there is the potential for women to become ‘attached’ to the increase 
monitoring or technology used. This may have the unintended behavioural 
consequences of reducing self-monitoring of fetal movements, or increasing desire for 
monitoring and interventions in labour, which in turn may lead to adverse 
events[58,59].  This issue was not addressed in the research in this review. 
This review is limited by the number and quality of the studies investigating these 
prenatal screening tests. There is a larger body of research on the psychological effects 
of prenatal screening for conditions that relate to fetal health than there is for the 
psychological effects of screening for conditions relating to the health of the mother. 
Furthermore, the studies of prenatal screening tests regarding fetal health generally used 
more consistent methodological approaches, aiding comparison across studies. This 
may be because screening for fetal conditions is often conducted with the aim of 
providing reproductive choice[1], which has clear psychological consequences. With the 
advent of screening tests for conditions such as pre-eclampsia, which provide 
information about the risk for a condition with a high risk for maternal death but no 
known treatment, there is a need to investigate the psychological impact of providing 
this information before symptoms develop. This will enable women, in partnership with 
their healthcare professionals, to assess the overall benefits of these prenatal screening 
tests, while allowing clinicians to minimise any harms and maximise benefits to women 
and their families. 
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4.6  CONCLUSION 
This systematic review synthesised a large body of literature that assessed the 
psychological impact of prenatal screening tests. No research was identified that 
considered a screening test that had consequences for both mother and fetus, that had no 
diagnostic test attached, or that presented a long-term health consequence to the mother. 
Each of the screening tests reviewed here, therefore, differ to the pre-eclampsia 
screening test. It is currently unknown if the findings presented here will be applicable 
to the pre-eclampsia screening test.  
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5.1  ABSTRACT 
Objective : A new first-trimester universal prenatal screening test for pre-eclampsia 
was introduced into two UK hospitals. The aim of this study was to investigate the 
potential psychological benefits, harms and acceptability of providing pregnant women 
with formal risk information for pre-eclampsia 
Design:  Cross-sectional interview study. Women were interviewed using a theoretically 
informed semi-structured schedule and transcripts were analysed thematically using 
Framework Analysis  
Setting and participants: Primigravid women receiving prenatal care at a central 
London National Health Service Foundation Trust found either high-risk or low-risk for 
pre-eclampsia. 
Findings: 15 primigravid women who received high risk (n=10) or low risk (n=5) 
results of a 12-week pre-eclampsia screening test were interviewed. Two types of 
coping typologies were evident from the data. The first were “danger managers” who 
had an internal sense of control, were focused on the risk that pre-eclampsia presented 
to them and exhibited information seeking, positive behaviour changes, and cognitive 
reappraisal coping mechanisms. The second were “fear managers” who had an external 
sense of control, were focused on the risk that pre-eclampsia presented to the fetus, and 
exhibited avoidance coping mechanisms. In addition to these typologies, three universal 
themes of ‘medicalising the pregnancy’, ‘embracing technology’ and ‘acceptability’ 
emerged from the data.  
Conclusions: There are potential positive and negative unintended consequences 
following a first-trimester screening test for pre-eclampsia. A positive consequence 
could be self-instigated behaviour change, whereas a negative consequence could be 
reduced self-monitoring of fetal movements as the pregnancy develops. 
Implications for practice: This study indicates that women with an increased risk of 
pre-eclampsia would be willing to engage in efforts to reduce their risk of pre-
eclampsia, and there is a potential to use this screening test as a basis for improving 
health more broadly. 
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5.2  BACKGROUND 
Chapter four identified that there are differing psychological impacts of prenatal 
screening, depending on whether the focus of that screening test is the mother or the 
fetus. Pre-eclampsia is a condition of pregnancy that impacts both mother and fetus. It is 
therefore currently unclear whether a first-trimester screening test to identify women at 
high risk of developing it will affect women in a similar or different way to previously 
studied screening tests.  
Various first-trimester biochemical screening tests are now available for pre-eclampsia, 
a serious obstetric complication with harmful consequences for the mother and fetus  [1, 
2].  The development of these tests have been based on extensive research [3, 4] and 
supported by the World Health Organisation [5]. The various forms of published pre-
eclampsia screening tests use a variety of information including maternal 
characteristics, family history and biophysical and biochemical information.  
Pre-eclampsia currently lacks a confirmatory diagnostic test, such as an amniocentesis 
for Down’s syndrome or glucose tolerance test for gestational diabetes. Moreover, there 
are no proven interventions to reduce the risk of pre-eclampsia following a positive 
screening test result, although there is evidence suggesting both pharmacological [6] 
and behavioural [7] interventions could reduce risks. Therefore, these pre-eclampsia 
screening tests, along with ones for conditions such as pre-term birth, macrosomia and 
microsomia, mark a shift in prenatal screening, from screen-to-treat to screen-to-
observe. There are ethical considerations related to introducing a screen-to-observe test 
as it is unclear if they meet global screening criteria. Two of the World Health 
Organisation’s screening criterion - ‘an accepted treatment for patients with recognised 
disease’ and ‘facilities for diagnosis and treatment should be available’ [8] are not easily 
met at the point of a high-risk diagnosis when screening for pre-eclampsia. Another 
criterion, ‘the test should be acceptable to the population’, also requires investigation. 
The lack of immediate diagnosis, treatment or risk reduction intervention may mean that 
these screening tests are experienced differently than previous prenatal screening tests. 
It is as yet unknown how acceptable women will find a prenatal screening test that is 
not associated with a specific treatment or intervention. A recent systematic review 
demonstrated that psychological reactions to prenatal screening tests differ when the test 
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screening tests that assess problems in the mother (e.g., gestational diabetes) [9]. As pre-
eclampsia can harm both fetus and mother, the reactions of pregnant women who 
undergo a screening test for it should be investigated.  
Women’s reactions to a pre-eclampsia screening test is likely to be influenced by their 
perception of their risk, in other words, their expectation regarding the probability of the 
condition occurring [10]. A woman’s assessment of her risk for pre-eclampsia may be at 
odds with her medically determined risk [11], which may influence her willingness to 
follow health advice [12, 13]. The attribution of a ‘high-risk’ label in pregnancy has 
been shown to negatively influence self-esteem and mastery [14]. Conversely, there is a 
potential protective benefit to anticipating the development of pre-eclampsia, since the 
unexpected occurrence of the condition has been found to lead to increased cases of 
post-traumatic stress disorder and postnatal depression [15]. Alongside the potential 
harms or benefits of receiving such risk information, there are potential consequences of 
the increased monitoring that is likely to occur following a high-risk result, influencing 
the place of birth women choose [16] or satisfaction with increased continuity of care 
and carer [17].   
A well supported psychological theory that explains individual reactions to screening 
information is the Common-Sense Model of self-regulation (CSM)[18]. This is a 
parallel processing model explaining how people react to, evaluate and cope with 
threatening health information. The parallel processes for dealing with a given health 
threat involves managing the danger (the behavioural pathway) and the fear (the 
emotional pathway) of the presented information. According to this model, an 
individual compares new risk information, such as that provided by a screening test 
result, with their prior sense of risk developed from their own experience and more 
general understanding. This leads to an ‘illness representation’, consisting of six key 
dimensions: identity (the distinctive label and symptoms that an individual associates 
with the threat), causes (e.g. genetics versus luck versus behaviour), control/cure (how 
the threat can be managed, reduced or cease e.g. medicine, exercise, time) consequences 
(e.g. how much it will disrupt daily activity), coherence (how the person makes sense of 
the condition) and timeline (e.g. when the condition is likely to develop, and how long it 
will last for). Following this evaluation, coping mechanisms are instigated to relieve 
emotional (fear responses) or cognitive (danger responses) reactions to the threat. 
Research has shown [19] that the choice of coping mechanism is affected by the 
individual’s perception of the controllability and consequences of the threat. This Page 122 of 316    Chapter 5: Women’s Qualitative Study  
research suggests that perceiving oneself to have more control over pre-eclampsia will 
result in less distress, and greater initiation of problem-solving or self-care behaviours 
(such as changing diet).  
This study investigated the psychological impact on women of receiving results of a 
prenatal screening test for pre-eclampsia, drawing on the CSM theory and using an 
exploratory qualitative method. The focus was on the potential psychological benefits 
and harms for pregnant women after being informed of their screening test results, and 
to assess the acceptability of the screening test to pregnant women. 
5.2.1  RESEARCH AIMS 
This exploratory work aimed to provide a preliminary understanding of the potential 
impact a pre-eclampsia screening programme may have on the intended population. It  
identifies issues that arise from a first-trimester screen for pre-eclampsia, and discovers 
pregnant women’s views about the benefits and burdens of the pre-eclampsia screening 
test. 
The aims of this study were three-fold. Firstly, to explore what, if any, psychological 
effects resulted from the introduction of a prenatal screening test for pre-eclampsia. 
Secondly, to discover how women conceptualised their risk for pre-eclampsia, and 
what, if any, mechanisms were used to aid this conceptualisation. Finally, it aimed to 
determine how acceptable women found the screening test, in light of the WHO 
recommendations on the introductions of population level screening tests, discussed in 
section 1.3.1.    
5.3  MATERIALS AND METHODS 
5.3.1  DESIGN AND SETTING 
This study used a qualitative semi-structured interview design and Framework Analysis 
[20]. The systematic review (Chapter two) identified that no research had been 
previously conducted that could be directly applied to the pre-eclampsia screening test. 
Due to the novelty of providing risk information following a prentatal screening test for 
a condition that has no associated treatment options or risk-reduction interventions, an 
exploritative qualitative approach was used. As the research aims involved assessing the Page 123 of 316    Chapter 5: Women’s Qualitative Study  
individual affects, conceptualisation of the risk, and acceptability of the screening test,  
one-to-one interviews rather than focus groups was most appropriate. Individual 
interviews provide an opportunity for detailed investigation of a person’s personal 
perspectives, and enables in-depth understanding of the personal context of the research 
phenomena [20]. Although the group process afforded by a focus group design may 
have borne alternative themes, it may also have inhibited discussions regarding personal 
thoughts and feelings of risks. The theoretical basis for the study required a form of 
structure to the interviews, as there was a desire to ensure all of the illness 
representations from the CSM were explored fully by all participants. This precluded 
use of unstructured interviews as used in narrative or conversational interview data 
collection 18(Corbin & Morse, 2003). However, as the topic was likely to be highly 
personal to the woman being interviewed, with a requirement to gain trust and rapport 
during the interviews, the rigidity of a structured interview was also deemed 
inappropriate. Therefore, a semi-structured interview format was selected.  
This cross-sectional semi-structured interview study included pregnant women under 
the care of a large UK teaching hospital. At the time of the interviews, the study hospital 
had been offering all women a prenatal screening test for pre-eclampsia for over a year. 
The screening test is a biochemical universal screening test detailed in Poon et al [21]. It 
was offered during an ultrasound appointment at 11-12 weeks’ gestation alongside other 
prenatal screening tests, including a screening test for Down’s syndrome. The pre-
eclampsia risk is calculated using a combination of maternal history, mean arterial blood 
pressure, body mass index, uterine artery pulsatility index (measured via ultrasound), 
and the hormones pregnancy-associated plasma protein-A (PAPP-A) and placental 
growth factor (PlGF).  Women are informed of all of the screening test results the same 
day. The pre-eclampsia screening test result was presented as a bivariate category of 
‘high-risk’ or ‘low-risk’, with an accompanying printed report that provided a 
probability (e.g. 1:50). The risk components split into three categories – the risk of 
developing pre-eclampsia prior to 34 weeks gestation, after 34 weeks gestation and of a 
hypertensive disorder of pregnancy. Women determined to be at high risk were verbally 
informed of the results, and an appointment made for a ‘hypertension clinic’ run by a 
specialist team of obstetricians and midwives within one week of the first scan, and then 
routinely (four-six weekly) throughout the pregnancy. Women determined to be low risk 
were verbally informed of the results and continued on the low-risk care pathway.  Page 124 of 316    Chapter 5: Women’s Qualitative Study  
5.3.2  SAMPLE 
A purposive sample of high and low-risk primigravid women with no other pregnancy 
complications, other than any pre-diagnosed hypertension, were fluent in English and 
had been offered a screening test for pre-eclampsia, were interviewed within one month 
of receiving their pre-eclampsia screening test result. Women were recruited in two 
ways; initially the lead researcher (JH), previously unknown to them, approached 
women in the waiting area of the hospital ultrasound department and gave them the 
study information leaflet. If they wished to participate, contact information was 
collected and they were contacted the following day to arrange a convenient time and 
location for the interview. However, due to the small number of women found high-risk 
for pre-eclampsia, six of the high-risk participants were recruited directly from the 
hypertension clinic, with the same procedure being completed in the waiting area of that 
clinic. Recruitment ceased when analysis showed no new themes emerging (i.e., 
“saturation” [22] was reached), for a final sample of 10 high-risk and 5 low-risk 
women.  
5.3.3  PROCEDURE 
A National Health Service research ethics committee gave ethics approval 
(ref:10/H0806/83). Potential participants were given 24 hours to consider a study 
information leaflet prior to giving informed written consent. The lead researcher (JH) 
conducted the interviews at a location and time chosen by each participant, each 
conducted by the lead researcher (JH). Five interviews were conducted in the woman’s 
home, five at or near their place of work and five at the study hospital. Audio recordings 
of the interviews were anonymised prior to transcription to protect confidentiality.   
Semi-structured interviews were conducted according to an interview guide that started 
with open-ended questions to explore psychological benefits or harms after receiving 
the pre-eclampsia screening test results, and an assessment of its acceptability (Figure 
5.1). The second part explored the illness representations outlined in the CSM (Figure 
5.2). Amplificatory probes were used to ensure a full description of the woman’s views. 
The interview guide was developed in consultation with members of a maternity service 
users group to ensure clarity and acceptability of the questions, and was piloted to Page 125 of 316    Chapter 5: Women’s Qualitative Study  
assess coherence and logical flow. Following this, some questions were re-ordered but 
none reworded.  
5.3.4  TRANSCRIPTIONS 
Recordings were transcribed verbatim.  The lead researcher completed six 
transcriptions, with the remainder completed by an authorised transcription service (see 
Appendix 9 for confidentiality agreement).  
 
5.3.5  VALIDITY 
This study took the following steps to minimise bias and increase reliability, in 
accordance with Yardley [23]: theory informed the design and analysis of the study, two 
members of a patient liaison group for maternity care provided advice on the study 
protocol and interview guide, and two independent coders analysed the transcripts.  
5.3.6  ETHICAL CONSIDERATIONS 
The local National Health Service research ethics committee gave ethics approval (ref: 
10/H0806/83, approval letter in Appendix 10), the process of which included gaining 
1.1. 
Did you have an ultrasound scan last week? 
1.2. 
 [If yes] can you tell me about it? 
1.3. 
What did the scan [use women’s language] involve? 
1.4. 
Did it involve one test or more than one? 
1.5. 
What was it/them for? [ensure go through each one, one at a time] 
prompt – baby’s health, your health? 
  If not mentioned pre-eclampsia 
1.6. 
Did you have a test for pre-eclampsia? [If not] Did you have a test for tendency to high blood 
pressure? 
1.7. 
[If yes] have you been given your results? 
1.8. 
What were you told?  
1.9. 
What do you understand that to mean?  
Ensure prompts so you get a full understand of what the woman understands by the results 
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site-specific authority from the NHS trust that data were collected. An information 
leaflet describing the study was given to potential participants (see Appendix 11). A 
period of at least 24 hours was allowed between receiving the information leaflet and 
the researcher contacting the women to ask if they were allowed to take part. This 
enabled sufficient time to consider the leaflet. Prior to commencing the interview, 
consent was gained and women being asked to sign a consent form (Appendix 12). 
Participation in this study was confidential. Although transcripts and other data were 
shared with the whole research team, there was no sharing of identifying data. 
Individual semi-structured interviews can be intrusive and some people can find the 
questions uncomfortable or distressing to answer. In order to protect women, certain 
safeguards were put in place. All interviews were conducted in a respectful and non-
threatening manner. If participants showed evidence of becoming distressed, the 
researcher or the woman had the right to terminate the interview. At the end of the 
interview women were given the opportunity to ask any questions or raise any concerns 
that they had. An Obstetric Counsellor attached to the NHS trust was contacted prior to 
commencing the study, and assurances gained that women would be able to contact 
them if they required following the interview. This service was not needed by any 
women interviewed.  
The researcher, also a qualified midwife, was conscious of his professional 
responsibilities as outlined by the Nursing and Midwifery Council code of conduct [24]. 
If any clinically significant information was disclosed during the interviews (for 
example, if there was potential for harm), the researcher would have discussed with the 
woman the option of further involvement from an appropriate service. The researcher 
was also able to seek assistance via midwifery supervision [25].  
Data were, and continues to be, stored in accordance with the Data Protection Act 1998 
and Caldicott principles [26]. All information was anonymised as soon as possible, and 
stored on a secure server. No transcriptions with identifiable data were made. 
Anonymised transcripts and digital recordings alongside consent forms will be stored 
for 5 years.  
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FIGURE 5.2 - INTERVIEW STRUCTURE, THEORETICAL QUESTIONS 
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TABLE 5.1 - ILLUSTRATION OF THE DEVELOPMENT OF THE CODING STRUCTURE 
Coding Structure A   Coding Structure B  Final Coding Structure 
Cause  Cause    Sub theme 
Coherence  Consequences 
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Cause 
Consequences  Coherence  Consequences 
Control-cure  Control - Cure  Coherence 
Identity  Emotions  Control-cure 
Perception of risk  Identity of PE risk  Emotion 
Emotions  Perception of Risk  Identity 
Behavioural Changes  Timeline  Perception of risk 
Experience of scan  Experience of Scan  Timeline 
Faith in doctors and screening 
process 
Experience, Knowledge and 
Emotions 
Confusion/ contradictions  
Reference to own/others 
experiences  
Reference to own or others 
previous experiences  
C
o
p
i
n
g
 
m
e
c
h
a
n
i
s
m
s
  Behaviour change 
Passive bystander  Passive by-stander in the 
screening process 
Information seeking 
Personal health findings  Personal Health Findings  Cognitive reappraisal  
Personal responsibility  Personal Responsibility  Avoidance 
Opinion of others  Reference to Baby or Pregnancy  Acceptability 
Reference to partners feelings  Other's opions  Sharing the result 
Reference to spirituality  Reference to partner's 
feelings_views 
S
c
a
n
 
p
r
o
c
e
s
s
 
Communication and consent 
issues 
Reference to baby  Reference to spirituality  Length of scan 
Reference to being pregnant  References to Baby  Medicalisation 
Sources of information  References to being pregnant  Thoughts on clinic 
Timeline  Sources of information  Understanding the risk 
  Behavioural changes 
P
r
e
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n
c
y
 
s
p
e
c
i
f
i
c
 
i
s
s
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e
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Fetal attachment 
  Comparison to other pregnant 
women 
Views of Health care 
professionals 
  Faith in Doctors/screening 
process  
Threat to mother or fetus 
    Medicalisation 
    Prior experiences of 
PE/Hypertension 
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5.3.7  ANALYTICAL METHODS 
OVERVIEW OF THE FRAMEWORK METHOD 
The framework analysis method was developed by researchers at the UK National 
Centre for Social Research [20]. The reason for the selection of the framework method 
is discussed in Chapter 3 – section 3.5. The approach involves a five-stage process to 
develop a hierarchical thematic framework to classify and organise data. Following a 
process of coding and summation (detailed below), the data were organised into a 
framework, or matrix. The developed matrix is organised with different respondents in 
rows, and different themes in columns, with the individual cells relating to that 
individuals view on that theme. This matrix aids identification of main themes, 
subdivided by a succession of related subtopics.  
FIVE STAGES OF FRAMEWORK ANALYSIS 
The content of the transcripts was analysed for emergent themes and coded using the 
matrix-based thematic method of the National Centre for Social Research (Framework 
analysis). This approach “facilitates rigorous and transparent data management such that 
all the stages involved in the analytical hierarchy can be systematically conducted for 
ordering and synthesising data” [20]. The approach uses five phases – initial 
familiarisation of the data set included listening to recordings and reading the transcripts 
several times. Initially this was done by the lead researcher himself transcribing audio 
recordings. However, it was recognised after the transcription of six recordings that this 
step was not needed to aid familiarization, and an approved transcription service was 
used instead. Each transcript was read while listening to the audio recording at least 
twice immediately prior to coding that transcript.   
Following familiarisation of the whole data set, an initial coding scheme was developed. 
The ‘code’ within Framework is synonymous with a ‘theme’ within other qualitative 
methodologies. The decision on what constitutes a ‘code’ is a key decision. The 
guidance of Braun and Clark [27] was used to help decide the constitute parts of the 
code.  
The coding scheme contained the illness representations from the CSM, as well as other 
themes that were judged to be important following the familiarisation stage. An 
additional coding option of ‘other’ remained on all coding schemes. This was then 
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systematically in turn. When a section of transcript was felt to match a particular theme 
within the coding structure, it was highlighted and allocated to that theme. An iterative 
approach was used, so that the coding scheme was adjusted during analysis. Following 
an adaptation of the coding scheme, all transcripts were re-coded. For example, if 
following the coding of a transcript a pertinent theme had been identified within the 
‘other’ code then that theme would be added to the coding scheme, and previously 
coded transcripts re-coded with the new scheme.  
After codes were assigned, the data were systematically summarised. This involved 
reviewing all segments of a particular woman’s transcript that had been coded into that 
section of the coding scheme, and summarising the viewpoint on that code. The NVIVO 
programme automatically populates the Framework matrix with all of the selected 
quotes for that theme, to aid the summation process. The aim was to summarise several 
quotations into as few a lines as possible, without diminishing or distorting the opinion 
of the woman.  
Following the synthesis, the summarised findings were reviewed within the matrix, 
where each row represented a woman, and a column a section from the coding scheme. 
An intersecting cell within the matrix therefore represents one woman’s data on that 
particular theme. This tabulation eased the categorisation stage where comparisons are 
made within and between women and themes.  
The codes were systematically compared for similarities and differences. The 
positioning of themes and women were changed to aid the process, and to test proposed 
models. Again, this process was simplified by the use of the NIVIVO programme, 
which allowed easy moving of columns and rows. As the completed matrix was large, at 
times only selected participants and/or themes were reviewed at one time.  
The coding scheme and its allocations were developed methodically and agreed upon by 
JH and BG.  Coding and the summation were independently verified by SM and BG, 
and an independent researcher, with the coding and summation each transcript reviewed 
by at least two researchers. The stages of the Framework process can be seen in 
Appendix 13. 
STAGES OF THE ITERATIVE PROCESS 
The process outlined above was completed three times in total. The initial occurrence 
was completed to assess data saturation. The data were revisited at a later date to ensure 
all themes had been extracted; this second review of the data resulted in a new coding Page 131 of 316    Chapter 5: Women’s Qualitative Study  
scheme being developed. The findings of the second process were presented formally to 
a seminar group of health psychologists. The group aided a discussion on the potential 
literature that could explain or refute the findings found. This prompted a further review 
of the literature, and a third analysis of the data, with minor changes to the coding 
scheme being made. The third process was aided by the release of NVivo Version 9.2, 
which is optimised for the framework approach. Table 5.1 illustrates the development of 
the coding structure over the three separate coding processes. 
5.4  RESULTS 
Of the 22 women invited to participate, 15 agreed, with those declining (four low-risk 
and three high-risk) citing lack of time as their reason. The demographic characteristics 
for each woman are shown in Table 5.1. As the richest data came from the women found 
high-risk for pre-eclampsia, the results focus on this sub group, with the women found 
to be low risk described briefly.  
5.4.1  LOW RISK WOMEN 
Low risk women were universally reassured by their low risk result, although all 
recognised that it did not exclude them from developing a hypertensive disorder of 
pregnancy. Low risk women tended to focus on the mechanisms of the screening test – 
issues with venepuncture, delays in getting results – rather than the positive result. 
While there was an indication that screening for pregnancy complications could impact 
on the perception of pregnancy being a normal life event (see quotation from woman 2 
in the medicalising the pregnancy section below), this was evident in one low risk 
woman only. All of the low risk women stated they would accept the offer of the pre-
eclampsia screening test in a future pregnancy.  
5.4.2  HIGH RISK WOMEN 
The data suggest that those found to be high risk for pre-eclampsia did not perceive 
themselves to be at risk for the condition.  
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TABLE 5.2 - DEMOGRAPHIC DETAILS OF THE WOMEN INTERVIEWED 
Code  Risk 
category  Age  Gestation at 
interview  Ethnicity (Nationality)  Profession 
LR 1  Low  31  13+5  Asian (Indian)  Nurse 
LR 2  Low  35  13+1  White (NZ)  Nanny 
LR 3  Low  32  14+1  White (German)  Management 
LR 4  Low  32  13+4  White (British)  PhD Student 
LR 5  Low  32  13+4  White  (American)  Management 
HR A  High  33  16+1  White (British)  Interior Designer 
HR B  High  35  14+4  White (Italian)  Lawyer 
HR C  High  29  15+3  White (British)  Journalist 
HR D  High  31  13+2  White  (British)  Health Policy 
HR E  High  36  14+2  Chinese (Australian)  Solicitor 
HR F  High  32  15+3  White (Slovakian)  Sales Assistant 
HR G  High  33  16+2  White (British)  Solicitor 
HR H  High  31  14+5  Chinese (British)  Health Economist 
HR I  High  34  13+2  White (British)  Academic 
HR J  High  28  14+1  White (British)  Journalist 
 
Two typologies of high-risk women emerged from the transcripts: 
1.  Danger managers (behavioural pathway): These women were focused on the 
maternal consequences of pre-eclampsia. Their interviews revealed a high sense 
of internal control and coping strategies that included information seeking, 
positive behavioural changes and cognitive reappraisal. They had a low 
perception of risk, regardless of being medically determined as high risk. 
2.  Fear managers (emotional pathway): These women focused on the fetal 
consequences of pre-eclampsia. Their interviews revealed a high sense of 
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avoidance. They also had a low perception of risk, regardless of being medically 
determined as high risk.  
These typologies are discussed below, with further supportive quotes provided in Table 
5.2. In addition to these typologies, three universal themes of ‘medicalising the 
pregnancy’, ‘embracing technology’ and ‘acceptability’ emerged from the data. These 
are also summarised below.  
DANGER MANAGERS 
Despite pre-eclampsia presenting a risk to both mother and fetus, the high-risk women 
appeared to polarise this risk, focusing on either the possible effects to themselves or 
their fetus. No women focused on both. This sub group of women were concerned about 
the risk that the high-risk result presented to their personal health, such as hypertension 
or maternal death, rather than the potential risks to the fetus. 
“I think the risk to me – I don’t know because my theory with preeclampsia is it’s 
something bad that happens to the mother, the baby’s actually fine inside you, they’ve 
just got to get it out because your body can’t cope with it. So you kind of already feel 
like a bit of a failure that your body can’t cope with having a baby.” (Woman C, high-
risk) 
This group also expressed a sense of personal responsibility (‘internal control’) 
regarding the health threat 
“Um… Well, I suppose I don’t think it’s true that there’s nothing you can do about it. I 
think there are some things that you can do that help reduce the risk factor.” (Woman F, 
high-risk) 
Three coping strategies were commonly reported by these women when presented with 
risk information. Initially, they sought further information, generally from Internet 
searches, on how pre-eclampsia could affect them. Despite being given no advice to 
change their behaviour, they often instigated positive health-behaviour changes, 
including dietary change, more exercise and stress-reducing activities. The women 
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reduce their risk of pre-eclampsia developing. Third, the women reappraised their given 
risk, so that they no longer felt they would develop pre-eclampsia. To illustrate this 
process, three quotes from one woman (Woman A, high-risk) are given below; an initial 
emotional reaction to the risk information she was given, followed by seeking 
information from the Internet, instigating behaviour changes and then concluding that 
the threat was not real. Further supportive quotes can be found in Table 5.2. 
“Erm, I didn't really know anything about it before, but then I did kind of a lot of 
reading on Google, which was probably a terrible mistake, it was awful.” (Woman A, 
high-risk) 
“I’m definitely taking it easier than I was with everything, with work with sleep with 
resting, so maybe in that sense it was quite good, it made me slow things down quite a 
bit” (Woman A, high-risk) 
 “No, but only because the last few times that they’ve taken my blood pressure it’s been 
normal and they’ve been quite happy with how everything looks on scans and…  To be 
honest since the…  Well after the first hypertension appointment I didn’t really feel like 
high-risk.” (Woman A, high-risk) Page 135 of 316    Chapter 5: Women’s Qualitative Study  
 
FEAR MANAGERS 
The Fear manager group was concerned with the risk that pre-eclampsia posed to the 
developing fetus, rather than to their own health. They focused on consequences such as 
pre-term birth and growth restriction: 
“And the result is the blood flows too quickly, so the baby doesn’t get the nutrients, so 
the baby becomes small and underweight.  And possibly premature. Because it’s small, 
it might come out earlier.  And also they may want to take it out earlier, the baby is not 
getting her nutrient.”  (Woman E, high-risk) 
These women did not report instigating any behaviour changes. They exhibited a 
reliance on the healthcare professionals and the additional monitoring that the 
hypertension clinic presented.  
“But I think I have really taken the attitude that “Well I’ll just kind of go along with 
what the hypertension clinic do.”  And I won’t really ask that many questions and you 
know if they’re happy, they’re happy, I’m happy.  And I’ve, it’s quite unusual but I’ve 
FIGURE 5.3 - PICTORIAL REPRESENTATION OF DANGER MANAGER GROUP, AS ADAPTED 
FROM THE CSM 
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sort of switched off really from trying to know everything.  And as long as they’re happy 
I feel happy so that’s kind of it.” (Woman G, high-risk). 
The increase in monitoring provided a way in which these women could check on the 
health of their pregnancy, in addition to, or instead of, self-monitoring.  
“No. Like yesterday when I went there I was like, “I haven’t been feeling the baby move 
at all yet. Oh my God...” This is great because I’m going to see it and hear the heart 
beat and it’s going to be alive hopefully.”(Woman H, high-risk) 
Like the Danger manager group, many of the Fear managers sought information on the 
health threat on the Internet. However, this group were more selective of the type of 
information that they sought, avoiding potential anxiety-provoking information.  
“Well, I googled preeclampsia but literally probably – not the top hit, because the top 
hit was a Wikipedia site, but like the second or third hit was NHS sites. And the other 
sites were like information places for mothers and pregnant women which I find a little 
bit too scaremongery sometimes and in some cases overly negative.”(Woman I, high-
risk) 
“Wikipedia preeclampsia. And I have to say I was none the wiser.” (Woman D, high-
risk) 
These women appeared to cope with the health threat by not engaging with the concept 
of being high-risk for pre-eclampsia: 
“Well, they don't tell me that I was high risk, they was the…the…value was slightly 
high, er…. they’re talking about it might be, but it might be not. And it wasn't a… they 
told me it wasn't a high risk that they told to me, just to check, just in case, to prevent 
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Woman B’s discord between her communicated and perceived risk appears to be 
influenced by her beliefs about the type of people who are likely to develop pre-
eclampsia, or have high blood pressure.  
 “but I thought maybe with people with problem of weight, and erm maybe or suffering 
from high blood pressure, so, not me, not - because it wasn't a story of my family, so I… 
it felt so strange for me, I think ‘what?!’.” (Woman B, high-risk) 
Unlike woman A, this woman had little sense of control over pre-eclampsia, specifically 
mentioning that there was nothing she could do to stop it from happening.  
 
5.4.3  GENERAL THEMES  
MEDICALISING THE PREGNANCY 
The screening process changed the way in which many of the women regarded their 
pregnancy, shifting it from it being a normal life event to something to worry about. 
This was evident with both high and low-risk women. The number of screening tests 
FIGURE 5.4 - PICTORIAL REPRESENTATION OF FEAR MANAGER GROUP, AS ADAPTED FROM 
THE CSM 
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that were conducted at one time led women to interpret pregnancy as ‘not as 
straightforward’ as previously anticipated. 
“I think it’s just this contradiction of the pregnant woman not being a patient and not 
being ill, but at the same time being treated as if it was –…you know you see the 
machines and the environment is just… as if you are a patient and the way they treat 
you feels that way and that’s the weird contradiction that makes you feel you should be 
very relaxed about it and its the most normal thing in the world and at the same time 
you have [things] to worry about”(Woman 2, low-risk) 
Those found to be high-risk reported that their excitement was tempered by the result, 
and that despite the exciting news that all was well with the fetus, they could not be 
completely happy. 
“So we were kind of thinking “This is brilliant, we can tell everyone now and it’s…”  
Isn’t it fun kind of thing.  And then to get the phone call it was sort of “Oh it’s not quite 
as straightforward as I thought.”(Woman G, high-risk) 
EMBRACING TECHNOLOGY 
Despite the reservations described above, the high-risk women expressed pleasure about 
the subsequent increased ultrasound tests they were to have. It gave them greater 
opportunities to ‘see’ their baby, and to attribute to it personality characteristics. This 
was seen as the key reason for attending these appointments, rather than for monitoring 
the progression of pre-eclampsia. Blood-pressure measurements and blood test results 
did not appear to be valued as highly  as that the ultrasound.   
 “that's why I’m still quite, any time I come here, I’m just excited and worried, but not 
because of pre-eclampsia but because its, every time I saw, I can see my baby”(Woman 
B, high-risk) 
There was some evidence that the increased ultrasound monitoring led to a decrease in 
self-monitoring of personal or fetal wellbeing, such as less monitoring of fetal 
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“But I do think that’s because I feel really comfortable with the hypertension team so it’s 
not like I’m delegating to them but I kind of feel like if there was anything wrong they 
would pick it up, so I don’t need to” (Woman G, high-risk) 
ACCEPTABILITY  
As there are no current treatment options for pre-eclampsia, many women discussed 
whether knowing they were at high risk was worth the increase in worry that it may 
cause. The majority felt that being prepared was an advantage, that it is ‘best to know’ 
in advance about the risk of developing a potential worrying condition. Women reported 
that, by knowing they were at increased risk of pre-eclampsia, they would be more 
likely to recognise the onset of the disease if it developed. However, only two women 
were able to identify soft symptoms of pre-eclampsia such as headaches, photophobia 
and epigastric pain. 
 “No, because you are prepared.  You can plan and prepare and read up on it, get your 
information on it, have time to think about it.  I don’t think it causes you extra worry.  It 
would be more worrying if it’s happened to you and you have no idea what’s happening 
and what the symptoms were.”(Woman E, high-risk) 
A minority of women questioned the usefulness of providing information for a 
condition that had no treatment or risk-reduction interventions associated with it, 
suggesting that the screening programme had the potential to increase anxieties without 
providing a clear benefit: 
 “it might actually strangely have an affect on my body, and to carry that for sort of 20 
weeks worrying erm I’m not sure that is a good thing because in the end if you are 
going to develop it regardless then if you’re told at that point, you know when you 
develop it then you know, there is nothing that can be done either way, so…”(Woman A, 
high-risk)  
Alongside the discussion of the usefulness of the screening test, some women discussed 
the risk reduction interventions they would engage with if they were available. There 
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because medicines were perceived to carry with them additional risks that may 
outweigh the risk for pre-eclampsia.  
“Like a special kind of exercise every day? I would.  That of course I would.  But to eat 
chemicals, and especially when you are pregnant, I would think very much about it.  I 
don’t think – well, if they said to me, “Look, if you don’t take this tablet your baby might 
die or whatever,” of course I will.  I’m not being unreasonable.  But as a choice I would 
say no.” (Woman F, high-risk) 
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TABLE 5.3 - FURTHER ILLUSTRATIVE QUOTES OF THE TWO TYPOLOGIES FOUND 
 
Danger Managers  Fear Managers 
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“But I suppose what it has done is made me conscious 
I’m somebody that will push myself to the absolute limit 
on my day to day life… And it’s made me realise that I 
can’t do that. I need to perhaps take – not give up on life 
but you know, take it a bit more easy or put my feet up. 
Or if I’ve got a headache, try and sleep or rest to try and 
get rid of it. Or something rather than just think “Oh, it’s 
fine. No problem.” (Woman D, HR, 344-351) 
 
“I don’t think I can fully control. I think I can help 
reduce the risk. By managing stress – trying to manage 
stress, exercising to what’s recommended, I suppose, 
eating healthily and being good.” (Woman H, HR, lines 
374-379) 
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“This is the thing because there’s nothing I can do about 
it. There’s nothing I can change. Apparently, anyway; 
this is what I have been told. There’s nothing you can 
do, nothing you can change. You don’t need to eat 
anything differently. Nothing you can do. Just tough shit 
basically…So there’s not any other way you can deal 
with that other than go, ‘It could happen to anybody.’ ” 
(Woman E, HR, lines 745-756) 
 
Whereas now I feel I’ve got a monthly appointment and 
any anxieties I have I can do that instead of looking at 
crazy mumsnet discussions or something like that.” 
(Woman J, HR, lines 164-165) 
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“I felt like all of the other risks that you are screened for 
about the baby, but when I read more about pre-
eclampsia I sort of, apart from premature delivery 
premature birth I couldn't really see, it didn't seem like 
there were long term effects after the birth for the baby 
and I was more worried about me because I felt like if I 
was getting into trouble” (Woman A, HR, lines 457-465) 
 
“I know pre-eclampsia’s quite risky and stuff for the 
mother and things, but I didn’t realise it affected the 
child as well, I knew it was something to do with high 
blood pressure, I know it can cause migraines and 
epilepsy in the mother” (Woman H, HR, lines 184-188) 
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“You do tend to kind of think about the effect that it will 
have on the baby more, I think I think about that more 
than me only in the sense that I know at the moment if I 
got it tomorrow then it wouldn’t, well I don’t think we’d 
have a baby if it was really serious then we would lose 
the baby.” (Woman G, HR, lines 752-755) 
 
“The main concern I think was the fact that the baby 
may not grow as well as expected for it, so that was 
really my main concern, I think. Yes, whether he’ll be 
okay after delivery and things. If that’s an option at that 
point or whether his growth is going to be particularly 
affected up until delivery, that’s probably another issue 
as well. So yes, just to make sure that he’s okay.” 
(Woman I, HR, lines 161-165) 
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“So I suppose I know I’ve got a high risk. I’m taking 
mitigating actions and therefore, until I start getting 
symptoms, I’m not going to worry about it.” (Woman H, 
HR, lines 332-334) 
 
“I feel it’s really strange because I feel like my take on 
this has just completely done a u-turn in a month and 
maybe it shouldn't have but a few weeks ago I would 
have absolutely said much much more likely and now I 
just feel after what the doctor said and after how I feel, I 
wouldn't say I feel much more likely” (Woman A, HR, 
lines 319-321) 
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“The clinic doesn’t mention preeclampsia, they seem to 
log lots of measurements, blood flow, blood supply to 
my heart, my heart’s moving through the cord and lots 
of things, and they seem to be happy with what they see 
for the findings. So that’s really telling me, oh yes, you 
are not going to get preeclampsia.  But you have to 
continue to go back to the clinic.” (Woman E, HR, lines 
319-323) 
 
“I feel really like I’m having a healthy pregnancy and I 
really feel like I’m being monitored for something that I 
don’t really feel I’m at risk of.”  (Woman J, HR, lines 
270-271) 
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 “I think its simply that I cant work out why I am so 
therefore my gut says if I don't fall into all of the high 
risk categories and the blood pressure is supposed to be 
ok, and the second scan blood flow is ok, there is nothing 
indicating at the moment that I should be worried” 
(Woman A, HR, lines 267-271) 
 
“Which is why I think I kind of feel like I am a bit of a 
fraud because perhaps the only reason why it was high at 
8 weeks and 12 weeks was because I was quite stressed 
out anyway about telling work.”  (Woman F, HR, lines 
359-361 
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 “They seem to be happy with what they see for the 
findings.  So that’s really telling me, oh yes, you are not 
going to get preeclampsia.” (Woman E, HR, lines 321-
323) 
 
“But at this point I just refuse to believe that I will get 
it, and I don’t want it.  I mean, who wants to?  So I just 
hope and believe that no.” (Woman G, HR, lines 338-
341) 
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5.5  DISCUSSION 
To the best of our knowledge this research is the first investigation into the experiences 
and perceptions and potential psychological effects of providing prenatal screening 
information for pre-eclampsia. This study found that women undergoing a first trimester 
screening test for pre-eclampsia regarded it as generally acceptable, with a minority 
questioning its usefulness in the absence of associated treatments. The results suggested 
two typologies of women, differing in their illness representations and associated 
coping strategies to mitigate the health threat. They also suggested potential positive 
and negative unintended consequences of the screening test. The most obvious were 
self-instigated behaviour changes with positive consequences for health, and a decrease 
in self-monitoring which may have negative consequences as the pregnancy develops.   
The typology characterised as the ‘danger managers’ showed evidence of positive 
behaviour changes without prompting from care providers, suggesting that this screen 
may have health benefits to these women. This is consistent with findings that women, 
when presented with a prenatal screening test that affects maternal health, show positive 
changes in their behaviour, such as improving diet after being screen positive for 
gestational diabetes [28] and improving safer-sex practices after being screened for HIV 
[29]. However, screening-tests focusing on the fetus have not been found to have the 
same effect. For example, ultrasound screening has not been found to reduce smoking 
rates in pregnancy [30]. The findings from the present study showed a similar pattern; 
where the women who were concerned about the consequences of pre-eclampsia to their 
own health instigated behaviour changes, while those who were concerned about the 
consequences to the fetus did not. The data suggest that this is related to the greater 
sense of control that some women expressed in relation to the test’s consequences for 
themselves, as demonstrated by the spontaneous behaviour changes. This finding is 
supported by many psychological theories of behaviour, including the CSM, which 
feature control as a central construct. There is evidence that certain personally 
modifiable behaviours, including rest at home [31], consumption of antioxidants [32] 
and increased calcium consumption [33] reduces the risk of pre-eclampsia. Given the 
potential for behavioural interventions to have benefits beyond Pre-eclamspsia risk, and 
the relatively small investment in research in this area to date, a priority for research 
into behavioural interventions to reduce pre-eclampsia and other pregnancy risks is 
warranted.  Page 143 of 316    Chapter 5: Women’s Qualitative Study  
Central to the CSM is the belief that once presented with a health threat, individuals 
attempt to associate perceived causes of the threat with perceived beliefs about its 
treatment [34]. The ‘danger manager’ group appeared to have a clear model linking an 
increase in their blood pressure with health behaviours, and therefore instigated these 
behaviour changes. However, the ‘fear manager’ group, who perceived the 
consequences of pre-eclampsia to be preterm birth and fetal growth restriction, had no 
such clear model on how to reduce this threat. The associated lack of internal control 
appeared to increase their reliance on their care providers. There was some evidence in 
this study that this increased reliance on care providers might also lead to a decrease in 
self-monitoring. As the pregnancy develops, so ‘soft symptoms’ (e.g.,epigastric pain, 
photophobia) and/or a reduction in fetal movements may be ignored until the next 
appointment. In view of this care providers will need to ensure that women appreciate 
the importance of self-monitoring personal and fetal wellbeing. 
The women found to be at high risk for pre-eclampsia did not perceive themselves to be 
at high risk, and the women found to be at low risk were not always reassured by the 
low-risk information they were given. It has been shown previously that pregnant 
women may interpret results of screening tests differently than their providers [35, 36]; 
therefore, a woman’s assessment of her risk is often at odds with those of her care 
providers [11]. Women’s understanding of their screening test results are influenced by 
their common-sense representations of the health threat [34]. In this study, the 
perception of low risk by the high risk group did not appear to have an impact on 
adherence to the recommended increased monitoring. The women in this study were 
motivated to attend the additional monitoring offered because of the high value they 
placed on ultrasound scans. It is unknown if an intervention that did not provide a visual 
image of the fetus, such as increased community-based blood pressure monitoring, 
would have been as valued.  
This study was exploratory in nature, and it was not intended to be an exhaustive 
assessment of all the possible psychological effects of this new screening test. There are 
several lines of future enquiry that are suggested by this study, such as how the results 
of this screening test would impact on obstetricians’ and midwives’ management of 
pregnant women, and effects throughout the pregnancy on factors such as perceptions of 
health, birth choices and prenatal attachment. Further research is also needed to 
determine if these findings are generalisable to other conditions with screening tests for 
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The study findings should be considered in light of its limitations, including the small 
number of participants, opportunistic recruitment and the over representation of well-
educated, employed women, which limit the generalisability of the findings to the wider 
population of pregnant women. Potential for bias in the interviews and analysis related 
to the beliefs and assumptions of the midwife interviewer was mitigated in several 
ways, including conducting the study in a setting where the midwife researcher was not 
a member of the care team, input from a multidisciplinary research team and clinicians 
in constructing the interview guide and in the analysis.  Nonetheless, this study provides 
strong preliminary evidence upon which future studies can build. 
The larger bioethics debate continues as to whether or not screening programmes should 
be introduced when there is no cure for the screened-for condition, or any risk-reduction 
interventions [37]. The women interviewed in this study were all supportive of the 
screening test, advising that they would have it again in a subsequent pregnancy if 
offered. However, a minority did question its usefulness in the absence of treatments. 
Research is on-going into the efficacy of preventative treatments for pre-eclampsia [38], 
which may enable a move from ‘screen-to-monitor’ to ‘screen-to-prevent’. If this 
research is successful, there is potential for these novel screen-to-monitor tests to 
decrease maternal and fetal morbidity and mortality in the future. However, the position 
of the UK’s national screening committee is that their clinical utility remain unproven 
[39] and the potential ramifications of providing pre-eclampsia risk information to 
pregnant women are under-researched.  
5.6  CONCLUSION 
Women appeared to broadly welcome the pre-eclampsia screening programme, and 
were receptive to the increased monitoring that a high-risk result leads to.  This study 
indicates that women with an increased risk of pre-eclampsia would be willing to 
engage in efforts to reduce their risk of pre-eclampsia, and there is a potential to use this 
screening test as a basis for improving health more broadly. 
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CHAPTER 6 - BARRIERS AND FACILITATORS TO 
OFFERING A UNIVERSAL SCREENING TEST FOR PRE-
ECLAMPIA AS PERCEIVED BY MIDWIVES AND 
OBSTETRICIANS: A QUALITATIVE STUDY 
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6.1  ABSTRACT 
Objective : A new first-trimester universal prenatal screening test for pre-eclampsia 
was introduced into two UK hospitals. The aim of this study was to investigate the 
barriers and facilitators to healthcare professionals of providing pregnant women with 
formal risk information for pre-eclampsia 
Design:  Cross-sectional interview study. Healthcare professionals were interviewed 
using a theoretically informed semi-structured schedule and transcripts were analysed 
thematically using Framework Analysis  
Setting and participants: Obstetricians and midwives at a central London National 
Health Service Foundation Trust providing care for women who had undergone a 
screening test for pre-eclampsia. 
Findings: 10 obstetricians and 10 midwives were interviewed. Facilitators included 
optimism (the potential to improve outcomes) and environmental resources (specialist 
clinics increased time for low-risk women). Barriers included beliefs about 
consequences (potential increase in anxiety for screen-positive women), beliefs about 
capabilities (the accuracy of the test was questioned), characteristics of outcome 
expectancies (the screening test may ‘medicalise pregnancy’), and organisational 
culture (lack of expected consultation prior to introduction). 
Conclusions: Broadly, midwives were more accepting of the screening test than 
obstetricians. The majority of concerns with the screening test were limited to concerns 
related to the specific screening test that had been introduced into the study hospital, 
rather than pre-eclampsia screening in general. 
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6.2  BACKGROUND 
The qualitative study described in Chapter five of this thesis discovered that women 
labeled as high-risk for pre-eclampsia were influenced by their care providers’ opinions 
of the screening test result. These data, alongside other studies [1-3] illustrate the way 
healthcare professionals (HCPs) attitudes can affect the individuals they care for.  
The views of HCPs regarding screening tests have been sought both generally and for 
specific tests. Two studies have shown that although women and HCPs generally agree 
on the usefulness of prenatal screening tests, HCPs tend to prioritise the accuracy of a 
test while women focus on safety aspects [4,5].  
All healthcare decisions involves bringing together a healthcare professional, 
considered a scientific expert on the decision to be made and the individual, considered 
an expert in their own personal values [6]. Despite a push for ‘consumer led healthcare’ 
[7], the views of obstetricians and midwives are over represented in organisations such 
as the National Institute for Clinical Excellence and the National Screening Committee 
[8]. HCPs therefore may have a greater influence on policy than pregnant women. Any 
assessment of a change in prenatal screening provision requires an exploration of the 
potential barriers and facilitators to HCPs offering and recommending that screening 
test.  
Professional identity within maternity care is complex, with different professionals 
having contrasting models of pregnancy and birth. A dichotomy exists between a 
‘midwifery model’ and a ‘medical model’ of maternity care. The ‘midwifery model’ 
assumes that pregnancy is a natural, non-pathological process. Midwives favour a 
partnership care approach, prioritising preventative and qualitative dimensions of care 
[9]. Conversely, the ‘medical model’ anticipates “pathology and abnormality, is 
concerned with managing risk and liability, and devoted to protecting the status of 
scientific medical knowledge and technology” [10]. It has also been shown that despite 
overall support for prenatal screening programme, obstetricians tend to have more 
positive attitudes towards them than midwives [3]. The provision of a first-trimester 
screening test for pre-eclampsia could be interpreted as supportive of the medical 
model, as it facilitates risk management and anticipates problems. However, it is 
currently unclear if its provision will be universally interpreted in this way. Screening 
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reduction intervention is available. Health professionals may see the provision of this 
screening test as a first step towards preventing women becoming seriously ill, and 
thereby protecting the low-risk status of maternity care.  
HCPs views of screening tests have been sought previously. Two studies have shown 
that although women and HCPs generally agree on the usefulness and acceptability of 
screening tests, HCPs prioritise test accuracy while women focus on the safety aspects 
of the screening test. Two studies looking at HCP attitudes towards screening for 
postnatal depression illustrated that HCPs need to feel confident about all areas of a 
screening test before they feel able to both offer the test and interpret the results [11,12]. 
Further research suggests that HCPs conduct an assessment of the potential 
psychological and physical costs before offering a screening test; some HCPs would not 
offer a screening test when only marginal benefits were anticipated [13]. 
No research was found that investigated HCPs views on pre-eclampsia screening. The 
research presented within this chapter aimed to explore the views of midwives and 
obstetricians on this new provision. The research was informed by various health 
psychology theories, including the CSM (discussed in Chapter 3) and the theoretical 
domain framework (TDF) [14]. The TDF was developed to facilitate the accessibility of 
psychological theories for behaviour change in the development of interventions. 
Developed via a consensus approach [14], it consists of fourteen domains including (i) 
knowledge; (ii) skills; (iii) social or professional role and identity; (iv) beliefs about 
capabilities; (v) beliefs about consequences; (vi) memory attention and decision 
processes; (vii) environmental context and resources; (viii) social influences; (ix) 
emotions; (x) behavioural regulation and (xi) optimism; (xii) reinforcement; (xiii) 
intentions and (xiv) goals.  
6.2.1  RESEARCH QUESTIONS 
This exploratory work aimed to provide a preliminary understanding of the potential 
barriers and facilitators for midwives and obstetricians in regards to first-trimester 
screening for pre-eclampsia.  
This study had two aims. Firstly, to explore what were the HCP’s experiences related to 
the introduction of this screening test at their trust, including an exploration of any 
barriers and facilitators they identified to its nationwide introduction. Secondly, to 
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(Chapter 5).  
6.3  MATERIALS AND METHODS 
6.3.1  DESIGN 
This study used a qualitative semi-structured interview design and Framework Analysis 
[20]. The systematic review (Chapter two) identified that no research had been 
previously conducted that could be directly applied to the pre-eclampsia screening test. 
The justifications for a qualitative, exploratory semi-structured interview design are 
explained in both Chapter 3 and 5.  
6.3.2  SETTING 
The study was conducted in a large teaching hospital in central London serving a multi-
ethnic population. At the commencement of data collection, screening for pre-eclampsia 
had been routinely offered for around 2 years. A woman’s first appointment is with a 
midwife around 3 weeks prior to the pre-eclampsia screening test taking place. The 
midwife takes a detailed family and medical history in order to judge if referral to an 
obstetrician is needed. Pregnancies identified as ‘low-risk’ remain under midwife led 
care, while those identified as ‘high risk’ follow a care pathway specific to that problem. 
The screening tests are conducted during the first ultrasound scan. Being found screen 
positive for pre-eclampsia did not in of itself result in a pregnancy being considered 
high-risk, although factors contributing to a screen-positive result (previous pre-
eclampsia) may have done. Therefore women found screen positive could have 
remained under midwife-led care, or have received obstetric-led care. Following a 
positive pre-eclampsia screening test, women are referred to a hypertension clinic. 
These appointments can be in addition to, or instead of, the routine appointments, as 
decided by the pregnant woman.  
6.3.3  SAMPLE 
Purposive sampling methods were used to investigate the views of the range of 
disciplines within the two professions providing healthcare for pregnant women at this 
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midwives, hospital care midwives and intrapartum midwives. No other categories of 
HCP provide prenatal care at this hospital. The sample will include those who work 
with women who are labeled as high-risk as a result of the pre-eclampsia screening test, 
as well as those who work in low-risk setting with women who have been labeled as 
low-risk as a result of the pre-eclampsia screening test. Ten individuals from each 
profession (obstetrics and midwifery) were interviewed. Following this, an assessment 
of the richness and completeness of the data collected was made. Inclusion criteria 
included working at a hospital that offers a pre-eclampsia screening test, knowing about 
that test, and providing care for a woman who had undergone the screening test. 
Exclusion criteria included not being an obstetrician or midwife, having no prior 
knowledge of the pre-eclampsia screening test, and not being fluent in English. 
6.3.4  PROCEDURE 
A National Health Service research ethics committee gave ethics approval 
(ref:10/H0806/83). Potential participants were given 24 hours to consider a study 
information leaflet prior to giving informed written consent. The lead researcher (JH) 
conducted the interviews at a location and time chosen by each participant, each 
conducted by the lead researcher (JH). All interviews were conducted at the study 
hospital. Audio recordings of the interviews were anonymised prior to transcription to 
protect confidentiality.  Semi-structured interviews were conducted according to an 
interview guide (Figure 6.1) that that aimed to explore the healthcare professionals 
experiences of the pre-eclampsia screening test, and attempted to identify any barriers 
and facilitators to the tests introduction. Amplificatory probes were used to ensure a full 
description of the professional’s views. The interview guide was piloted to assess 
coherence and logical flow. Following this, some questions were re-ordered but none 
reworded. Recordings were transcribed verbatim.  All transcriptions were completed by 
an authorised transcription service (see Appendix 9 for confidentiality agreement). 
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This study took the following steps to minimise bias and increase reliability, in 
accordance with Yardley [23]: theory informed the design and analysis of the study, two 
members of a patient liaison group for maternity care provided advice on the study 
protocol and interview guide, and two independent coders analysed the transcripts.  
6.3.6  ETHICAL CONSIDERATIONS 
The local National Health Service research ethics committee gave ethics approval (ref: 
10/H0806/83, approval letter in Appendix 10), the process of which included gaining 
site-specific authority from the NHS trust that data were collected.  
An information leaflet describing the study was given to potential participants (see 
Appendix 14). A period of at least 24 hours was allowed between receiving the 
  We are here to discuss a new prenatal screening test. Can we start by 
discussing what your views of screening are generally? 
  What do you know about the pre-eclampsia screening test that women are 
given at 11 weeks?  
  Do you know how the results are given? 
o  Prompt – are you aware of the cut offs for High-risk, and what happens 
to these women? 
o  What are your thoughts on the screening process?  
  Ensure prompts so you get a full understand of what the HCP thinks about the 
screening process and its results 
  Have you had any positive or negative experiences regarding the PE screening 
test to date? 
o  Could you envisage any positive or negative side affects of the 
screening process for women?  
o  For you as a professional? 
  What could be changed to help you trust the screening test more? 
  What would make you trust the screening test less? 
  Does the pre-eclampsia screening test affect the care or advice you give to 
women? 
o  Prompt: Do you review the results during a consultation? 
o  Prompt: Does it affect birth planning advice that you give? 
  How do you feel the screening test may change your work in the future? 
  Would you recommend that a friend had the screening test? 
  If you had limitless resources, would you change the screening program at all?  
o  Prompt: If you changed hospitals, would you recommend an 
introduction of a screening program for PE? 
 
FIGURE 6.1 - INTERVIEW GUIDE Page 155 of 316                          Chapter 6: Healthcare Professional’s Qualitative Study  
information leaflet and the researcher contacting the women to ask if they were allowed 
to take part. This enabled sufficient time to consider the leaflet. Prior to commencing 
the interview, consent was gained and professionals were asked to sign a consent form 
(Appendix 15). Participation in this study was confidential. Although transcripts and 
other data were shared with the whole research team, there was no sharing of 
identifying data. Individual semi-structured interviews can be intrusive and some people 
can find the questions uncomfortable or distressing to answer. In order to protect 
women, certain safeguards were put in place. All interviews were conducted in a 
respectful and non-threatening manner. If participants showed evidence of becoming 
distressed, the researcher or the professional had the right to terminate the interview. At 
the end of the interview professionals were given the opportunity to ask any questions 
or raise any concerns that they had.  
Data were, and continues to be, stored in accordance with the Data Protection Act 1998 
and Caldicott principles [26]. All information was anonymised as soon as possible, and 
stored on a secure server. No transcriptions with identifiable data were made. 
Anonymised transcripts and digital recordings alongside consent forms will be stored 
for 5 years.  
6.3.7  ANALYTICAL METHODS 
The data were analysed using the Framework Analysis method [20]. The reason for the 
selection of the framework method is discussed in Chapter 3 – section 3.5. A detailed 
account of the methodology is given in Chapter 5.  
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6.4  RESULTS 
Of the 27 healthcare professionals invited to participate, 20 agreed, with those declining 
(four obstetricians and three midwives) citing lack of time as their reason. The 
demographic characteristics for each professional are shown in Table 6.1. Broadly, 
midwives were more supportive of the screening test than obstetricians, although 
individual variation occurred.  
TABLE 6.1 - DEMOGRAPHIC DETAILS OF THE WOMEN INTERVIEWED 
Code  Profession  Current grade  Area of work 
(midwives only) 
MW1  Midwife  Band 6  Community 
MW2  Midwife  Band 7  Fetal Medicine 
(research) 
MW3  Midwife  Band 7  Community 
MW4  Midwife  Band 8C  Birth Centre 
MW5  Midwife  Band 7  Antenatal Clinic 
MW6  Midwife  Band 8D  Management/Policy 
MW7  Midwife  Band 8C  Management/Policy 
MW8  Midwife  Band 7  Postnatal Ward 
MW9  Midwife  Band 6  Community 
MW10  Midwife  Band 6  Labour Ward 
OB1  Obstetrician  Consultant (Reader)   
OB2  Obstetrician  Consultant (Senior Lecturer)   
OB3  Obstetrician  Consultant (Professor)   
OB4  Obstetrician  Senior Registrar   
OB5  Obstetrician  Senior Registrar (Research Fellow)   
OB6  Obstetrician  Registrar   
OB7  Obstetrician  Registrar   
OB8  Obstetrician  ST2   
OB9  Obstetrician  ST2   
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Many HCP’s presented a mixed opinion of the screening test, providing positive and 
negative feelings during the interview. The results presented below are grouped into 
facilitators and barriers to the screening test’s introduction. 
6.4.1  FACILITATORS 
Facilitators included optimism (the potential to improve outcomes) and environmental 
resources (specialist clinics increased time for low-risk women). 
OPTIMISM – IMPROVED OUTCOMES 
When discussing screening for pre-eclampsia generally, many HCP’s were excited with 
the potential research potential that the screening test presented. They felt that it was a 
first step to finding a treatment for a very serious condition.  
“So I think the more information we have about it the better and maybe one 
day we will be able to find out what the cause is. And, you know, possibly in 
the future we will be able to prevent it.” (MW6) 
“I think it’s a good idea for research purposes, but I think it is a good idea 
for... not just women now, but, you know, women in ten years’ time, women 
in twenty years’ time. Because if it turns out that screening isn’t worth it 
and it’s not helping anybody and it’s not beneficial, then that saves women 
in ten, twenty years’ time needing screening. But actually if we do find 
something from the screening, that could equally go and help future women 
have healthier pregnancies.” (MW9) 
Alongside these anticipations for the future, some HCP’s anticipated the screening test 
improving outcomes immediately.  
“I guess so that we can be more aware of these women and treat women - 
for example these women who are considered high risk, if they have a sort 
of blood pressure that’s a bit borderline maybe you would bring them back 
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“I guess you're being seen more regularly so it means you're more likely for 
it to be picked up sooner rather than later. And that if it is picked up is 
beneficial because the earlier you act presumably the easier - you know, the 
earlier you're involved the earlier you kind of prevent full blown eclampsia 
or you can manage people’s blood pressure and...”(OB10) 
One respondent was able to give specific examples of women they cared for that had 
benefited from the screening test.  
And the positive is that I’ve known quite a few women who have had the 
screening and then they have picked up pre-eclampsia on them and the 
baby’s been alright and she’s been alright so that’s a positive. (MW7). 
ENVIRONMENTAL RESOURCES – SPECIALIST CLINICS  
There was a general consensus that providing high-risk clinics could be beneficial. This 
would help both the high-risk women get additional monitoring, and could change the 
pattern of care for low risk-women. Many midwives felt that the introduction of a 
hypertension clinic for those at risk meant that the model of care for low risk women 
could be altered, so that the physical monitoring that took a lot of time during their 
antenatal appointments could be given less priority, and the emotional elements of 
pregnancy could be given more attention.  
“If we could concentrate our efforts on taking blood pressure and testing 
urine on those and doing the social model of midwifery for the others, in a 
different format, and offering them different choices for both groups, I think 
that could be a win/win solution in the long-term.”  (MW1) 
“And that we don’t just have 15 minute slots for women where we don’t 
barely talk to them and take their blood pressure, their urine, and do this 
measuring, because all of our screening will show up the ones that might 
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“because in principle it is a good idea, identifying women who can be 
managed in a high risk setting, followed up frequently, and those who can 
be - and this is actually as important, is to let the vast majority have a much 
looser level of antenatal care because they are clearly at low risk.” (MW 6) 
It was also felt that the clinics would ensure that any problems would not be missed by 
the inherent constraints of routine care, and that additional monitoring would have an 
inherent benefit in detecting disease that may otherwise be missed.  
“So presumably if you’re saying this group for given reasons has the 
potential and you’re looking at them more closely, then they’re not slipping 
through the net and you may end up delivering them earlier when - before 
the womb environment has reached its optimum venue date kind of thing.” 
(MW2) 
“I think if women are receiving more care they're less likely to be in 
emergency situations and that’s definitely something that’s - if we can 
reduce the number of women who are affected by preeclampsia then that 
would be great.” (OB4)  
6.4.2  BARRIERS 
Barriers included beliefs about consequences (potential increase in anxiety for screen-
positive women), beliefs about capabilities (the accuracy of the test was questioned), 
characteristics of outcome expectancies (the screening test may ‘medicalise 
pregnancy’), and organisational culture (lack of expected consultation prior to 
introduction). 
BELIEFS ABOUT CONSEQUENCES – INCREASES TO ANXIETY 
There was a feeling that providing the screening information would increase the anxiety 
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“And they may have much more anxiety and much more perception that 
they're unwell and their baby’s unwell  due to the screening.”(MW9) 
“Well, so essentially what you’ll do is you’ll tell somebody that they’re at 
risk of a disease which might at its worst kill them, or lead to very 
premature delivery of their baby, but actually there’s not very much we can 
do about it. And to me that seems - particularly when a lot of them then 
won’t have that, it seems to be totally unnecessary anxiety.” (OB1) 
This belief in an anxiety increase was seen by the obstetricians to counteract any 
benefits that the screening test may present.  
“Because I think that there isn’t a clear treatment and I think that the 
anxiety and the tests are complicated and the anxiety that it would give rise 
to would hugely outweigh the potential.” (OB2) 
“It could be diminished so that it is of no benefit whatsoever.  Indeed there 
are harmful effects of screening in that it certainly creates anxiety if you are 
labelled as high risk.  (OB 5)” 
There was evidence within the midwifery subsample of a professional conflict, between 
a professional role that was supposed to relieve pregnancy related anxieties, and a 
screening test that could potentially increase them. 
“And in these high risk women the biggest risk is we damage their self-
esteem because it gets them worried. And so can we put more resource into 
thinking, In the face of uncertainty and anxiety how do we build self-
esteem?”(MW6) 
I think it makes a lot of people very anxious. And I think that that in itself - 
like I think women often are anxious enough in pregnancy and part of our 
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chances are statistically they're probably fine and they're healthy and all 
that. (MW7) 
BELIEFS ABOUT CAPABILITIES – QUESTIONS OF ACCURACY  
There was a sense of distrust of the screening test in many of those interviewed. The 
HCPs questioned the accuracy of the screening test, with a belief that the screening test 
that had been introduced was not as accurate as it should be.  
“At the moment, I don’t think the sensitivity specificity is enough for us to 
be able to apply it as a screening test and I think the application has not 
been fully evaluated and that’s what’s going on.” (OB3) 
“I don’t know how accurate the screen is, so how many false positives we 
get. My maybe limited understanding is that there are quite a lot of false 
positives and therefore that is possibly not the best screening test” (MW10) 
This lack of trust in the screening test resulted in HCPs not referring to the screening 
test result during consultations, and questioning if the hospital should continue to use it.  
“Absolutely not, never.  I did look at it and I saw a woman who had near 
end stage kidney disease and so very high risk of preeclampsia with 
hypertension and she was given something like a one in ten thousand risk of 
preeclampsia.  I thought ‘" This cannot be right’. Since that moment and I 
don't know whether they have refined things, that was about a year ago, I 
have not looked at it whatsoever.” (OB2) 
there were some emails last week which said [the Clinical Director] was 
asking whether we should keep it on the fetal assessment and I said no, I 
think we should use the NICE guidelines for predicting preeclampsia which 
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that unless there is compelling evidence, new evidence to support this 
screening process.  I don't know about that.(OB3) 
CHARACTERISTICS OF OUTCOME EXPECTANCIES – MEDICALISING 
PREGNANCY 
The Midwifery subsample was concerned that screening for pre-eclampsia was 
pathologising the pregnancy journey. While they recognised that the high-risk clinics 
had advantages to low risk women, in that the package of care could be altered (see 
above), offering the test was seen as encouraging women to view pregnancy as a 
medical problem, rather than a normal-life-event.  
“But I can’t help but feel that there is an element of raising people’s anxiety 
level because of sort of false positive results or turning pregnancy into an 
illness” (MW4) 
They should be able to take reassurance from the well being of their baby 
through fetal movement, through what is usually reasonably obvious, the 
growth of the uterus, through their change in shape and size. Through 
hearing fetal heart when they go for ante natal appointments, but I suppose 
it’s part of the medicalisation of childbirth and what’s expected.(MW2) 
All of the midwives interviewed felt the screening test would decrease the number of 
women that selected a low-technology birthplace, such as a homebirth or birthcentre.  
I think it definitely has the potential to affect birth choices, because again, 
if you’ve been labelled, when someone says something about the birth 
centre, you may think, “Oh, no, that’s not for me. I’m high-risk so I ought to 
be on the labour ward and maybe I ought to be asking for an elective 
Caesarean section so my blood pressure doesn’t get high in labour.” You 
know, I think it definitely has that impact. They’re probably almost 
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And then I think you then get to a labour and they’ve had this kind of 
medical involvement in their antenatal care and then they feel that actually 
that should be continued through their labour and that they don’t feel that 
they can trust themselves to some extent. Like there’s this sort of secret 
thing going on in their body that’s going to start causing trouble. I think it 
kind of knocks their faith in their kind of abilities sometimes.(MW9) 
This new screening test was seen as a latest addition of obstetric technologies that were 
working against the concept of normal, low risk pregnancies.  
“The only thing that worries me is that it seems like we keep introducing 
more and more screening.  Which might be a good idea but women 
sometimes are sort of bombarded with research studies and screening for 
this and that and the other.”(MW7) 
Well, I suppose if you look back at things like the home birth rate, the 
introduction of the CTG, you know, it’s still relatively recent that babies 
were born in hospital and that care was provided by doctors as opposed to 
midwives. And probably current generations don’t appreciate that. And that 
the evidence base for that, I mean, particularly around CTGs, is so 
minimal.(MW3) 
The midwives were concerned that women were unable to refuse obstetric technologies, 
in case they were perceived as ‘bad mothers’. Some felt this was an extension of a 
societal problem with trying to control women. 
“Because if you don’t have a scan, you're bad. If you don’t have screening, 
you're a bad person. And why are you a bad person? Because you don’t care 
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“And I think that’s something that women probably feel quite a lot in society 
generally. You're not thin enough or you're not this enough. And you're not 
doing that right. You're a stay at home mum or you're a working mum. And 
everything is kind of like - I think it’s quite difficult to be a woman in this 
day and age. I feel like that it can come across that the medical professions 
don’t trust women to be pregnant. Like you can’t do it by yourself and you 
can’t just do it with a midwife. You need to have all these machines and all 
this stuff to make sure that you're doing it”(MW5) 
Now it seems to me that we’re quite aggressive in our approach to 
screening. It’s an expectation that if a woman’s going to be a ‘good’ 
pregnant woman, and a ‘good’ mother, then she should want to know. And I 
don’t entirely approve of this, even though I play this game too. So I don’t 
divorce myself from any of what’s going on. (MW 8) 
These factors were seen as a negative contribution to the trust for the midwifery 
profession. The midwives felt they were no longer trusted to look after women in a safe 
way, and that technology was required to monitor them. 
“I suppose I worry that there are more and more things being kind of taken - 
more and more assumptions being made about the risks of pregnancy. That I 
think has a negative impact on midwifery. I think it undermines us as 
practitioners, as specialists in normality.” (MW7) 
I don’t know. It just makes me feel uneasy. I don’t know. Like I feel like a lot 
of the time there’s research that says that this is safe and you are safe and 
midwifery is safe but that actually the sort of mood towards it actually is 
that that’s probably not true and you probably need a doctor. And the 
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ORGANISATIONAL CULTURE - LACK OF CONSULTATION 
The three consultant obstetricians all expressed disappointment at how the screening 
test had been introduced. They felt they had not been adequately consulted on whether 
or not the screening test was accurate or of benefit to women in the trust.  
“What I really develop antibodies against is its implementation without any 
kind of effort at persuasion of us that this is a good test. It is clearly not as 
good as it is set out to be and for those of us who practice high risk 
pregnancy medicine, we do need to hear, especially if it is from in-house 
generated research about the pros and cons of such a thing.” (OB3) 
“ Nobody has made any effort to persuade me that this was a good or a bad 
thing.  I have read the papers and I am unconvinced.”(OB2) 
“The way it was implemented, it was sort of foisted upon us and then the 
first I knew about it was when someone said " What about this risk, I'm okay, 
I have only got one kidney and I have only got a one in 10,000 risk."   What is 
this rubbish?” (OB1) 
While more junior obstetricians and midwives did not express as vocal concerns, it was 
clear that they were not clear on the specifics on the test. This raised concerns on how 
they would gain informed consent for undergoing the test, and how they would 
communicate with women about their results. The quotations below are from midwives 
that would routinely conduct the booking appointment, the appointment where consent 
to undergo this screening test would take place. 
“I guess they combine everything all up and using some fancy computer 
programme generate a number, a one in such and such number.”(MW9) 
“Not a great deal. I know that it’s done when they have their - like around 
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lot. And I'm assuming that the scan is looking at placental flow and things 
as well. But I don’t actually know.”(MW3) 
“Very little I think. I know that it’s a blood test and there are also 
measurements taken of the foetus and those together give a risk of 
preeclampsia developing; something to do with doplars as well. I wish I 
knew more. I'm feeling very dumb. That’s the most I know.”(MW1) 
“I think from... like, you know, I wouldn’t be 100% sure, I think there are 
some bloods and something on one of the... when the booking scans, they do 
look at, but actually what they’re looking at, I don’t know.”(MW5) 
 
 Page 167 of 316                          Chapter 6: Healthcare Professional’s Qualitative Study  
6.5  DISCUSSION 
To the best of our knowledge this research is the first investigation into the barriers and 
facilitators to offering a universal screening test for pre-eclampia as perceived by 
midwives and obstetricians. 10 obstetricians and 10 midwives were interviewed. A 
mixture of barriers and facilitators were identified. Facilitators included optimism (the 
potential to improve outcomes) and environmental resources (specialist clinics 
increased time for low-risk women). Barriers included beliefs about consequences 
(potential increase in anxiety for screen-positive women), beliefs about capabilities (the 
accuracy of the test was questioned), characteristics of outcome expectancies (the 
screening test may ‘medicalise pregnancy’), and organisational culture (lack of expected 
consultation prior to introduction). 
The sub-sample of obstetricians noted that it was the particular test that had been 
introduced that caused them concerns, rather than the concept of pre-eclampsia 
screening in general. These concerns centred on the perceived accuracy of the test. 
Many of the healthcare professionals expressed concerns regarding the accuracy of the 
test. They had seen examples of women with false-negative results and women with 
false-positive results. Concerns were raised over the methodology used to calculate the 
algorithm for predicting a woman’s risk for developing pre-eclampsia.  
The second concern expressed by healthcare professionals, primarily from the sub-
sample of midwives, related to ‘medicalising pregnancy’. Maternity healthcare 
professionals have experience of new technologies being introduced that result in 
unintended consequences [15-17], which may explain their desire to consider these 
issues prior to large-scale introduction of such testing. Implementing research evidence 
into clinical practice is challenging, and once a technology is adopted, de-
commissioning it is likely to prove difficult [18]. A strand of midwifery discourse 
highlights concerns with the apparent acceptance of prenatal screening tests, in that 
technological advancements in maternity care may be ‘sold’ as choices. It is unclear if 
these advances would be accepted and taken up if it were not for the respect given to 
medical and scientific discourse within Western society [19]. The rise of ‘individual 
choices’ has led to interventions such as caesarean sections and induction of labour 
being presented as choices without clinical indication [20-23], while non-medical 
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[19,24,25]. Despite this, the concerns raised by the midwives related to medicalisation 
were often counterbalanced with support for pre-eclampsia screening, and concerns 
appeared to stem from a wider issues regaurding societal perceptions of pregnancy and 
birth.  
A healthcare professional can influence the value a woman places on the offer of a 
screening test and the interpretation of the results received. Many factors may influence 
healthcare professionals when discussing prenatal screening tests, including personal 
opinions and attitudes [26], knowledge levels [27], and workplace and social context 
influences [28]. It has shown that a healthcare professional’s attitude towards the 
conduct of prenatal screening have the potential to affect their practice, and that they 
can exert a great influence on the people they care for [29,30]. 
It has been shown that women and healthcare professionals focus on different elements 
of prenatal screening tests. Healthcare professionals tend to value the accuracy and 
gestation that tests are conducted [4,31]. Pregnant women, however, value the safety 
elements of a screening test more [4,31]. This is supported when you compare the data 
presented here with those of the women’s study in Chapter 5. Some of the concerns 
highlighted by the HCPs here related to medicalisation are supported by the Women’s 
study. There was evidence of an attachment on technology and additional monitoring. 
However, the previous study provided little support for the concerns raised here about 
the potential for raising anxiety in pregnant women.   
This study was exploratory in nature, and it was not intended to be an exhaustive 
assessment of all the possible barriers and facilitators to the introduction of this new 
screening test. There are several lines of future enquiry that are suggested by this study. 
This includes investigating if the screening test does medicalise pregnancy, and/or 
impact on birthplace choices. Other work could include if HCP’s were more accepting 
of a screening test with greater accuracy than the one presented.  
The study findings should be considered in light of its limitations, including the small 
number of participants and opportunistic recruitment, which limit the generalisability of 
the findings to the wider population of HCPs. Potential for bias in the interviews and 
analysis related to the beliefs and assumptions of the midwife interviewer was mitigated 
in several ways, including input from a multidisciplinary research team and clinicians in 
constructing the interview guide and in the analysis.  Nonetheless, this study provides 
strong preliminary evidence upon which future studies can build. Page 169 of 316                          Chapter 6: Healthcare Professional’s Qualitative Study  
The larger bioethics debate continues as to whether or not screening programmes should 
be introduced when there is no cure for the screened-for condition, or any risk-reduction 
interventions [37]. The HCPs interviewed in this study did not give clear support for the 
introduction of this screening test, although concerns tended to focus on the particular 
screening test of study, rather than the concept of pre-eclampsia screening.  
6.6  CONCLUSION 
Broadly, midwives were more accepting of the screening test than obstetricians. The 
majority of concerns with the screening test were limited to concerns related to the 
specific screening test that had been introduced into the study hospital, rather than pre-
eclampsia screening in general. 
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7.1  ABSTRACT 
Objective: To investigate the relationship between frequency of ultrasounds and 
birthplace preference. 
Study design: Retrospective case-control study with the number of ultrasounds as the 
exposure and the pregnant woman’s preference to give birth in a low-technology setting 
(midwifery-led unit or home) or a high-technology setting (obstetric unit) as the primary 
outcome. 
Sample and Setting: Low-risk primigravid women receiving prenatal care at a central 
London academic medical centre. 
Measurements: Prenatal ultrasound frequency; birthplace preference at the initial 
pregnancy appointment (T1) and at the commencement of labour (T2); demographic 
data including ethnicity, index of multiple deprivation, age, and body mass index. 
Findings: 1100 cases were reviewed. Women received an average of 4.03 ultrasounds 
during their pregnancy (sd=1.96, range 2-14). The frequency of ultrasounds for women 
who had a low-technology T2 birthplace preference was significantly lower than for 
those who had a high-technology T2 birthplace preference (t=2.98, df=1098, p=0.003, 
r=0.1), and women who had a constant low-technology birthrate preference had 
significantly less ultrasounds than other women (F (3,644) = 3.475, p=.02). However, 
within a logistic regression the frequency of ultrasound was not associated with T2 
birthplace preference, after controlling for T1 birthplace preference.  
Conclusions: The findings of this investigation suggests that a preference made early in 
pregnancy is a greater predictor of birthplace preference than exposure to prenatal 
ultrasounds.  
Implications for practice: Further research is required to inform interventions that 
would encourage low risk pregnant women to select a low-technology place of birth. 
7.2  INTRODUCTION 
The two qualitative studies presented here (chapters 5 and 6) both presented data 
on the possibility that the pre-eclampsia screening test may ‘medicalise’ the pregnancy 
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eclampsia, any screened women who were incorrectly identified as high-risk - that is 
identified at higher risk for developing pre-eclampsia, but who do not go on to develop 
it during their pregnancy – may make choices based on the information that could have 
negative consequences, such as choosing a high-technology birthplace without cause. 
While the earlier studies considered the impact of the screening test itself, it is also 
important to consider the consequence of a high-risk result. Women found screen 
positive were offered a monthly ultrasound scan, to detect the on-set of disease at the 
earliest opportunity. This study considers if this additional monitoring impacted on 
birthplace preferences.  
Women in the UK are encouraged to plan for their birth during their pregnancy 
[1]. Women without pregnancy-related complications or other risk factors, and receiving 
care in the UK’s NHS, are able to choose to deliver their infant in an obstetric unit 
(high-technology) or in a midwife-led unit or at home (low-technology) [2]. There 
appears to be clinical [1,3], economic [4,5] and increased satisfaction [2,6] justifications 
for low risk women to choose low-technology birth locations. It is therefore important 
to ascertain if any routine antenatal procedures influence a woman’s birthplace 
preference.  
The predictors of birthplace preference are multifactorial, with 
sociodemographic factors [7,8], previous experiences [9] social influences [10] and 
physical factors such as body mass index (BMI) [3] all being shown to influence 
decisions. An understudied factor that may influence birthplace preference is the 
frequency of prenatal exposure to obstetric technologies, notably the exposure to 
ultrasound scans (US). Frequent US that do not reveal any potential problems may be 
reassuring to women, and therefore encourage them to make a low-technology 
birthplace preference. Alternatively, increased exposure to US prenatally may lead to a 
desire for technology during labour, such as continuous fetal monitoring. There is some 
evidence to support the latter hypothesis. A prospective study of 625 low-risk Dutch 
women found a positive correlation between choosing high technology delivery settings 
and acceptance of obstetric technologies and intrapartum interventions [4]. A significant 
association between the use of prenatal US and a subsequent caesarean mode of 
delivery have been found in three retrospective studies [11-13]. These correlational data 
do not clarify whether caesarean delivery rate is influenced by maternal request, 
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Little is known about the general frequency of prenatal US exposure in low risk 
women. One recent retrospective study of 100 pregnancies demonstrated an average of 
7.7 US per pregnancy [14]. National guidelines within the UK recommend two routine 
US, one in the first trimester to confirm gestation and as part of Down’s syndrome 
screening, and one in the second trimester to screen for structural anomalies [15]. There 
is growing support to introduce a routine third-trimester US to detect growth-restricted 
foetuses [16-18].  
There is no evidence that US causes physical harms to the pregnant woman or 
fetus [19]. However, a recent systematic review demonstrated it can affect emotions, 
cognitions and behaviours (Chapter 4). Given the limited data on the topic and its 
potential influence on healthcare outcomes and costs, the objectives of this study were, 
for a sample of low risk primigravid women, to investigate (1) the frequency of prenatal 
US exposure and differences in the frequency based on demographic factors; (2) the 
association between the frequency of US and birthplace preference; and (3) predictors 
of US frequency and birthplace preference decisions, while controlling for potential 
confounders. 
7.3  METHODS 
7.3.1  STUDY DESIGN 
A retrospective case-control design was used to investigate the relationship between 
number of prenatal US (exposure) and birthplace preference (outcome).  
This study aimed to test the following hypotheses: 
H1 The frequency of US will differ between the high technology and low technology 
birthplace preference groups at the start of labour; 
H2 There will be a significant difference in the frequency of US between those who 
have a constant birthplace preference (low technology at initial pregnancy 
appointment (T1) and low technology at the commencement of labour (T2) or 
high technology at T1 and high technology at T2) and those who alter their 
birthplace preference (low technology at T1 and high technology at T2 or high 
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H3 The frequency of ultrasound scans will predict birthplace preference at the start 
of labour, after controlling for initial birthplace preference, and will have a 
larger predictive value than other factors on birthplace preference. 
7.3.2  SAMPLE 
The sample was selected from the population of women classified as low risk on 
commencement of labour, as identified by the National Institute of Health and Care 
Excellence intrapartum guidelines [15], who received prenatal and intrapartum care at 
the study hospital, and who experienced a live birth between January and December 
2011. Prenatal appointments were provided in either the hospital antenatal clinic, or 
community centres, depending on the woman’s address and preference. Exclusion 
criteria were: multigravid women, women who did not go into spontaneous labour, 
women who did not have their first appointments at the study hospital, and women who 
declined any US.  
The exposure group consisted of primigravid women who selected a low-technology 
birthplace preference (midwife-led unit or at their own home), and the control group 
consisted of women who selected a high-technology (obstetric unit) birthplace 
preference. The study hospital’s birth centre is an ‘alongside’ birth centre, located on a 
different floor from the obstetric delivery suite. The controls were matched to the cases 
based on the following characteristics: ethnicity, index of multiple deprivation (IMD; 
[20]), age and BMI. When data were available, the birthplace preference was recorded 
at two time points, T1 and T2.  
7.3.3  VARIABLES 
The independent variable was the number of US conducted during the pregnancy. 
Prenatal US were classified in one of three categories: (i) 0-11 week early pregnancy 
US (early); (ii) US conducted after 11 and before 37 weeks gestation (mid) and (iii) late, 
post 37 week US (late).  
The dependent variable was birthplace preference, defined as the setting a woman 
intended to start her labour (irrespective of the actual location of delivery), recorded as 
one of two categories, high-technology (obstetric unit) or low-technology (midwife-led 
unit or home) and recorded at the T1 and T2 time points when available. Page 178 of 316                              Chapter 7: Case-Control Study  
Demographic data included: ethnicity, IMD, age (at T2), and BMI (at T1). 
7.3.4  SAMPLE SIZE CONSIDERATIONS 
The number of eligible low-technology birthplace preferences at the commencement of 
labour (T2) during the study period determined the sample size. As the literature 
provided no guidance on potential effect sizes, it was assumed that the effect size would 
be small (0.2). Therefore, with a power of 80%, a confidence level of 95%, and a 
significance (alpha) level of 5%, a minimum sample size of 273 cases was estimated.  
7.3.5  SETTING 
Prenatal and perinatal medical records at an academic medical centre in central London 
from 01
st January 2011 to 31
st December 2011 were retrospectively reviewed. During 
the study period, the usual protocol at this hospital was to conduct two to three routine 
US for all pregnant women: a first trimester US conducted between 11 and 13 weeks 
gestation; a second trimester US conducted between 20 and 22 weeks gestation; and a 
third ‘post dates’ US conducted after 40 weeks for those women who had not yet gone 
into spontaneous labour.  
7.3.6  PROCEDURE  
Data were obtained and verified from four hospital electronic databases - the record of 
births in 2011; the record of US conducted between 2010-2011; the record of transfers 
from the birth centre; and the record of planned home births. Data from these four 
sources were entered into a database programme (Microsoft Access) and accuracy 
verified by two of the authors (JH and SW).  
7.3.7  ANALYSIS 
The proportion of women in each birthplace preference group at T1 and T2 and the 
number of US for women in the groups, and at each stage of pregnancy, were 
calculated. To ensure an adequately matched dataset, between-group differences in T2 
birthplace preference selection based on ethnicity, IMD, maternal age or BMI were 
examined using Chi square (Χ
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The analysis was conducted to address the hypothesis in the following order: 
Independent-samples t-test was used to determine if there were differences in the mean 
number of US by birthplace preference at T2 (H1). The association of total, early, mid 
and late US on birthplace preference were assessed separately. A one-way ANOVA was 
conducted to compare the frequency of US between the four comparison groups 
outlined above (H2). The factors influencing birthplace preference at T2 were evaluated 
using stepwise binary logistic regression, with T2 birthplace preference at the start of 
labour as the dependent variable and number of ultrasounds, previously stated 
birthplace preference (T1 preference), ethnicity, IMD, maternal age and maternal BMI 
as dependent variables. A forward selection stepwise approach was used in the absence 
of any rationale for selecting the most influential dependent variables (H3).   
A 5% significance level was used throughout. All analysis was completed using IBM
ﾮ 
SPSS
ﾮ Statistics 21.0 (Somers, NY). 
7.3.8  ETHICAL CONSIDERATIONS 
This study used secondary, retrospective data and was considered audit rather than 
research by the academic medical centre’s Research and Development Office. All data 
were stored according to Caldicott principles [21].   
7.4  FINDINGS 
550 primigravid healthy women made a low-technology birthplace preference in 2011. 
These women were matched to 550 primigravid healthy women who made a high-
technology birthplace preference, for a total sample of 1100 women. Table 7.1 shows 
the demographic characteristics of the sample. 
7.4.1  THE FREQUENCY OF US EXPOSURE 
Women were exposed to an average of 4.03 (SD 1.96, range 2-14) US during the study 
period. The modal frequency of US was 3 (27.1%); 21.2% of women had the 
recommended two US during their pregnancy. Over one quarter of the sample (29.6%) 
were exposed to 5 or more US. Women had 0.48 early US (SD 0.92, range 0-9) 3.19 
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US during pregnancy was significantly correlated with maternal age (r=.097, p =0.01), 
and BMI (r=.068, p =0.05). However, the correlations were very small, indicating an 
inconsequential effect size. Therefore, the demographic factors assessed here are 
unlikely to effect US frequency, and the significant values instead reflect the large 
sample sizes.  
TABLE 7.1 - DEMOGRAPHIC CHARACTERISTICS OF CASES AND CONTROLS 
    Low Technology  High Technology  Total 
Ethnic group White   291  52.9%  291  52.9%  582  52.9% 
Black   16  2.9%  16  2.9%  32  2.9% 
Asian  24  4.4%  24  4.4%  48  4.4% 
Chinese  8  1.5%  8  1.5%  16  1.5% 
Mixed  6  1.1%  6  1.1%  12  1.1% 
Other  14  2.5%  14  2.5%  28  2.5% 
Χ
2=0.00 
(NS) 
Undisclosed  189  34.4%  189  34.4%  378  34.4% 
Index of 
multiple 
deprivation 
0 – 5000  97  17.6%  96  17.5%  193  17.5% 
5001-10,000  214  38.9%  218  39.6%  432  39.3% 
10,001 – 
15,000 
88  16.0%  87  15.8%  175  15.9% 
15,001 – 
20,000 
74  13.5%  71  12.9%  145  13.2% 
20,001 – 
25,000 
52  9.5%  53  9.6%  105  9.5% 
25,001 – 
30,000 
24  4.4%  23  4.2%  47  4.3% 
Χ
2=0.47 
(NS) 
30,001 +   1  0.2%  2  0.4%  3  0.3% 
Maternal 
Age 
17-20  17  3.1%  15  2.7%  32  2.9% 
21-25  59  10.7%  61  11.1%  120  10.9% 
26-30  126  22.9%  120  21.8%  246  22.4% 
31-35  221  40.2%  251  45.6%  472  42.9% 
36-40  110  20.0%  89  16.2%  199  18.1% 
Χ
2=4.72 
(NS) 
41-45  17  3.1%  14  2.5%  31  2.8% 
BMI  17.0-19.9  71  13.5%  56  10.7%  130  12.4% 
20.0-22.9  218  41.5%  255  48.7%  479  45.7% 
23.0-25.9  141  26.9%  145  27.7%  287  27.4% 
26.0-28.9  49  9.3%  49  9.4%  99  9.4% 
29.0-31.9  29  5.5%  18  3.4%  47  4.5% 
32.0-35.0  17  3.2%  1  0.2%  7  0.7% 
Χ
2=10.685 
(NS) 
Missing  25  4.5%  26  4.7%  51  4.6% 
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7.4.2  DIFFERENCES IN THE FREQUENCY OF US BY BIRTHPLACE 
PREFERENCE AT START OF LABOUR 
The frequency of US by birthplace preference is shown in Figure 7.1. Women who 
selected a low technology birthplace preference at the commencement of labour had an 
average of 3.85 US (range 2-14, SD 1.9). Women who selected a high technology 
birthplace preference at the commencement of labour had an average of 4.2 US (2-14, 
SD 2.0). Significantly more US were conducted on women who chose a high-
technology birthplace preference at the commencement of labour compared to those 
who chose a low-technology birthplace preference, each with a small effect size of 0.1 
(Table 7.2). There is therefore support for H1. 
FIGURE 7.1 - THE TOTAL NUMBER OF ULTRASOUND SCANS COMPARED BY BIRTHPLACE 
PREFERENCE 
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TABLE 7.2 - AVERAGE NUMBER OF ULTRASOUNDS BY BIRTHPLACE PREFERENCE AT START 
OF LABOUR 
Ultrasound 
Category 
Low technology  High technology   
  Mean  SD  95% CI   Mean  SD  95% CI  Independent samples 
Test 
Total  3.85  1.902  3.69-4.01  4.2  1.998  4.03-4.37  t = 2.983 (df = 1098), 
p=0.003, r = 0.1 
Mid 
pregnancy 
US 
3.01  1.395  2.89-3.13  3.27  1.547  3.14-3.40  t = 2.968 (df = 1098), 
p=0.003, r = 0.1 
Early 
pregnancy 
US 
0.48  0.927  0.40-0.56  0.47  0.920  0.40-0.55  t = 0.131 (df = 1098), 
p=0.896 
Late 
pregnancy 
US 
0.36  0.596  0.31-0.41  0.46  0.631  0.40-0.51  t = 2.555 (df = 1098), 
p=0.01, r = 0.1 
CI – Confidence interval 
7.4.3  BIRTHPLACE PREFERENCE OVER TIME 
A T1 birthplace preference was recorded for 645 (58.6%) pregnant women in the 
sample. This consisted of 360 (65.5%) women who went on to make a low-technology 
birthplace preference and 285 (51.8%) women who went on to make a high-technology 
birthplace preference at the start of labour (T2). Table 7.3 shows the demographic 
characteristics of women by the four possible birthplace preference classifications at the 
two time points. There were no significant differences in the demographics of these 
women across or between the different choice groups.  
For the subset of women with both T1 and T2 birthplace preference data, there were 
71.9% constant-choice women and 28.1% altered choice women in the sample. The 
lowest frequency of total US was found in those that indicated a constant preference for 
low-technology birthplace (mean=3.83 US), while the highest was for those who had a 
constant preference for high-technology birthplace (mean=4.39 US). Figure 7.2 shows 
the mean frequency of total US and US conducted between 11 and 37 weeks gestation 
by birthplace preference at the two time points. An ANOVA comparing these mean 
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F (3,644) = 3.475, p=.02; Mid US - F (3,644) = 3.644, p=.01). No significant result was 
found for early or late US. There is therefore support for H2. 
FIGURE 7.2 - MEAN FREQUENCY OF US BY BIRTHPLACE PREFERENCES AT T1 AND T2 WITH 
95% CONFIDENCE INTERVAL ERROR-BARS. 
 
7.4.4  FACTORS PREDICTING BIRTHPLACE PREFERENCE 
A stepwise binary logistic regression was conducted, with the T2 birthplace preference 
at start of labour as the dependent variable, and the covariates of T1 birthplace 
preference, total US, BMI, ethnicity, age and IMD. The T1 birthplace preference (OR 
0.17, 0.12-0.24, p=<0.001) and BMI (OR 1.07, 1.01-1.13, p=0.02) were the only 
significant predictors in the final model. The analysis was re-run using mid pregnancy 
frequency of US and the results were similar: T1 birthplace preference (OR 0.17, 0.12-
0.24, p=<0.001) and BMI (OR 1.07, 1.01-1.13, p=0.02). Therefore, H3 was not 
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TABLE 7.3 - DEMOGRAPHICS OF CASES CONSIDERING T1 AND T2 BIRTHPLACE 
PREFERENCE 
  
Constant Choice  Altered Choice 
Total  T1 Low, T2 
Low 
T1 High, T2 
High 
T1 Low, T2 
High 
T1 High, T2 
Low 
n  %  n  %  n  %  n  %  n  % 
Ethnic 
Group 
White  151  53.9%  105  57.1%  55  54.5%  39  48.8%  350  54.3% 
Black  7  2.5%  11  6.0%  1  1.0%  6  7.5%  25  3.9% 
Asian  14  5.0%  6  3.3%  5  5.0%  2  2.5%  27  4.2% 
Chinese  4  1.4%  2  1.1%  2  2.0%  2  2.5%  10  1.6% 
X
2=47.464 
(NS) df=39 
Mixed  2  0.7%  3  1.6%  3  3.0%  1  1.3%  9  1.4% 
Other  6  2.1%  6  3.3%  4  4.0%  2  2.5%  18  2.8% 
Undisclosed  96  34.3%  51  27.7%  31  30.7%  28  35.0%  206  31.9% 
Index of 
multiple 
deprivation 
<= 5000  49  17.5%  33  17.9%  18  17.8%  13  16.3%  113  17.5% 
5001 - 
10000  108  38.6%  76  41.3%  41  40.6%  30  37.5%  255  39.5% 
10001 - 
15000  40  14.3%  23  12.5%  14  13.9%  12  15.0%  89  13.8% 
15001 - 
20000  41  14.6%  26  14.1%  13  12.9%  10  12.5%  90  14.0% 
X
2=17.72 
(NS) df=18 
20001 - 
25000  29  10.4%  14  7.6%  10  9.9%  10  12.5%  63  9.8% 
25001 - 
30000  13  4.6%  12  6.5%  5  5.0%  3  3.8%  33  5.1% 
30001+  0  0.0%  0  0.0%  0  0.0%  2  2.5%  2  0.3% 
Maternal 
Age 
<= 20  6  2.1%  6  3.3%  5  5.0%  5  6.3%  22  3.4% 
21 - 25  33  11.8%  18  9.8%  9  8.9%  4  5.0%  64  9.9% 
26 - 30  59  21.1%  47  25.5%  19  18.8%  16  20.0%  141  21.9% 
X
2=13.78 
(NS) df=15 
31 - 35  128  45.7%  69  37.5%  41  40.6%  37  46.3%  275  42.6% 
36 - 40  46  16.4%  36  19.6%  23  22.8%  14  17.5%  119  18.5% 
41+  8  2.9%  8  4.4%  4  4.0%  4  5.0%  24  3.7% 
BMI 
<= 19.9  35  12.5%  28  15.2%  10  9.9%  8  10.0%  81  12.6% 
20.0 - 22.9  131  46.8%  63  34.2%  44  43.6%  41  51.3%  279  43.3% 
23.0 - 25.9  63  22.5%  48  26.1%  27  26.7%  20  25.0%  158  24.5% 
26.0 - 28.9  29  10.4%  20  10.9%  9  8.9%  8  10.0%  66  10.2% 
X
2=22.08 
(NS) df=15 
29.0 - 31.9  9  3.2%  9  4.9%  6  5.9%  0  0.0%  24  3.7% 
32.0 - 35.0  1  0.4%  6  3.3%  3  3.0%  0  0.0%  10  1.6% 
Missing  12  4.3%  10  5.4%  2  2.0%  3  3.8%  27  4.2% 
Total  280  100%  184  100%  101  100%  80  100%  645  100% 
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7.5  DISCUSSION 
The relationship between US frequency and birthplace preference is not straightforward. 
Women who made a high-technology birthplace preference at the start of labour had 
more US than those who made a low-technology birthplace preference, and those that 
had a constant low-technology birthplace preference had significantly less US than 
others. However, the logistic regression suggests that this reflected a birthplace 
preference made at the start of pregnancy, and after controlling for this, there was no 
association with exposure to US over the course of the pregnancy. Women who altered 
preference from low-technology to high-technology had less US than those that 
switched from high-technology to low-technology. It may be that preferences at the start 
of pregnancy influence US frequency; i.e. a desire for a high-technology birthplace 
preference at the start of pregnancy leads to more US being conducted. Similarly, the 
women who expressed a desire for a low-technology birthplace preference in early 
pregnancy may have declined non-routine US [4]. Alternatively, a third factor not 
studied here could influence both birthplace preference and US frequency. An 
association between US and birthplace preference has been found in other secondary-
data investigations [11-13]. However, these studies did not consider the effect of the 
intentions that women have at the start of pregnancy, before their interaction with the 
obstetric team. Women in this sample received on average twice the recommended US 
during their pregnancy. While 21% of the sample had two US during their pregnancy, 
11% had over six. The maximum number of US recorded was 14, which equates to one 
US every other week between 11 weeks and term. This demonstrates wide variation in 
the level of resource allocated to each pregnancy episode in low risk women. The 
reasons for such wide variation found in this study are not clear. The results presented 
here indicates the need for further, multicentred studies on US decision making. Of the 
demographic factors examined, only BMI at the initial pregnancy appointment was 
found to influence T2 birthplace preference. 
It is difficult to isolate the frequency of US as an independent factor influencing 
birthplace preference given the complex pattern of care even for low risk women in the 
UK. The study design did not allow for an assessment of why each US was conducted. 
Nor was it possible to assess the number of US that were offered and declined, or 
requested but not conducted. This information is best acquired in a prospective study 
because of inconsistency in the level of detail of medical note narratives. Non-routine Page 186 of 316                              Chapter 7: Case-Control Study  
US for low-risk women are conducted for a number of reasons, including concerns with 
fetal growth, presentation queries, and participation in research studies [15]. The reason 
for the US may have more of an impact on perceiving pregnancy as a high-risk event 
than the exposure to the technology itself. For example, a referral because of a 
suspected problem could have a different impact than one conducted for a research 
study, to determine the sex the fetus, or a US conducted at maternal request. Similarly, 
the outcome of the US is likely to have an effect on perceptions. Low-risk women may 
have only received reassuring results from the US, resulting in less or no impact to their 
birthing intentions. Future studies should focus on US decision-making during low risk 
pregnancies. 
Birthplace preference is likely to be multifactorial. Selection of a high-technology 
birthplace preference likely involves more than just perception of pregnancy to be a 
medical event requiring technological support. Nevertheless, healthcare professionals 
have raised concerns regarding the increasing use of US beyond the frequency outlined 
in national recommendations, and its association with the medicalisation of childbirth 
[22,23]. The findings of this investigation provide no evidence that increased exposure 
to US in pregnancy results in an increased preference for high-technology birthplaces, 
after controlling for initial birthplace preference. Considering the clinical, economic and 
well-being benefits of a low-technology birthplace preference, further research is 
required to inform interventions that would encourage selection of low-technology 
places of birth. If the findings of the present study are corroborated, such an 
intervention would need to occur at very early pregnancy or perhaps prior to 
conception.   
The findings should be considered in light of the study limitations. The power 
calculation of this study suggested a sample size of 273 cases. The final data set 
consisted of 1100 cases for H1 and 645 for H2 and H3. This larger than required sample 
could have resulted in the detection of a statistical significant result, with little or no 
clinical importance (H1 and H2), or alternatively a Type 2 error (H3). Indeed, the 
reported effect size of 0.1 for H1 suggests that any impact that frequency of US had on 
birthplace preference is small. 
 The greatest potential for bias within this study lay with the risk that the control group 
included high-risk women rather than a preference for a high-technology birthplace. 
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observations for mother and fetus, the ‘any complications – mother’ and ‘any 
complications – baby’ field in the birth register, the prenatal admissions field within the 
electronic patient records and maternal factors such as BMI and age that would exclude 
a low-technology birth. The retrospective nature of this study design resulted in an 
inability to characterise how the T1 birthplace preference question was asked, and 41% 
of the original sample did not have a T1 birthplace preference recorded. It is unclear 
why these data were missing and if women did not express a preference in early 
pregnancy, or were simply not asked for their birthplace preference. The study included 
only one hospital site and, therefore, has limited generalisability to other similar 
academic medical centres. Strengths of this study include use of the whole population of 
primigravida low-risk women that selected a low-technology birthplace preference and 
exclusion of multigravida women so that the effect of previous pregnancy and birth 
experiences were not confounders. Future studies should consider inclusion of medical 
record note review or prospective recording of the reason that the US is conducted.   
 
7.6  CONCLUSION 
The frequency of prenatal US does not appear to influence a low-risk primigravid 
woman’s birthplace preference. Conclusions remain tentative but suggest that concerns 
relating to the increasing use of US and its association with the medicalisation of 
childbirth appear unwarranted. Further research is required to inform interventions that 
would encourage low risk pregnant women to select a low-technology place of birth. 
The findings of this study do not appear to support the concerns highlighted within 
Chapter 6, that the increased monitoring associated with the pre-eclampsia screening 
test would medicalise pregnancies. The study did not focus on the screening test itself as 
there were insufficient data on screen-positive women for a meaningful ananlysis. 
However, when considering the repercussions of a screen-positive result – the increased 
number of US – there are no data to support the premise that increased monitoring 
results in a preference for high-technology birthplaces.  
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CHAPTER 8 - IDENTIFYING ATTRIBUTES THAT 
PREGNANT WOMEN AND HEALTHCARE PROFESSIONALS 
VALUE WHEN CONSIDERING A PRENATAL SCREENING 
TEST FOR PRE-ECLAMPSIA   
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8.1  ABSTRACT 
Objective: To identify the attributes that pregnant women and healthcare professionals 
value when considering a prenatal screen for pre-eclampsia. 
Study design: Cross sectional. 
Method:  Respondents considered 11 attributes of a pre-eclampsia screening test, 
identified through published systematic reviews and qualitative studies. Respondents 
were asked to rank attributes as ‘very important’, ‘neutral’ and ‘not very important’. 
They were subsequently asked to further rank the attributes they had identified as ‘very 
important’. 
Findings: 10 pregnant women and 22 healthcare professionals were recruited. Six 
attributes were ranked most highly – accuracy (sensitivity), accuracy (positive 
predictive value), testing procedure, level of information, follow up (what happens as a 
result of a screen positive result) and consequences (the negative effects of receiving a 
screen positive result). While both women and healthcare professionals ranked the same 
attributes in the top six, the order of preferences differed. Women ranked accuracy 
(sensitivity) as the most important attribute, followed by follow-up. Healthcare 
professionals ranked testing procedure as the most important attribute, followed by level 
of information. 
Conclusions: Based on these data women value accuracy most, while healthcare 
professionals value testing procedures when considering pre-eclampsia screening. This 
difference may be due to the uncertainty surrounding this novel screening test.  
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8.2  INTRODUCTION 
The qualitative studies presented within this thesis identified limited  concerns amongst 
pregnant women and healthcare professionals in relation to the introduction of a first-
trimester screening test for pre-eclampsia. Some concerns were raised about the 
appropriateness of introducing a screening test without a risk reduction intervention, its 
accuracy and the invasiveness of the screening test (see Chapter 4 and 5).  
To test the appropriateness of the screening test, a discrete choice experiment (DCE) 
was designed. This chapter details how the attributes for the DCE were identified. The 
DCE findings is reported in the next chapter.  
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8.3  BACKGROUND 
There has been much interest in the development of a biochemical prenatal screening 
test to predict the pregnancies most at risk of pre-eclampsia, a major cause of fetal and 
maternal morbidity and mortality [1-3]. Ninety-eight biochemical prenatal screening 
methods for pre-eclampsia have been identified in two separate meta-analyses [1,2]. 
The biochemical screening tests differ in their timing (first or second trimester 
screening tests), the screened population (universally screening all pregnant women, or 
those at ‘high-risk’ only), and the type of pre-eclampsia that is identified (‘early pre-
eclampsia’, developing pre-eclampsia prior to 34 weeks, or ‘all pre-eclampsia’, which 
identifies the chance of pre-eclampsia developing at any gestation). Sensitivity
8 of the 
screening tests range from 5.9% to 100%, with specificity
9 ranges of 47% to 100%.  An 
improvement in sensitivity generally trades against specificity accuracy. For example, 
one test published 100% sensitivity scores with 76% specificity [4] while another 
published 71% sensitivity with 100% specificity [5]. Increases in accuracy also come at 
a cost to the type of information gained. For example one test presents 100% sensitivity 
for detecting pre-eclampsia prior to 35 weeks gestation, while only providing 29% 
sensitivity for detecting pre-eclampsia post 35 weeks gestation [6].  
It is currently unclear which of these differences matter most to pregnant women and 
healthcare professionals. If certain attributes are more valued than others, then research 
can focus on improving tests on those attributes, thereby increasing the appeal of the 
screening test.  
This study aimed to identify which attributes of the pre-eclampsia screening test women 
and healthcare professionals value most.  
8.3.1  RESEARCH QUESTIONS 
The following study was designed to assess the perceived importance of attributes of 
biochemical screening tests for pre-eclampsia amongst key stakeholders,pregnant 
women and healthcare professionals..  
                                                 
8 Sensitivity -the proportion of those who develop the condition that are 
correctly identified as at risk 
9 Specificity -the proportion of those who do not develop the condition that 
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The following research questions were identified: 
  What are the potential attributes to consider with a pre-eclampsia screening test? 
  Which of these attributes are viewed as most important when considering accepting 
or offering this screening test? 
  Do the preferences of women and healthcare professionals differ? 
8.4  METHODS 
This study had two stages – stage one was to identify all of the potential attributes that 
stakeholders may value when considering a screening test for preeclampsia; stage two 
was a ranking exercise to rate the importance of the identified attributes.  
8.4.1  STAGE ONE - IDENTIFYING THE ATTRIBUTES 
Three steps were taken to identify the total number of potential attributes applicable to a 
pre-eclampsia screening test:  
(i)  A systematic review of discrete choice experiments conducted on health 
related screening tests was conducted. The search strategy was informed by 
two previous reviews on the subject [7,8]. Nineteen search terms were 
applied to three electronic databases (PubMed, EMBASE and Maternity and 
Child health). Studies were included if they were choice-based, published as 
a full text article in English, and applied to health care. Only articles 
published between 2008 and 2013 were included. Data on the attributes used 
and how they were selected were extracted, alongside recruitment strategies, 
design and analysis information to inform the design of the subsequent DCE 
study.  
(ii)  The list of identified test attributes was compared with two recently 
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whether they could be applied to pre-eclampsia screening. Attributes were 
included if they had been reported in a published article on a pre-eclampisa 
screening test. Any test attributes identified within the pre-eclampsia 
systematic reviews, that were not already identified, were also included. 
(iii)  The list of attributes was compared with the findings of two qualitative 
studies (Chapters 4 and 5) to identify any further attributes regarding pre-
eclampsia screening. 
The final list was discussed with four experts from relevant disciplines – a consultant 
midwife, a professor of health psychology, a professor of nursing for clinical relevance 
and a genetic counsellor with expertise in DCE methodology.  
8.4.2  STAGE TWO - RANKING EXERCISE 
SAMPLE AND RECRUITMENT 
PREGNANT WOMEN  
Pregnant women were recruited in the maternity department of a London Hospital. 
Recruitment took place within the outpatients department of a maternity hospital, in 
waiting rooms of the antenatal clinic, ultrasound department or day assessment unit. A 
research midwife provided women with an information leaflet, and answered any 
questions regarding the study.  If they agreed to take part, they completed a consent 
form and a time was given on the same day for them to attend and complete the ranking 
exercise. Prior to the completion of the online ranking exercise, the research midwife 
discussed each attribute, and answered any questions. Specific examples of each 
attribute were given to aid understanding. All women confirmed understanding prior to 
completing the ranking exercise. As this was a pilot study for a larger investigation, no 
power calculation was performed. Instead, the study aimed to recruit an opportunistic 
sample of ten pregnant women. 
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HEALTHCARE PROFESSIONALS 
Healthcare professionals were recruited via their work email addresses. The email 
contained a link to the online ranking exercise. As this was a pilot study for a larger 
investigation, no power calculation was performed. Instead, the study aimed to recruit 
an opportunistic sample of ten healthcare professionals. 
PROCEDURE 
A  questionnaire designed using the Qualtrics Research Suiteﾩ (Version 37,883 
Qualtrics, Provo, UT) was used for the ranking exercise. Initial information was given 
explaining pre-eclampsia, the development of a screening test, and the different 
attributes (see Appendix 16 for a copy of the text used). Respondents were then asked to 
answer two questions, as follows: 
(i)  “Below is a list of the different characteristics of a pre-eclampsia screening 
test, with an explanation statement. We are trying to work out which of these 
characteristics are of most importance to women when they decide whether 
or not they have this test. Please read the statement, then decide if this 
characteristic would be ‘very important’, neither important nor unimportant’ 
or ‘very unimportant’ to your decision on whether or not to have the test.” 
(Figure 8.1). 
(ii)  Below are the characteristics that you selected as “very important” to the 
question above. Please rank these characteristics into an order of importance, 
with the characteristic that you would find most important at the top, and the 
least important at the bottom” (Figure 8.2). 
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FIGURE 8.1 - EXAMPLE OF QUESTION ONE IN RANKING EXERCISE 
 
 
FIGURE 8.2 - EXAMPLE OF QUESTION TWO IN RANKING EXERCISE 
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The seven attributes identified as very important were allocated a ranking score, so that 
the most important received a score of seven, the second most important six and so 
forth. A ‘ranking score’ was calculated via a cumulative total for each attribute. 
The rankings of each attribute were cross-tabulated to aid comparison between the two 
recruitment groups. 
8.5  RESULTS 
8.5.1  IDENTIFYING THE ATTRIBUTES 
Eighteen attributes were identified from the systematic review, within 16 studies. The 
spread of the use of attributes can be seen in Table 8.1. The second phase involved 
comparing these identified attributes with two recently published systematic reviews on 
pre-eclampsia screening tests [1, 2], to ascertain whether the identified attributes could 
be applied to pre-eclampsia screening. A ‘monetary cost’ attribute was excluded as the 
UK does not charge directly for health screening. Four attributes (preparation; risk of 
screening test; screening interval; waiting time for results) were eliminated, as no 
published screening tests involve these attributes. Two new attributes, positive 
predictive value and negative predictive value were identified. As certain attributes had 
very similar characteristics when applied to pre-eclampsia screening, they were merged 
to aid comprehension. Therefore, three attributes, pregnancy gestation at test time, 
location of test and duration of test, were merged into an ‘inconvenience and timings’ 
attribute, and the ‘pain/discomfort’ attribute was incorporated into the ‘testing 
procedure’ attribute.  
The third phase involved comparing this list of attributes with the findings of two 
qualitative studies (Chapters 4 and 5) to identify any further attributes regarding pre-
eclampsia screening.  One attribute was added through this process – ‘consequences of 
a positive result’. The final 11 attributes are listed in Table 8.2 in three groups –
accuracy, testing costs and characteristics, and effects of positive result. 
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TABLE 8.1 - DISTRIBUTION OF ATTRIBUTES USED IN DCE ASSESSING PREFERENCES FOR 
SCREENING TESTS FROM 2008-2013 
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8.5.2  RANKING EXERCISE 
Ten pregnant women and 22 healthcare professionals completed the ranking exercise. 
Eleven attributes were judged to be ‘very important’ at least once. The ranking scores 
for each attribute for both sample groups are given in Table 8.3. Both pregnant women 
and healthcare professionals ranked the same six attributes as most important. However, 
the order of importance varied between the two groups. Women ranked accuracy 
(sensitivity) as the most important attribute, followed by follow-up. Healthcare 
professionals ranked testing procedure as the most important attribute, followed by level 
of information. 
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TABLE 8.2 – LIST OF 11 IDENTIFIED ATTRIBUTES RELEVANT TO PRE-ECLAMPSIA 
SCREENING 
Accuracy  Testing Costs and 
Characteristics 
Effects of positive results 
Sensitivity  
The ability of the screening test to 
correctly identify the number of 
people that will go on to develop 
pre-eclampsia 
Level of information 
Whether the test advises of the 
risk for all types of pre-eclampsia, 
or just the types with the most 
severe consequences 
Follow up  
What happens if you are found 
high risk for pre-eclampsia 
 
Positive predictive value  
The percentage of women who are 
identified as higher risk of getting 
pre-eclampsia who actually go on 
to develop it 
Testing procedure 
The processes that happen to you 
so your risk of developing pre-
eclampsia can be calculated, 
considering any pain or 
discomfort. 
Risk reduction  
The effect of knowing that you are 
at risk of developing pre-
eclampsia has on your chances of 
it actually developing. 
Specificity  
The ability of the screening test to 
correctly identify the number of 
people that will not go on to 
develop pre-eclampsia 
Type of staff seen  
Who explains and conducts the 
pre-eclampsia screening test 
 
Consequences of a positive result  
Explaining the negative effects of 
being found high risk for pre-
eclampsia 
Negative predictive value The 
percentage of women who are 
identified as lower risk of getting 
pre-eclampsia who do not go on to 
develop it 
Inconvenience and timings 
Where and when the pre-
eclampsia test is conducted 
 
 
 
TABLE 8.3 - RANKING SCORES FOR EACH ATTRIBUTE BY SAMPLE GROUPS 
Attribute  Rank score- women  
(rank position) 
Rank score – 
Healthcare 
professionals (rank 
position) 
Total Rank score 
 
Testing procedure  34 (4
th)  82 (1
st)  116 
Level of information   36 (3
rd)  75 (2
nd)  111 
Follow up   40 (2
nd)  70 (3
rd)  110 
Consequences of a positive result   32 (5
th)  75 (4
th)  107 
Sensitivity   42 (1
st)  61 (6
th)  103 
Positive predictive value  24 (6
th)  67 (5
th)  91 
Risk reduction  12 (8
th)  51 (7
th)  63 
Specificity  2 (10
th)  33 (8
th)  35 
Inconvenience and timings   12 (8
th)  14 (9
th)  26 
Type of staff seen  10 (9
th)  16 (10
th)  26 
Negative predictive value  0 (11
th)  6 (11
th)  6 
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8.6  DISCUSSION  
To the best of our knowledge this research is the first investigation into the importance 
of attributes of a first-trimester screening tests for pre-eclampsia. The systematic review 
conducted as part of this study highlighted the popularity of the discrete choice 
experiment (DCE) methodology in considering the acceptability of screening tests, with 
16 studies published in a five-year period. This study found that pregnant women and 
healthcare professionals identify the same six attributes as most important to help them 
consider a pre-eclampsia screening test. However, they differ on which of the attributes 
is most important.  
The most striking result from this small-scale investigation was that, when only 
considering the top six attributes, the most important attribute for women (sensitivity of 
the screening test) was the least important for healthcare professionals. This is contrary 
to other studies that have assessed the importance of test attributes in prenatal screening, 
which have often shown that healthcare professionals value accuracy more than women 
[15,26]. In light of this finding, subsequent research using these attributes should use 
the top six ranked attributes, to ensure the attributes deemed important by both women 
and healthcare professionals are considered.  
While this study identified attributes that women and healthcare professionals value 
when considering the screening test, it does not tell us what characteristics of those 
attributes they value most. For example, the attribute ‘testing procedure’ in relation to 
pre-eclampsia screening could constitute taking a medical history, or taking a blood test, 
or conducting an internal vaginal ultrasound scan. There is currently no empirical data 
identifying which of these options would be seen as acceptable to stakeholders.  
The data presented here should be considered in light of the study limitations. Sample 
sizes were small, and all respondents were recruited from one UK hospital. However, 
the aim of these data were to inform the design of a DCE to test the acceptability of a 
first trimester screening test amongst a larger, more representative sample. 
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8.7  CONCLUSIONS 
Based on these data considering a first trimester screening test for pre-eclampsia, 
pregnant women rank accuracy (as measured by sensitivity) as the most important 
attribute, followed by follow-up. Healthcare professionals rank testing procedure as the 
most important attribute, followed by level of information. This difference may be due 
to the uncertainty surrounding this novel screening test. As yet it is unknown if these 
findings would extend to differences in preferences for different types of screening 
tests. 
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CHAPTER 9 - KEY STAKEHOLDERS PREFERENCES FOR 
UNIVERSAL FIRST TRIMESTER SCREENING TESTS FOR 
PRE-ECLAMPSIA: A DISCRETE CHOICE EXPERIMENT 
COMPARING BIOCHEMICAL TESTS WITH HISTORY 
TAKING. 
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9.1  ABSTRACT 
OBJECTIVE: To compare the preferences for key attributes of universal first trimester 
screening tests for pre-eclampsia amongst pregnant women, women who had 
experienced pre-eclampsia in a previous pregnancy and healthcare professionals.  
STUDY DESIGN: Discrete choice survey experiment 
SAMPLE AND SETTING:  Respondents compared choice sets with four attributes – 
accuracy of test, level of information, schedule of follow-up, and test format. Responses 
were randomised into a sensitivity or population prevalence accuracy condition. The 
attribute levels were assigned based on current practice and a published high-accuracy 
biochemical screening test.  
FINDINGS: 119 pregnant women, 111 women with previous pre-eclampsia and 76 
healthcare professionals recruited by a combination of face-to face, social networking 
and posted questionnaires were analysed. 95% of respondents indicated a preference for 
a biochemical screening test, with no differences in sample group or accuracy condition. 
All recruitment groups valued greater accuracy of the screening test (p<0.000 in all 
cases). A blood test was valued over medical history in all but one scenario (p<0.003 in 
all cases). Sub-group analysis demonstrated that those who perceived pregnancy risk to 
be low and had low anxiety scores were likely to consider each aspect of the test, while 
those with perceived higher risk and were more anxious tended to focus on the accuracy 
of the test.  
CONCLUSIONS: Based on the evidence presented here, there is overwhelming 
support for a first-trimester screening test for pre-eclampsia, when compared with 
current methods. Accuracy was a constantly valued attribute. Increased levels of anxiety 
and perception of pregnancy risk result in a greater focus on the accuracy of the 
screening test.  
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9.2  INTRODUCTION 
The qualitative studies presented within this thesis did not identify any psychological 
concerns in relation to the introduction of a first-trimester screening test for pre-
eclampsia. However, some concerns were raised regarding both the appropriateness of 
introducing a screening test without a risk reduction intervention, and issues with the 
test itself, including its accuracy and the invasiveness of the screening test (see Chapter 
4 and 5).  
To test the appropriateness of the screening test, a discrete choice experiment (DCE) 
was designed. The previous chapter details how the attributes for the DCE were 
identified. This chapter details the DCE itself.  
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9.3  BACKGROUND 
There has been much interest in the development of a biomedical screening test to 
predict the pregnancies most at risk of pre-eclampisa, a major cause of fetal and 
maternal morbidity and mortality [1-3]. The UK’s National Institute of Health and Care 
Excellence guidelines for antenatal care recommends more frequent blood pressure 
measurements if the initial pregnancy appointment reveals a woman has any of nine 
pre-eclampsia risk factors [4]. These are: nulliparity (first pregnancy); age 40 years or 
more; a body mass index (BMI) of 30kg/m
2 or above; a pregnancy interval of more than 
10 years; a family history of pre-eclampsia; previous personal history of pre-eclampsia; 
pre-existing vascular disease such as hypertension; pre-existing renal disease; and a 
multiple pregnancy (such as twins). The healthcare professional and the woman must 
decide, in partnership, if any specific risk factor warrants increased monitoring. A large 
percentage of pregnant women fall into these groups. Over 44% of births in 2011 within 
the UK were to first time mothers and/or women over 40 [5] and around 5% of pregnant 
women have a BMI of over 35 [6]. Therefore as many as 1 in 2 pregnancy episodes 
could meet the first three risk factors outlined above. Indeed, figures from a 
retrospective case control trial [7] identified that this methodology has a positive 
predictive value
10 of 4.12%. Therefore this method can result in nine out of every ten 
woman receiving additional monitoring unnecessarily. To combat these problems, there 
have been efforts to develop an accurate biochemical screening test for pre-eclampsia to 
improve its prediction [3]. The aim is for improved identification methods to improve 
monitoring and outcomes of at-risk pregnancies [8,9].  
Ninety-eight biochemical prenatal screening methods for pre-eclampsia have been 
identified in two separate meta-analyses [1,2]. The biochemical screening tests differ in 
the gestation of application (first or second trimester screening tests), the screened 
population (universally screening all pregnant women, or those at ‘high-risk’ only), and 
the type of pre-eclampsia that is identified (‘early pre-eclampsia’, developing pre-
eclampsia prior to 34 weeks, or ‘all pre-eclampsia’, which identifies the chance of pre-
eclampsia developing at any gestation). Sensitivity
11 of the screening tests range from 
                                                 
10 Positive predictive value -the proportion of positive test results that are true positives 
11 Sensitivity -the proportion of those who develop the condition that are correctly 
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5.9% to 100%, with specificity
12 ranges of 47% to 100%.  An improvement in 
sensitivity generally trades against specificity accuracy. For example, one test published 
100% sensitivity scores with 76% specificity [10] while another published 71% 
sensitivity with 100% specificity [11]. Increases in accuracy also come at a cost to the 
type of information gained. For example one test presents 100% sensitivity for detecting 
pre-eclampsia prior to 35 weeks gestation, while only providing 29% sensitivity for 
detecting pre-eclampsia post 35 weeks gestation [12]. It is unclear how many of these 
tests have moved from research protocols to being introduced into a wider-clinical 
context. We know of two NHS hospitals have introduced a universal first-trimester 
biochemical screening programme, a recent consultation by the UK’s National 
Screening Committee concluded that there was currently insufficient value in 
introducing a pre-eclampsia screening test [13]. 
Research suggests that pregnant women and healthcare professionals have some 
concerns about the introduction of a screening test for pre-eclampsia in routine care (see 
Chapters 4 and 5). These included (i) a lack of trust in the accuracy of the results given; 
(ii) questioning the appropriateness of introducing a screening test without a risk 
reduction intervention and (iii) concerns regarding the invasiveness of the screening 
test. Despite this, the women found high risk for pre-eclampsia were positive about the 
screening programme and its accompanying increased monitoring, and reported that 
they would request it again in a subsequent pregnancy. This current study aimed to test 
the acceptability of this new screening test via a discrete choice experimental (DCE) 
design. It seeks the views of three stakeholders - pregnant women, women who had pre-
eclampsia in a previous pregnancy and maternity healthcare professionals.  
DCEs are a preference elicitation methodology that have been widely used in health 
research to examine the preferences and acceptability of various factors within 
healthcare [14]. In a standard binary choice DCE, a series of paired options are 
presented and participants are asked to choose between them. Each pair provides details 
of the test’s ‘attributes’, that is the pre-selected important characteristics of the options, 
such as test accuracy and convenience. Each attribute differs on ‘levels’, that is pre-
selected differences within the attributes, such as test accuracy of 90% versus 75%.  
Following completion of the survey, an assessment can be made on individual 
preferences and the priorities of the various attributes being assessed. For example, 
                                                 
12 Specificity -the proportion of those who do not develop the condition that are 
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accuracy of a screening test may be a priority for some, while others may value 
convenience more. DCE has been used in maternity healthcare research to assess 
preferences for a variety of healthcare choices including packages of care [15], 
additional ultrasound scans [16] and Down’s syndrome screening options [14].  
A ranking exercise conducted on ten pregnant women and 22 healthcare professionals 
(Chapter 7) showed a preference for six different attributes of pre-eclampsia screening – 
accuracy as expressed by the sensitivity of the screening test, accuracy as expressed by 
the positive predicative value of the test, the level of information given by the test, the 
testing procedure, follow up (what happens following a high-risk result), and the 
consequence of a screen positive result.   
Uptake of screening varies [17,18], influenced by factors such as age, ethnicity, marital 
status, anxiety and perceived risk [19-21]. Few of these factors have been investigated 
as part of a DCE; a study of preferences for a third-trimester ultrasound scan [16] found 
that primigravidas, those reporting higher stress and older women valued the additional 
scan more. Knowing if these demographic factors and the psychometric measures of 
anxiety and perception of risk contribute to pregnant women’s preferences for pre-
eclampsia screening will enable adequate tailoring of pre-test advice.  
9.3.1  RESEARCH QUESTIONS 
The following study was designed to test key stakeholders’ views (Pregnant women, 
HCPs and mothers who had experienced pre-eclampsia during their pregnancies) on 
biochemical screening tests for pre-eclampsia. It compared a highly accurate 
biochemical test with the current history-taking methodology recommended by NICE.  
The following research questions were identified: 
  Do the preferences of the three stakeholder groups (pregnant women, women with 
experience of pre-eclampsia and HCPs) differ? 
  Which attributes most influence preferences for pre-eclampsia screening tests?  
  Does the way in which ‘accuracy’ is presented (sensitivity versus positive predictive 
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  Do demographic factors, anxiety scores and perceptions of pregnancy risk affect the 
screening test attributes that pregnant women prefer?  
9.4  METHODS 
9.4.1  STUDY SAMPLE AND RECRUITMENT 
This study recruited participants from three groups – pregnant women, previous pre-
eclamptics and HCPs.  
PREGNANT WOMEN  
Pregnant women were recruited in three ways 
– face-to-face in the maternity department of a 
London Hospital, postal from the same 
hospital, and via social media. Face-to-face 
recruitment took place within the outpatients 
department of a maternity hospital, in waiting 
rooms of the antenatal clinic, ultrasound 
department or day assessment unit. Either 
clinic receptionists or a research midwife 
provided women with a study pack containing 
an information leaflet explaining the study, a 
consent form and a questionnaire. 
Postal recruitment was planned via posting a recruitment leaflet, explaining the study 
and containing the link to the electronic survey, to 500 women along with their first 
pregnancy appointment letters. While assurance was gained that the leaflets would be 
sent, the mechanisms of the trust meant that no guarantees of postage could be sought. 
A researcher oversaw the inclusion of the first 10 leaflets. The response rate from the 
leaflets was very low (4 responses received). It is unclear if this was due to a lack of 
interest or a lack of postage of the leaflets.  
Social Media recruitment for pregnant women took place via Facebook, Twitter and 
forum postings. Facebook recruitment involved a small advert being targeted to female 
users of Facebook aged between 18 and 40 who had indicated that they were 
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newlyweds, parents, expectant parents or newly engaged. The advert cost £45, was 
displayed on 41,036 Facebook pages, and resulted in 182 clicks onto the survey, 
suggesting a price of £0.25 per click, and a click-through rate of 0.4%. A sample of the 
advert can be seen in Figure 9.1. A twitter account for the study was created and tweets 
sent to various pregnancy related accounts to encourage promotion of the survey. Ten 
respondents were gained from twitter. In addition to this, a post was placed on 
MumsNet (usual £30 charge waived by the site, zero respondents gained) NetMums (no 
cost, two respondents), the front page of the Antenatal Results and Choices website (no 
cost, 5 respondents) and the front page of the Bliss charity website (no cost, no 
respondents).   The final sample was 119 pregnant women. 
WOMEN WITH PREVIOUS PRE-ECLAMPSIA 
Recruitment of the women who had previously experienced pre-eclampisa came mostly 
via the charity Action on Pre-eclampsia, who posted links to the survey on both their 
Facebook page and on their website. There was no charge for this, and the posting 
received over 100 responses in the first three days. Six women who had previously had 
pre-eclampsia (and were pregnant again) were recruited face-to-face. The final sample 
was 111 women with previous pre-eclampsia. 
HEALTH PROFESSIONALS 
HCPs were recruited either via email sent to global email addresses in the study trust, or 
via social networking. Two emails were sent one month apart to all midwives and 
obstetricians in the trust (42 respondents). Other recruitment methods included the 
Facebook advert explained above (which asked for pregnant women or healthcare 
professionals, 29 respondents) and a letter in the ‘Midwives’ periodical of the Royal 
College of Midwives (no cost, 5 respondents). Requests for promotion within other 
periodicals and journals were declined. The final sample was 76 healthcare 
professionals.  
9.4.2  INCLUSION AND EXCLUSION CRITERIA 
Responses were excluded from analysis if the respondent: (i) was not currently 
pregnant, had not previously had pre-eclampsia or was not a HCP; (ii) failed to 
complete six or more of the eight choice sets presented or (iii) failed the validity checks 
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9.4.3  MEASURES - QUESTIONNAIRE DESIGN 
  The DCE aimed to compare the attributes of two screening tests for pre-
eclampsia: (i) the current screening test of maternal history and physical characteristics 
recommended by NICE discussed in the introduction [22], and (ii) the current best 
performing biochemical universal first trimester screening test in the published 
literature [12]. These tests differ in many ways. The levels for each attribute were 
selected from these published screening tests. These are outlined in Table 9.1. As the 
‘consequence of a screen positive result’ attribute is the same for each of the two tests, 
no value can be added by including it within the choice sets, therefore this attribute was 
excluded. 
A full-factorial design of a questionnaire with four attributes, each with two levels 
would present 16 (4
2) different choice sets; previous studies have shown that 
participants get overwhelmed when presented with more than 10 choice sets. Therefore 
a fractional factorial design was used, devised via the Hahn and Shapiro [23] catalogue 
to ensure D-efficiency. This considered level balance (ensuring the levels of each 
attribute occur with equal frequency), orthogonality (ensuring that the variation in the 
levels of each attribute is independent over choice sets) and minimal overlap (ensuring 
that a level does not repeat itself within a choice set). Each respondent was therefore 
presented with eight choice sets. Choice one and eight for each respondent was a 
comparison of the actual levels for the attributes of the two comparison tests, while the 
other six choice sets varied the attribute levels, enabling attribute preferences to be 
elicited.  
Introduction text explained the effects of pre-eclampsia (taken from published literature, 
see Appendix 16) and the various attributes presented. This was followed by the choice 
sets, presented as two options – test A, test B. As one option referred to a screening test 
that involved medical history assessment only, an opt-out choice was not included. An 
example is given below in Figure 9.2. The questionnaire was presented either in paper 
form or electronically. When the electronic format was used the order of choice sets two 
to seven were randomised.  
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TABLE 9.1 – THE IDENTIFIED ATTRIBUTES AND CORRESPONDING LEVELS USED WITHIN 
THE EXPERIMENT 
Attributes  Levels based on  NICE guidelines 
 
Levels based on Spencer et al Biochemical test 
Accuracy - sensitivity  Test identifies 75% of pregnancies affected by 
pre-eclampsia, 95% of the most dangerous 
Test identifies 50% of pregnancies affected by 
pre-eclampsia 
Accuracy – Positive 
predicative value 
5% of those identified as high risk go on to 
develop pre-eclampsia 
25% of those identified as high risk go on to 
develop pre-eclampsia 
Level of information  Placed in ‘high risk’ or ‘low risk’ group  Risk given in numerical form (1 in 30, or 30% 
chance of developing pre-eclampsia) 
Testing procedure  Medical history assessment 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so no 
additional needles or ultrasounds needed), 
weight, blood pressure measurements, medical 
history assessment 
Follow up  Additional appointments as planned by women 
and healthcare professional 
Pre-arranged schedule of additional monitoring 
for blood pressure checks, blood tests and 
ultrasound scans 
Consequence of a 
screen positive result 
No consequences identified other than 
increased monitoring 
No consequences identified other than 
increased monitoring 
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Q1 – Please consider each choice separately and tick the box to show which option you would 
prefer – Test A or Test B. 
 
  Test A  Test B 
Accuracy  Test identifies 50% of pregnancies affected 
by pre-eclampsia 
Test identifies 75% of pregnancies affected 
by pre-eclampsia, 95% of the most 
dangerous 
Level of 
information  Placed in ‘high risk’ or ‘low risk’ group  Risk given in numerical form (1 in 30, or 
30% chance of developing pre-eclampsia) 
Testing 
procedure  Medical history assessment 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so 
no additional needles or ultrasounds 
needed), weight, blood pressure 
measurements, medical history assessment 
Follow up  Additional appointments as planned by 
women and healthcare professional 
Pre-arranged schedule of additional 
monitoring for blood pressure checks, blood 
tests and ultrasound scans 
 
Test A    Test B   
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9.4.4  MEASURES – ADDITIONAL INFORMATION  
To test if demographic factors, anxiety scores or perceptions of pregnancy risk affected 
the screening test attributes that pregnant women preferred, further information was 
collected from this group of participants.  
Demographic data collected included age, marital status, highest level of education, 
race, previous pregnancies, any previous pre-eclampsia, and postcode as a proxy 
measure of deprivation.  
Anxiety was measured by the STAI-6, a frequently used scale to measure state (how one 
is currently feeling) and trait (how one generally feels) anxiety. It consists of a six-item 
scale with a potential score of between 20 and 80. It was originally validated using a 
sample of pregnant women [24], and has been used in over 100 screening related 
studies. The questionnaire requires respondents to respond to a set of six statements 
such as ‘I feel calm’ and ‘I feel tense’. Respondents answer on a 1 to 4 scale to indicate 
‘not at all’, ‘somewhat’ ‘moderately’ or ‘very much’. These scores are tallied and 
multiplied to aid comparison with the original 20 point item.  
Perception of pregnancy risk was measures by the validated Perception of Pregnancy 
Risk Questionnaire (PPRQ), a nine item visual analogue scale [25]. A recent systematic 
review on measuring perception of risk in high risk pregnancies [26] found that this was 
the only validated scale to assess perception of pregnancy risk. It has been used in three 
studies to date, on a total of 484 pregnant women. Participants indicate their perceptions 
of risk to self in terms of four statements such as ‘the risk for myself during this 
pregnancy’ and risk to the fetus in five statements such as ‘the risk for my unborn baby 
during this pregnancy’. Women placed a mark on a 100-millimeter horizontal line 
anchored with ‘no risk’ at 0 and ‘extremely high risk’ at 100 millimeters. Adding the 
score for each of the nine items, and then dividing the total score by 9, to obtain a score 
out of 100, calculates the total PPRQ.  
9.4.5  PILOT TESTING 
An initial questionnaire was pilot tested (n=20). This questionnaire featured all five 
attributes in each choice set. Respondents took a long time to complete the 
questionnaire (mean 35.6 minutes, SD 18.96). The participants identified that presenting 
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that participants would be randomised to one of two conditions – a positive predictive 
value or sensitivity condition. 
9.4.6  PROCEDURE  
Questionnaires were completed either in paper form (face-to-face recruitment) or online 
using a specially designed questionnaire using the Qualtrics Research Suiteﾩ (Version 
37,883 Qualtrics, Provo, UT) (all other recruitment methods). Allocation to the 
sensitivity or positive predictive value condition was via alternate allocation when 
recruiting face-to-face, and via randomisation when using online recruitment. Specific 
recruitment procedures are detailed within the sample section above. A copy of both 
questionnaires can be found in Appendix 17.  
9.4.7  VALIDITY 
Two validity checks were included within the design, with inclusion within the analysis 
depending on the responses of the validity questions. This consisted of internal 
consistency measures and confidence ratings of choices made. Choice Set 1 and eight 
were the same for each respondent, but inverted so that Choice A in question one was 
Choice B in question eight. Respondents were asked to rank their confidence in their 
choices on a Likert scale of 1 (not at all confident) to 10 (extremely confident). There is 
debate in the choice modelling literature as to whether inconsistency is an appropriate 
reason to exclude a response set as the inconsistency may be a reflection of the utility of 
the choices presented. Therefore, a respondent needed to fail both validity checks to be 
excluded – that is, provide an inconsistent response to questions one and eight, and rank 
their confidence in their choices below eight.  
9.4.8  ETHICS 
Full NHS ethics approval was gained via the proportionate review process, reference 
13/LO/0811. Data were stored according to Caldicott principles and, other than 
postcode, no identifiable data were collected. Postcodes were amended to IMD scores 
as soon as possible and the original postcode deleted. Face-to-face recruitment resulted 
in signing a consent form to indicate consent. Online recruitment involved reading the 
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were made aware that they could stop at any time and that no question was compulsory, 
a point repeated prior to the anxiety and perception of pregnancy risk questionnaires and 
when asked for postcode.  
9.4.9  ANALYSIS 
The study design provides nine comparison groups - pregnant women, previous pre-
eclamptics and HCPs, each with a sensitivity, positive predictive value and accuracy-
combined condition. The demographic data of each comparison group were calculated 
and between-group and intra-group differences examined via Chi Square or Fishers 
Exact test.  
Differences in the frequencies of preferences for the two tests, as demonstrated by the 
responses to choices 1 and 8 in each questionnaire, were analysed via Fishers Exact test.  
The attributes that are important to each group when making a screening test decision 
were identified by coding choice data and analysing them using a conditional logit 
regression model in Stata 12.0 (StataCorp College Station, TX). Initially models were 
run for the separate samples within their accuracy conditions. The levels for accuracy 
were mean centred, and the other attributes were effects coded. The sign (+ or -) of the 
coefficients generated in the regression indicate the direction of the preference for each 
attribute, with a positive sign indicating preference for the levels taken from the 
biochemical test.  A further analysis was conducted combining the accuracy conditions, 
by dummy coding the accuracy condition to ‘higher accuracy’ or ‘lower accuracy’ 
levels. Additional subgroup analyses were performed to compare attribute preferences 
for women based on anxiety and perception of pregnancy risk scores.  
9.5  RESULTS  
434 completed questionnaires were received.  One-hundred-forty questionnaires were 
excluded for not meeting the inclusion criteria of not being pregnant, a HCP or had 
previous pre-eclampsia (n=15); completed less than 75% of the questionnaire (n=122); 
or failed the internal validity questions (n=3). This provided 294 unique respondents 
including 119 pregnant women (37 of which were also HCP, 16 of which had previous 
PE), 111 previous pre-eclampsia and 76 HCPs. Table 9.2 shows the demographic 
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 9.5.1 DIFFERENCES IN PREFERENCE FOR SCREENING TEST 
Over 95% of total respondents expressed a preference for the universal biochemical 
screening test when directly comparing the attributes of the NICE screening test with 
the best performing biochemical screening test. These findings are shown in Table 9.3. 
The preference for the biochemical test ranged from 90.7% (HCPs in the population 
prevalence condition) to 96.97% (HCPs in the sensitivity condition). There were no 
significant differences between accuracy conditions for any of the sample groups. The 
screening test preference did not differ by sample group (X
2 (2, N=294) = 0.98, 
p=0.61). Due to the small numbers of preference for the NICE screening test, a logistic 
regression was not run.  
9.5.2  ATTRIBUTE PREFERENCES  
The results from the conditional logistic regression are show in Table 9.4. The 
significant results are highlighted. A more accurate test was preferred for all samples in 
all conditions. Almost all conditions (other than HCPs/Population Prevalence) prefer a 
test that is calculated via blood tests and ultrasound scan rather than from medical 
history alone. The value that respondents placed on the attributes differed depending on 
the accuracy condition, so that pregnant women in the sensitivity condition valued all 
four attributes compared to only two (accuracy and format) in the population prevalence 
condition, and previous pre-eclamptics valued a set-schedule of follow up in the 
population prevalence condition more than in the sensitivity condition.  The coefficients 
and corresponding odds ratios were higher for the test format attribute than the accuracy 
attribute in all samples. However, the results of the accuracy scores (the only non-
categorical data within the regression model) show the outcome per unit increase, rather 
than the dummy-coded binary choice options within the categorical data. Therefore, the 
8% increased likelihood of a pregnant woman within the sensitivity condition picking 
the more accurate test equates to a 200% increased-likelihood of selecting a test with 
75% sensitivity compared to a test with 50% sensitivity.  This indicates that within this 
sample, accuracy was seen as the most important attribute for all respondent groups, 
with varying values placed on other attributes.  Page 222 of 316        Chapter 9: Discrete Choice Study 
 
TABLE 9.2 – DEMOGRAPHIC DETAILS OF RESPONDENTS (SOME LOW-RESPONSES EXCLUDED) 
 
Pregnant women  Previous pre-eclampsia  Health professionals 
Grand Totals 
Sensitivity   PPV  Total  Sensitivity  PPV   Total  Sensitivity   PPV   Total 
n  %  n  %  n  %  n  %  n  %  n  %  n  %  n  %  n  %  n  % 
Recruitment 
method 
Face-to-face  50  71.40%  32  65.3%  82  68.9%  4  7.1%  2  3.6%  6  5.4%  0  0.0%  0  0.0%  0  0.0%  82  27.9% 
Social network  12  17.10%  11  22.4%  23  19.3%  52  92.9%  53  96.4%  105  94.6%  17  51.5%  17  39.5%  34  44.7%  156  53.1% 
Postal /Email  8  11.40%  6  12.2%  14  11.8%  0  0.0%  0  0.0%  0  0.0%  16  48.5%  26  60.5%  42  55.3%  56  19.0% 
Age (mean)  32.29  30.9  31.71  29.77  30.89  30.32  23.06  24.98  24.12  29.18 
E
t
h
n
i
c
i
t
y
 
Asian  3  4.3%  4  8.2%  7  5.9%  1  1.8%  2  3.6%  3  2.7%  5  15.2%  2  4.7%  7  9.2%  18  6.1% 
Black  4  5.7%  2  4.1%  6  5.0%  2  3.6%  2  3.6%  4  3.6%  2  6.1%  0  0.0%  2  2.6%  10  3.4% 
White  52  74.3%  37  75.5%  89  74.8%  52  92.9%  50  90.9%  102  91.9%  24  72.7%  36  83.7%  60  78.9%  240  81.6% 
Mixed  3  4.3%  2  4.1%  5  4.2%  0  0.0%  0  0.0%  0  0.0%  1  3.0%  2  4.7%  3  3.9%  8  2.7% 
Other  7  10.0%  1  2.0%  8  6.7%  1  1.8%  1  1.8%  2  1.8%  1  3.0%  0  0.0%  1  1.3%  10  3.4% 
H
i
g
h
e
s
t
 
q
u
a
l
i
f
i
c
a
t
i
o
n
 
GCSE  5  7.1%  1  2.0%  6  5.0%  6  10.7%  8  14.5%  14  12.6%  1  3.0%  0  0.0%  1  1.3%  20  6.8% 
A-level  4  5.7%  1  2.0%  5  4.2%  10  17.9%  8  14.5%  18  16.2%  0  0.0%  2  4.7%  2  2.6%  25  8.5% 
First degree  37  52.9%  27  55.1%  64  53.8%  30  53.6%  21  38.2%  51  45.9%  18  54.5%  19  44.2%  37  48.7%  143  48.6% 
Masters  17  24.3%  16  32.7%  33  27.7%  8  14.3%  13  23.6%  21  18.9%  12  36.4%  10  23.3%  22  28.9%  74  25.2% 
PhD  6  8.6%  1  2.0%  7  5.9%  0  0.0%  4  7.3%  4  3.6%  2  6.1%  8  18.6%  10  13.2%  20  6.8% 
M
a
r
i
t
a
l
 
S
t
a
t
u
s
  Married  57  81.4%  33  67.3%  90  75.6%  47  83.9%  37  67.3%  84  75.7%  19  57.6%  18  41.9%  37  48.7%  202  68.7% 
Cohabiting  10  14.3%  9  18.4%  19  16.0%  7  12.5%  13  23.6%  20  18.0%  2  6.1%  4  9.3%  6  7.9%  41  13.9% 
Partner, not cohabiting  2  2.9%  0  0.0%  2  1.7%  0  0.0%  2  3.6%  2  1.8%  2  6.1%  2  4.7%  4  5.3%  8  2.7% 
Separated/ divorced  0  0.0%  0  0.0%  0  0.0%  1  1.8%  1  1.8%  2  1.8%  1  3.0%  6  14.0%  7  9.2%  9  3.1% 
Single  0  0.0%  4  8.2%  4  3.4%  1  1.8%  1  1.8%  2  1.8%  9  27.3%  7  16.3%  16  21.1%  22  7.5% 
Previous Pregnancy?  Yes  25  35.7%  19  38.8%  44  37.0%  56  100.0%  55  100.0%  111  100.0%  19  57.6%  24  55.8%  43  56.6%  184  62.6% 
Mean confidence rating, 
(min-max, standard deviation) 
7.87 (4-10, 
SD1.41) 
7.38 (1-10, 
SD1.97) 
7.71 (1-10, SD 
1.62) 
8.05 (4-10 SD 
1.48) 
7.33 (5-10 SD 
1.38) 
7.64 (1-10, SD 
1.78) 
8.35 (7-10 SD 
1.03) 
6.75 (1-9 SD 
2.29) 
7.57 (1-10, SD 
1.88) 
7.68 (1-10, SD 
1.72) 
Totals  70  58.80%  49  41.2%  119 
 
56  50.5%  55  49.5%  111 
 
33  11.2%  43  14.6%  76 
 
294 
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TABLE 9.3 – COMPARISONS OF PREFERENCE FOR NICE SCREENING TEST AND CURRENT BEST PERFORMING BIOCHEMICAL SCREENING TEST 
 
Pregnant women  Previous pre-eclampsia  Health professionals 
Totals 
Sensitivity   PPV  Total  Sensitivity  PPV   Total  Sensitivity   PPV   Total 
n  %  n  %  n  %  n  %  n  %  n  %  n  %  n  %  n  %  n  % 
NICE  3  4.3%  2  4.1%  5  4.2%  2  3.6%  2  3.6%  4  3.6%  1  3.0%  4  9.3%  5  6.6%  14  4.8% 
Biochemical  67  95.7%  47  95.9%  114  95.8%  54  96.4%  53  96.4%  107  96.4%  32  97.0%  39  90.7%  71  93.4%  280  95.2% 
Total  70  100%  49  100%  119  100%  56  100%  55  100%  111  100%  33  100%  43  100%  76  100%  294  100% 
Fisher Exact 
Probability Test  P=1, FET, NS  P=1, FET, NS  P=0.381, FET, NS   
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TABLE 9.4 - CONDITIONAL LOGIT ANALYSIS REGRESSION RESULTS FOR PREGNANT WOMEN, WOMEN WHO HAD EXPERIENCED PRE-ECLAMPSIA 
IN A PREVIOUS PREGNANCY, AND HEALTHCARE PROFESSIONALS, BY ACCURACY CONDITION 
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9.5.3  PRESENTATION OF ACCURACY 
The significant values of the regressions did not change according to how the accuracy 
information was presented. However, there were differences in the odds ratios. To aid 
comparison, these odds ratios, adjusted for the percentage differences in accuracy for 
each of the tests, were converted into the percentage-probability of selecting the more 
accurate test (odds/odds+1=probability, [27]) and are shown in Table 9.5. The data show 
that respondents were more likely to select a test based on accuracy scores when 
presented with sensitivity data than when presented with positive predictive value data. 
This difference was highest amongst those who had had pre-eclampsia, and smallest 
amongst pregnant women. The data shows that there was minimal difference in 
preference, irrespective of how accuracy was presented. Accuracy was still the greatest 
influence on test-choice selection in all samples, irrelevant of how it was presented. 
TABLE 9.5 – ODDS RATIOS AND PROBABILITIES OF SELECTING A TEST WHEN PRESENTED 
WITH SENSITIVITY DATA COMPARED TO POSITIVE PREDICTIVE VALUE DATA 
  Pregnant women  Prev Pre-eclampsia  HCPs 
OR  Probability  OR  Probability  OR  Probability 
Sensitivity – Odds ratio and 
probability of selecting a test with 
75% sensitivity over a test with 
50% sensitivity 
200  99.5%  182.5  99.5%  260  99.6% 
PPV – odds ratio of picking a test 
with 25% PPV over a test with 
5% PPV 
194  99.5%  102  99.0%  200  99.5% 
9.5.4  SUBGROUP ANALYSIS 
The STAI-6 scale was completed by 111 (93.28%) of the pregnant women. The PPRQ 
scale was completed by 98 (82.35%) of the pregnant women.  Women were categorised 
into ‘high’ or ‘low’ for perceived risk and for anxiety by calculating the median score 
for both scales. The conditional logistic regressions were then re-run for these 
subgroups. The results presented in Table 9.6 are for the accuracy conditions combined 
(accuracy dummy coded as ‘higher’ or ‘lower’ accuracy) to aid comparisons of 
coefficients and odds ratios. The results show that while those with higher perceptions 
of pregnancy risk and anxiety scores favoured the accuracy score when making a 
choice, those with lower scores considered all aspects of the screening test when 
making a preference.  Page 226 of 316    Chapter 9: Discrete Choice Study    Chapter 9: Discrete Choice Study 
 
TABLE 9.6 – CONDITIONAL LOGIT REGRESSION RESULTS FOR PREGNANT WOMEN BASED ON PERCEPTION OF PREGNANCY RISK AND ANXIETY 
SCORES. 
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9.6  DISCUSSION  
To the best of our knowledge this research is the first investigation into the preferences 
for first-trimester screening tests for pre-eclampsia. This study found overwhelming 
support for pre-eclampsia screening. In this study we have examined the preferences of 
pregnant women, those who had previously experienced pre-eclampsia and healthcare 
professionals for first-trimester screening tests for pre-eclampsia. There were minimal 
differences between the three recruitment groups, with the largest support coming from 
those who had experienced pre-eclampsia previously. The attribute that influenced 
preferences most was accuracy, irrespective of how it was presented. Psychometric 
measures of anxiety and perception of pregnancy risk show that pregnant women with 
more concerns focus more on the accuracy of the screening test, while those with lower 
concerns consider each aspect of the test.  
There is increasing research interest in introducing a first trimester screening test for 
pre-eclampsia, and some research intensive NHS trusts within the UK have introduced 
them despite recent guidelines from both NICE [28] and the National Screening 
Committee [13] questioning the tests’ clinical utility. Implementation of screening tests 
needs to consider more than just its utility or efficacy, and should take account of the 
needs and preferences of stakeholders in order to ensure the development of appropriate 
care pathways and to facilitate informed consent. The novelty of providing a prenatal 
screening test with no associated diagnostic test or risk reduction intervention meant the 
direction of any preferences was difficult to predict. The data presented here show 
strong support from all three sample groups for the introduction of a pre-eclampsia 
screening test.  
Previous DCE’s on prenatal screening tests have shown that healthcare professionals 
value the accuracy of a screening test over other attributes, and value this attribute more 
than pregnant women [14,29]. While accuracy was a key contributor to the selection of 
screening tests here, the format of the test was also a valued attribute. Interestingly, 
preferences were shown for a biochemical test, calculated via blood tests and ultrasound 
over a test that was calculated with medical history alone. A DCE is able to determine 
the value of each attribute independently, so that this result suggests that with all other 
attributes being equal, the more invasive test was preferred over the less invasive one. 
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that people give to a screening test is likely to be associated by how ‘sensible’ that test 
is, and linked to the perceived symmetry between the seriousness of the condition and 
the seriousness of the test [30]. For example, individuals have been shown to prefer an 
invasive bowel screening over a predictive genetic blood test as this was an easier to 
apply to their common-sense picture of bowel cancer [31]. It may be that the individuals 
studied here were better able to value a screening test for a serious pregnancy condition 
that involved an ultrasound and blood test over one that involved medical history alone.  
There are several ways to present the accuracy of screening tests. Traditionally, 
sensitivity data are presented in DCEs. It has been shown that both lay people and 
healthcare professionals are challenged when interpreting accuracy figures [32-34], and 
the pilot testing revealed that respondents struggled when presented with two different 
accuracy measures presented together. It was assumed that that there would be a 
dramatic difference between the valuing of the larger sensitivity accuracy data than the 
positive predictive values. However, when considering the probabilities of choosing one 
test over another, there seemed little difference in how accuracy was presented. The 
actual differences between the sensitivity and PPV in the two tests used here were 
similar – (75% compared to 50%, a 25% difference versus 25% compared to 5%, a 20% 
difference) and a greater difference in the two accuracy measurements may have altered 
the results.  
The women who had experienced pre-eclampsia previously were mostly recruited 
through a support charity. This suggests personal knowledge of the potential serious 
repercussions of pre-eclampsia. Experiential knowledge has previously been shown to 
play an important role in women’s decisions regarding prenatal testing [35,36]. The 
women who had previously had pre-eclampsia valued accuracy more than the other two 
groups.  
Any differences seen in the relative values women and healthcare professionals place on 
test attributes are important considerations for the implementation of any screening 
programme. Healthcare professionals play key roles in evaluating health innovations 
and establishing policy [37]. The attitudes of healthcare professionals has been shown to 
impact the uptake of prenatal screening tests [38]. While there was broad support for 
pre-eclampsia screening tests here, the largest descent was within the healthcare 
professional group. This is inline with the qualitative studies presented in Chapter 5 of 
this thesis. One potential reason for these differences is that women may not have the 
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also more likely to be aware of the professional guidance suggesting that these tests 
have not yet demonstrated clinical value. Consequently, the focused value placed on 
accuracy by healthcare professionals as compared with women in this study may, at 
least in part, be due to differences in their existing knowledge and concerns about the 
implementation of pre-eclampsia screening.  
It is uncommon for DCE’s to consider psychometric measures when comparing the 
value of attributes. A pregnant woman’s anxiety score and her perception of pregnancy 
risk influenced the attributes they valued. Those with lower scores considered all 
aspects of the screening test. Those with relative-increased anxiety scores were 
influenced by the accuracy of the test, while those with an increased perception of 
pregnancy risk considered both accuracy and format of the test. This is an important 
consideration. Extra care will need to be taken when gaining informed consent of 
women who are more prone to trait anxiety or to perceiving their pregnancy to be at 
greater risk, to ensure they consider all aspects of the test they are undertaking. Trait 
anxiety differs from pregnancy anxiety, and future research may wish to use a specific 
pregnancy anxiety measure, such as the Pregnancy Related Anxieties Questionnaire 
(PRAQ-R) [39] to consider pregnancy specific anxieties.  
It was felt that providing a ‘decline either test’ option was inappropriate in this 
experiment, as it was difficult to envisage a situation where a woman would decline to 
give her medical history to their midwife. However, forcing a choice between one test 
or the other may have inflated the perceived acceptability of the screening test. Other 
limitations include the relative homogenous demographics of the sample, despite 
several steps were taken to recruit a diverse population. As with all stated preference 
studies, the choices made in the questionnaire do not necessarily reflect the choices that 
would be made if participants were faced with real-life decisions. A DCE does not 
enable an analysis of the reasons behind the choices made, and despite the inbuilt 
validity checks, it is not possible to confirm how considered responses were.  
The implementation of pre-eclampsia screening into routine prenatal care will depend 
on many factors, including test accuracy, costs, and an ability to prove a clinical utility. 
The findings here suggest all stakeholders would be accepting of such a test, even in a 
situation without an approved risk reduction intervention. However, the artificial nature 
of a DCE may not translate into a clinical setting. Also, the acceptance of biochemical 
testing shown here was based on the published results of one screening test using 
secondary data; it is unclear if this test in question would maintain its high levels of Page 230 of 316    Chapter 9: Discrete Choice Study    Chapter 9: Discrete Choice Study 
sensitivity when used prospectively. It is also remains unknown if its use would 
improve outcomes.  
CONCLUSIONS 
Based on the evidence presented here, there is overwhelming support for a first-
trimester screening test for pre-eclampsia, when compared with current methods of 
screening. Both within and between group differences were observed between pregnant 
women, women who had pre-eclampsia previously and healthcare professionals when 
comparing the values placed on the attributes of pre-eclampsia screening. Accuracy was 
a constantly valued attribute in all cases. When comparing a highly accurate 
biochemical screening test with a lower performing medical history test, all groups were 
significantly supportive of the biochemical screening test. Increased levels of anxiety 
and perception of pregnancy risk result in a greater focus on the accuracy of the 
screening test.  
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10.1   INTRODUCTION 
The principle aims of this thesis were to explore the potential psychological impact and 
acceptability of a first trimester screening test for pre-eclampsia. The thesis addressed 
five research questions, detailed within section 10.2 of this chapter, using a variety of 
methods: systematic review, two qualitative interview studies, a case control study and a 
discrete choice experiment (DCE), drawing on theory and evidence from both 
midwifery and health psychology literatures. These results were then synthesised to 
answer the following questions – ‘What are the psychological impacts of pre-eclampsia 
screening?’ (addressed in section 10.3) and ‘Is the screening test acceptable to the 
intended population?’ (addressed in section 10.4).  
This thesis discovered that women experienced greater anxiety following prenatal 
screening tests that had an impact on fetal health compared with those that had an 
impact on maternal health. However, women are more likely to change behaviours 
following a prenatal screening test that had an impact on maternal health. It discovered 
that there are potential positive (self-instigated behaviour change) and negative (reduced 
self-monitoring of fetal movements) unintended consequences to providing formal risk 
information for pre-eclampsia. Broadly, midwives were more accepting of the screening 
test than obstetricians. A birthplace preference made early in pregnancy appears to be a 
greater predictor of eventual birthplace choice than any increase in ultrasound 
monitoring. And finally, there is great support for a first-trimester screening test for pre-
eclampsia, when compared with current methods.  
The findings suggested that pre-eclampsia screening does not cause psychological 
harms, may have some benefits, and appears to be acceptable to all stakeholders.  
10.2   EMPIRICAL FINDINGS: SYNTHESIS 
10.2.1 WHAT ARE THE PSYCHOLOGICAL EFFECTS FOR PREGNANT WOMEN OF 
SCREENING TESTS FOR CONDITIONS THAT AFFECT THEIR HEALTH, COMPARED 
TO THOSE THAT AFFECT THE HEALTH OF THE FETUS? 
This question was investigated in a systematic review of the research literature that 
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screening tests. It compared these tests to those for conditions that (primarily) present a 
health threat to the mother (such as diabetes and HIV) and to those that (primarily) 
present a health threat to the fetus. Studies using emotional, behavioural and cognitive 
psychological outcomes of screening tests were included. The review concluded that 
emotional effects, including anxiety and worry, were stronger when the health threat 
focused on the fetus, but that behavioural effects, including dietary changes and safer-
sex practices, were stronger when the health threat focused on the mother. Cognitive 
affects were varied. As pre-eclampsia is a health threat to both mother and fetus, this 
review suggested that this prenatal screening test for pre-eclampsia may have a different 
psychological impact on pregnant women than screening tests previously studied. This 
was likely to be dependent on whether women were more focused on the health threat to 
themselves or to the fetus.  
10.2.2 WHAT ARE THE POTENTIAL PSYCHOLOGICAL EFFECTS AND 
ACCEPTABILITY OF A PRENATAL SCREENING TEST FOR PRE-ECLAMPSIA TO 
PREGNANT WOMEN? 
A theoretically informed semi-structured interview using qualitative methodology 
explored the potential effects of pre-eclampsia screening. None of the high-risk women 
interviewed believed they were at high-risk for pre-eclampsia. It identified two 
typologies of women. The first -  ‘danger managers’ – had an internal sense of control, 
were focused on the risk that pre-eclampsia presented to themselves, and exhibited 
information seeking, positive behaviour changes, and cognitive reappraisal coping 
mechanisms. The second typology – ‘fear managers’ – had an external sense of control, 
were focused on the risk that pre-eclampsia presented to the fetus, and exhibited 
avoidance coping mechanisms. These two typologies were congruous with both the 
psychological theory that informed the study, the common-sense model of self-
regulation (CSM), and the findings of the systematic review, as those who perceived a 
threat to themselves reported changing their behaviour. Three cross-cutting themes were 
identified: (i) medicalising the pregnancy, whereby the screening test shifted the 
perception of pregnancy from a ‘normal life event’ to ‘something to worry about’ (ii) 
embracing technology, whereby high-risk women welcomed the increased use of 
ultrasound scans, and (iii) acceptability, whereby women debated the value of providing 
a screening test without an associated risk reduction intervention. While the majority 
felt it was ‘best to know’ in advance, a minority questioned the value of providing the Page 237 of 316    Chapter 10: discussion and conclusions 
information, suggesting that it could increase anxieties without providing a clear 
benefit.  
In general, pregnant women were found to welcome the pre-eclampsia screening test, 
although being found high-risk resulted in no interventions or consequences other than 
being offered additional ultrasound tests.  The data also suggested that women with an 
increased risk of pre-eclampsia would be willing to engage in efforts to reduce that risk, 
instigating changes that would improve health more broadly.  
10.2.3 WHAT ARE THE BARRIERS AND FACILITATORS TO OFFERING A 
UNIVERSAL SCREENING TEST FOR PRE-ECLAMPIA AS PERCEIVED BY 
MIDWIVES AND OBSTETRICIANS? 
A semi-structured qualitative interview study of the beliefs and attitudes of maternity 
healthcare professionals in relation to pre-eclampsia screening found mixed opinions on 
the introduction of the screening test, with both facilitators and barriers to the 
introduction of universal first-trimester pre-eclampsia screening identified. Facilitators 
included optimism (the potential to improve outcomes) and environmental resources 
(specialist clinics increased time for low-risk women). Barriers included beliefs about 
consequences (potential increase in anxiety for screen-positive women), beliefs about 
capabilities (the accuracy of the test was questioned), characteristics of outcome 
expectancies (the screening test may ‘medicalise pregnancy’), and organisational 
culture (lack of expected consultation prior to introduction). 
The concerns related to characteristics of outcome expectancies, especially related to 
how the screening test will medicalise the pregnancy, had limited support within the 
interview transcripts, and a larger support from the wider literature referred to elsewhere 
in this thesis (see sections 1.3.2, 1.3.3, 6.2 and 10.4 for summaries). 
Broadly, midwives were more accepting of the screening test than obstetricians. The 
majority of concerns with the screening test were limited to concerns related to the 
specific screening test that had been introduced into the study hospital, rather than pre-
eclampsia screening in general. 
10.2.4 DOES INCREASED MONITORING AFFECT THE BIRTH CHOICES OF 
PREGNANT WOMEN? Page 238 of 316    Chapter 10: discussion and conclusions 
A retrospective case control study investigated the impact of increased ultrasound 
monitoring following a screen-positive result from the pre-eclampsia screening test on 
behavioural choices about place of birth. An average of 4.03 ultrasounds were 
conducted on low risk women, twice the recommended amount. The frequency of 
ultrasounds for women who had a low-technology birthplace preference was 
significantly lower than for those who had a high-technology birthplace preference, and 
women who had a constant low-technology birthrate preference had significantly less 
ultrasounds than other women. However, the frequency of ultrasound was not 
associated with later birthplace preference, after controlling for earlier birthplace 
preference. These findings, based on data from a single site, suggest that birthplace 
preference is decided early in pregnancy, or pre-conception, and that prenatal 
interventions are unlikely to influence birthplace preference.  
10.2.5 DO PREGNANT WOMEN AND HEALTHCARE PROFESSIONALS FIND A 
BIOCHEMICAL SCREENING TEST FOR PRE-ECLAMPSIA ACCEPTABLE? 
Prior to conducting the DCE, pregnant women and healthcare professionals conducted a 
ranking exercise to identify the most important test characteristics of the pre-eclampsia 
screening test. While both groups ranked the same six characteristics as most important, 
the order of importance varied. Pregnant women rank accuracy (as measured by 
sensitivity) as the most important attribute, followed by follow-up. Healthcare 
professionals rank testing procedure as the most important attribute, followed by level 
of information. 
In the DCE conducted in this thesis work, the key attributes of screening tests for pre-
eclampsia studied were accuracy of test (either sensitivity or population prevalence), 
level of information, schedule of follow-up and test format. Over 95% of the sample of 
pregnant women, women with previous pre-eclampsia and healthcare professionals 
indicated a preference for a biochemical screening test over current practice. All groups 
valued greater accuracy of the screening test and women valued a blood test over 
medical history. Those who perceived pregnancy risk to be low and had low anxiety 
considered each aspect of the test, while those who perceived higher risk and were more 
anxious focused on the accuracy of the test. These findings suggest overwhelming 
support for a biochemical screening test, although the artificial setting of a DCE should 
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10.3   THE PSYCHOLOGICAL IMPACTS OF PRE-ECLAMPSIA 
SCREENING  
The body of work within this thesis suggests that pre-eclampsia screening will cause no 
psychological harm to pregnant women, and may have some positive consequences. 
Emotional consequences appear to be minimal and short-lived. There is some evidence 
of positive behavioural changes as a result of the screening test. Women’s perception of 
risk did not correspond with the high-risk status they were given.  
The emotional consequences of the pre-eclampsia screening test appear to be minimal 
and short-lived. This finding is consistent with research considering other prenatal 
screening tests  [1-4]. A systematic review of 106 studies assessing the psychological 
aspects of genetic screening tests for pregnant women suggested that an increase in 
anxiety following a screening test may be the result of the process of giving informed 
consent rather than of a negative impact on psychological well-being [1]. This may be 
because increased arousal is required to enable individuals to consider relevant 
information when making choices. There is some evidence that the pre-eclampsia 
screening test could improve health behaviours, as some participants reported seeking to 
mitigate their risk by amending diet or reducing stress levels. Additional ultrasounds 
that may occur following a screen-positive result do not appear to change behaviours in 
relation to birthplace preferences.  
A degree of increased anxiety and worry may be appropriate responses to a health 
threat, and to the potential challenges posed by informed decision-making [5]. It should 
not, therefore, necessarily be seen as a problem that prenatal screening increases anxiety 
to some extent. The systematic review presented here suggest that pregnant women 
have increased anxiety following a high-risk result regarding their fetus’ health, but not 
if they receive a high-risk result regarding their own health. This finding was replicated 
in the qualitative study.  
There is some evidence of positive behavioural changes following the pre-eclampsia 
screening test. As health promotion is a key aim of prenatal care [6], this finding 
highlight a potential benefit in its provision. Other studies have also found that 
screening tests can lead to positive behaviour changes [7,8]. The women interviewed 
who changed their behaviours due to a positive pre-eclampsia screening test all reported 
that they were not advised to do so. Spontaneous positive behaviour changes occurred Page 240 of 316    Chapter 10: discussion and conclusions 
in the group of women who focused on the consequences that pre-eclampsia would have 
for themselves, rather than those who focused on the consequences for the fetus. The 
CSM can help to explain this. Perceiving a sense of control over an illness or health 
threat has been shown to be positively associated with specific and general problem-
focused coping behaviours [9]. This was found in a meta-analysis of 45 empirical 
studies using the CSM, incorporating illnesses such as hypertension [10], diabetes [11] 
and positive cervical smear screening tests [12].  These behaviours, that include 
activities such as changing diet, increasing exercise, and/or reducing stress, were seen in 
the women who perceived that they could control the threat of pre-eclampsia. These 
women focused on the threat that pre-eclampsia presented to themselves. A potential 
explanation for this is that women could have a high sense of control and self-efficacy 
when presented with a threat to themselves [13]. The women who focused on the threat 
that pre-eclampsia presented to their fetus, all first time mothers in early pregnancy, 
were likely to have had less experiential knowledge and self-efficacy on how to 
improve outcomes to their fetus. It may be that they therefore devolved control 
externally to their healthcare professionals. The meta-analysis mentioned above [6] 
illustrated that a lack of control is associated with the use of an avoidance coping 
mechanism, as seen in the women who perceived that they could not control the threat 
of pre-eclampsia.  
While the case-control study suggests that any increase in monitoring was not 
associated with a change of birthplace preferences, the qualitative study suggested a 
negative impact on self-monitoring behaviours for some women. Since a high-risk 
result from prenatal screening tests generally leads to increased surveillance [14] there 
is the potential for women to become ‘attached’ to the increase monitoring or 
technology used. This may have the unintended behavioural consequence of reducing 
self-monitoring of fetal movements, or increasing desire for monitoring and 
interventions in labour which, in turn, may lead to adverse events [15,16]. Any 
introduction of increased monitoring should therefore be accompanied by detailed 
counselling ensuring that women continue to self-monitor signs of deterioration, both 
for themselves (epigastric pain, headaches) and the fetus (reduction in movements).  
The women found to be at high risk for pre-eclampsia did not perceive themselves to be 
at high risk, and the women found to be at low risk were not always reassured by the 
low risk information they were given. It has been shown previously that pregnant 
women may interpret results of screening tests differently than their providers [17,18]; Page 241 of 316    Chapter 10: discussion and conclusions 
therefore, a woman’s assessment of her risk is often at odds with those of her care 
providers [19]. Women’s understanding of their screening test results are influenced by 
their common-sense representations of the health threat [20]. In the qualitative study, 
the perception of low risk by the high-risk group did not appear to have an impact on 
adherence to the recommended increased monitoring. The women in this study were 
motivated to attend the additional monitoring offered because of the high value they 
placed on ultrasound scans. It is unknown if an alternative additional monitoring 
intervention, such as increased community-based blood pressure monitoring, would 
have been adhered to. Similarly, it is unknown if women would have been willing to 
follow a prescribed risk-reduction intervention following a high-risk result.  
The pre-eclampsia screening test appears to have limited adverse psychological 
consequences, and some potential benefits in the form of positive behaviour changes. 
The identified consequences – potential reduction of self-monitoring behaviours, low 
perception of risk – could be addressed by post-test counselling. Results are tentative 
due to a lack of longitudinal studies and validated measures of constructs such as 
anxiety and worry.  
 
10.4   THE ACCEPTABILITY OF PRE-ECLAMPSIA SCREENING 
The body of work within this thesis suggests a qualified support for a pre-eclampsia 
screening test. The qualitative study found that women who underwent the screen would 
all request it in a future pregnancy, and the DCE found that when presented with a 
biochemical screening test versus the current status quo, overwhelming support was 
given for the biochemical test. However, the qualitative study of healthcare 
professionals highlighted several concerns with the screening test, although this group 
also preferred it when compared to the current status quo within the DCE. 
The research literature shows that pregnant women broadly support prenatal screening 
tests, welcoming information in a time of uncertainty, and reporting that they would 
repeat screening in subsequent pregnancies [21-24]. Similar findings were found in the 
women’s qualitative study and the DCE conducted in this thesis work.  
Prenatal screening tests are often rated highly acceptable [1], although the views and 
motivations of pregnant women and healthcare professionals are seldom sought before Page 242 of 316    Chapter 10: discussion and conclusions 
the technology is introduced [25]. The literature on prenatal screening suggests that 
acceptability of screening has an impact on uptake, [26,27] and the effect of inaccurate 
results may extend over a considerable time period [28,29].  
The results from the DCE suggested strong acceptance of a universal first trimester 
screening test for pre-eclampsia. However, the two qualitative studies suggest 
acceptance is not as clear as this. Healthcare professionals expressed more concerns 
than women, questioning the screening test’s clinical utility, accuracy, and potential to 
increase anxiety and pathologise pregnancies.  
The pre-eclampsia screening test presented within the DCE had a higher sensitivity and 
specificity [30] than that experienced by both groups within the qualitative studies [31]. 
The sub-sample of obstetricians within the qualitative study noted that it was the 
particular test that had been introduced that caused them concerns, rather than the 
concept of pre-eclampsia screening in general. These concerns centred on the perceived 
accuracy of the test. This may explain the differences between this study and the DCE. 
Many of the healthcare professionals expressed concerns regarding the accuracy of the 
test. They had seen examples of women with false-negative results and women with 
false-positive results. Concerns were raised over the methodology used to calculate the 
algorithm for predicting a woman’s risk for developing pre-eclampsia. Conversely, the 
DCE asked individuals to accept the accuracy scores at face value.  
The second concern expressed by healthcare professionals, primarily from the sub-
sample of midwives, related to ‘medicalising pregnancy’. The data presented within this 
thesis do not support the suggestion that screening for pre-eclampsia will increase 
anxieties or pathologise pregnancies, despite the concerns expressed by the healthcare 
professionals. However, maternity healthcare professionals have experience of new 
technologies being introduced that result in unintended consequences [32-34], which 
may explain their desire to consider these issues prior to large-scale introduction of such 
testing. Implementing research evidence into clinical practice is challenging, and once a 
technology is adopted, de-commissioning it is likely to prove difficult [35].  
A strand of midwifery discourse highlights concerns with the apparent acceptance of 
prenatal screening tests, in that technological advancements in maternity care may be 
‘sold’ as choices. It is unclear if these advances would be accepted and taken up if it 
were not for the respect given to medical and scientific discourse within Western society 
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and induction of labour being presented as choices without clinical indication [37-40], 
while non-medical interventions such as homebirths or delaying induction of labour are 
discouraged [36,41,42].  
10.5   METHODOLOGICAL CONSIDERATIONS   
In interpreting the findings of the studies in this thesis, their methodological limitations 
should be considered. While no adverse psychological outcomes were identified, the 
sample sizes and the limits of sampling result in difficulties in generalising this finding 
across the diverse UK population.  Due to time limitations of a PhD thesis, it was not 
possible to conduct a longitudinal study of the impact of the screening test, and so 
inferences about causality are not possible. Future research should include a method that 
combined qualitative interviews with measurements of anxiety, illness perception 
questionnaires and perceptions of pregnancy risk undertaken pre-screening, 
immediately post screening, towards the end of pregnancy and postnatally. The ideal 
study design for testing impact of an intervention is the randomised controlled trial.  
However, this raises the issue of the nature of the control group. In established services, 
it is not possible to have a ‘not offered the test’ group, as all women are offered the 
screening test, and it would be unlikely to be considered ethically acceptable to 
withhold an established service. The only possibility is to identify services where this 
test is not routinely offered, or countries where it has not been introduced and 
randomisation could be conducted at hospital level across the country. 
This thesis sought the views of pregnant women, healthcare professionals and those 
who had previously experienced pre-eclampsia; however, it did not consider the views 
or responses of partners. Paternal involvement has been shown to increase positive 
health behaviours amongst mothers [43,44] as well as improving neonatal outcomes 
[45], Paternal influence also impact women’s decisions in pregnancy, including 
birthplace choices [46,47] and screening test uptake [48].  Maternity services have been 
criticised for ignoring the views of fathers and/or partners [49], with a recent meta-
synthesis suggesting an association between excluded fathers and increased levels of 
fear and uncertainty, which may reduce their ability to support their partners effectively 
[50]. Future research into the psychological impact of prenatal screening tests should 
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Upon reflection, some of the research questions and methodological approaches chosen 
could have been amended to better address the research aims of this thesis. The 
qualitative study interviewed women at one time point immediately after receiving their 
screening test result. It is likely that richer data may have been collected if interviews 
were repeated at different time points to assess the impact of the test over time, 
including a repeat interview conducted postnatally, when the women would have had 
personal knowledge of how accurate their screening result was for them.  
In the case control study, key data were missing from the analysis as certain data are not 
routinely recorded within the electronic databases that were accessed. This included 
both the reason for the ultrasound, its outcome, and the frequency and type of other 
prenatal appointments. As the study aimed to operationalise the medicalisation of 
pregnancy through ultrasound scan frequency, the clinical reason for conducting the 
ultrasound scan would most likely have an impact. For example, an ultrasound 
conducted due to concerns with fetal growth may have greater impact on subsequent 
birthplace preference than an ultrasound conducted at maternal request to discover the 
sex of the baby. An additional limitation is that data were only collected from one site. 
Ideally a future study addressing the same research question would collect data in 
multiple sites, and about the reasons for, and outcomes of, ultrasound tests conducted. 
Future research should consider other factors that may influence birthplace preference, 
including the frequency and type of prenatal appointments, unscheduled visits with 
healthcare professionals and prenatal screening test results.  
One of the most criticised aspects of stated preference methods, such as a DCE, is that 
they compare choices in an artificial way and are hypothetical in nature and hence 
suffer from ‘hypothetical bias’ [51]. Hypothetical bias is the difference in actual 
acceptance of a choice in an ecologically valid condition compared to an artificial 
expression of acceptance within the experimental condition. It has been observed in 
many choice based experiments [52,53]. Since participants’ responses have no 
consequences for them and they are just ‘pretending’ to choose a screening test, their 
responses may lack ecological validity. Steps were taken to reduce the hypothetical bias. 
Examples of available screening tests were given and validity was tested via a certainty 
scale, where respondents were asked to rate how confident they were with the answers 
they gave. In addition, internal consistency was tested by repeating one choice set at the 
beginning and end of the experiment. If pre-determined thresholds were not met (a 
certainty score of less than 7/10 and/or a consistency score of less than 100%), those Page 245 of 316    Chapter 10: discussion and conclusions 
responses were excluded from the analysis. Only a minority of respondents were thus 
excluded. A further concern about this study method comes from the data collection 
procedure: since pre-questionnaire information was given either on paper or online, 
depending on method of data collection, it is unknown how many respondents 
considered this information. An alternative approach of face-to-face interviews may 
have increased the validity of the data collected as the interviewer could have checked 
that the information had been received and understood.  
The DCE method has been used previously to compare different prenatal screening tests 
[54-56]. The method presented within this thesis has strengths.  The attributes were 
selected via a ranking exercise, ensuring that key attributes used in making decisions 
were included. Two different assessments of test accuracy were used, when generally 
only specificity is given. Also, the inclusion of measurements of anxiety and perception 
of pregnancy risk on pregnant respondents enabled comparisons between different 
groups.  
10.6   IMPLICATIONS FOR PRACTICE AND POLICY  
The implications of this research should be considered in the light of the small corpus of 
research presented here and the limitations described above. Given this, it is not 
possible to make recommendations on the type of pre or post-test counselling for this 
test if it were to be generally introduced. However, some recommendations are 
suggested by the findings, as outlined below. 
The findings presented here suggest that first-trimester screening for pre-eclampsia 
screening does not cause any major harms, may have some benefits, and appears to be 
acceptable to all stakeholders. While further research is required to validate these 
findings, no evidence has been found that should discourage policy makers from 
recommending its introduction. Questions remain on the clinical utility and economic 
benefits of the screening test. 
Chapter one of this thesis highlighted a large disparity in how ‘acceptability’ of 
screening tests is assessed. This reinforces the view that it is desirable to have a 
minimum quality standard of assessment of acceptability and consequences prior to a 
new obstetric technology being introduced clinically. A cost-effective approach would 
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tests, to enable policy makers to consider both clinical utility and wider impact prior to 
recommending wide-scale introduction. Many of the concerns expressed by the 
healthcare professionals within the qualitative study stemmed from a frustration in the 
way the screening test was introduced, with individuals considering that it was done 
without due care to clinical utility or repercussions. If the work presented here had been 
done prior to its introduction, the policy makers could have used the data gathered to 
address these concerns, or taken steps to reduce any barriers identified.  
Two studies within this thesis illustrated that pregnant women reacted differently to 
screening information depending on whether they were concerned by a threat to 
themselves or to the fetus. If replicated, this finding forms the basis of evaluating an 
approach that tailors information on this variable with the aim of minimising 
psychological distress and promoting adaptive behaviour. For example, there may be 
potential to use this information to motivate women to manage their weight, in order to 
reduce the impact of obesity in pregnancy. The data presented here imply that for 
successful behaviour change to occur to reduce weight, healthcare professionals should 
focus on the risks of obesity to the mother (increased risks of haemorrhage and 
hypertensive disorders), rather than any risks to the fetus (increased risk of anomalies 
and admissions to special care). However, this hypothesis requires more research before 
conclusions can be made. Drawing on theories of behaviour change [57-59] will aid the 
testing of this hypothesis, and the design of any interventions.  
To the author’s knowledge, the case-control study is the first that tests the assumption 
that ultrasound frequency impacts on birthplace preference. There is an assumption 
within midwifery discourse [40,60-64] that increased use of technology ‘medicalises’ 
and ‘pathologises’ pregnancy, and contributes to a decrease in women’s faith in their 
ability to labour without the use of technological and medical support [65,66].  This has 
been seen as contributing to a decrease in homebirth rates [67], and an increase in 
assisted and operative deliveries [68]. The healthcare professional qualitative study 
suggested that some midwives had similar concerns related to the pre-eclampsia 
screening test. However, the case-control study does not support this argument.  
It may be that an increased use of obstetric technology, including ultrasound scans, has 
contributed to a medicalisation of pregnancy. Their use could have led to a cultural shift 
in the perceptions of childbirth as a higher-risk event, and that this shift results in a 
desire for more interventions prior to, or at the onset of, pregnancy. However, their use 
is now an accepted and welcomed part of maternity care. The finding that the preference Page 247 of 316    Chapter 10: discussion and conclusions 
expressed at the first contact with maternity services had the greatest influence on 
birthplace preference suggests that factors prior to pregnancy impact birthplace 
preference. Any interventions to increase uptake of low-technology birthplaces may 
require a pre-conception intervention. 
Following this screening test, women found ‘screen-positive’, that is a risk of 1:100 or 
more, were categorised as ‘high-risk’, with all other women categorised as ‘low-risk’. 
This highlights a problem within health screening, and obstetric care particularly due to 
the dichotomy of ‘high’ and ‘low’ risk allocations. This dichotomy has been noted as 
false [70, 71] as risk is a continuous variable rather than a categorical one. Two women, 
one with a risk factor of 1:101, another with a risk of 1:100, have a nominal difference 
in risk of acquiring pre-eclampsia, yet using this model their care would be substantially 
different. 
10.7   IMPLICATIONS FOR FUTURE RESEARCH 
10.7.1 – REPLICATION AND CONFIRMATION STUDIES  
As the data in this thesis are hypothesis-generating rather than replicating already 
established evidence, the key findings within this thesis require confirmatory 
investigation. Future considerations of the impact of this screening test should use a 
longitudinal design, using both qualitative interviews and psychometric assessments at 
various time points to assess the impact of the screening test over the pregnancy period.  
The data suggesting that women are willing to undertake positive behaviour changes 
following a high-risk result for pre-eclampsia also warrants further investigation. If the 
findings are confirmed, this could make the argument for greater investment in 
behavioural research in this area. Much greater investment is currently committed to 
potential pharmacological risk-reductions for pre-eclampsia, especially aspirin [69]. 
Despite a greater number of studies investigating its effectiveness, there appears little 
advantage to aspirin compared to other interventions, including dietary and lifestyle 
interventions (see Chapter 2, section 2.3). If effective, and women are willing to 
undertake them, these interventions may not only reduce the incidence of pre-eclampsia 
[71,72], but improve maternal and neonatal outcomes more generally. As the research 
here suggests some women would be willing to engage in behavioural changes to Page 248 of 316    Chapter 10: discussion and conclusions 
reduce their risk for pre-eclampsia, a priority for research into behavioural interventions 
to reduce pre-eclampsia and other pregnancy risks is warranted.  
The data suggesting that increased monitoring during pregnancy does not impact on 
birthplace preferences also warrants further investigation. A multi-site, prospective 
design, capturing information such as the indication for the ultrasound would help to 
confirm or refute these initial findings. As there is now extensive data showing the 
benefits of low-technology birthplace preferences [32],  researchers now need to move 
towards developing an intervention to increase their uptake. It is important to ascertain 
if routine monitoring without clinical need influences these choices. 
The DCE compared the current status quo with the current best performing screening 
test for pre-eclampsia. While it demonstrated overwhelming support for the screening 
test, it suggested that there was no difference in treatment following a high-risk result 
other than increased monitoring. Further studies are required to inform offering possible 
interventions (such as receiving low-dose aspirin) to those found screen-positive. 
10.7.2 - EXTRAPOLATING RESULTS TO OTHER SCREENING TESTS 
The pre-eclampsia screening test is one of several ‘screen-to-observe’ maternity 
screening tests, including those that focus on a health threat to the fetus, such as one for 
pre-term birth (predicting risk of birth prior to 37 weeks gestation), macrosomia 
(predicting pregnancies that will result in a large for gestational aged baby), and fetal 
growth restriction (predicting pregnancies that will result in small, or poorly developed, 
babies), alongside screening tests that focus on a health threat to the mother, including 
ones for gestational diabetes, and post-partum haemorrhage (predicting pregnancies at 
risk of bleeding immediately after birth).  Future research should investigate the extent 
to which the findings presented here extend to these other similar tests, which remain 
little studied. Studying the impact of these other screening tests will facilitate 
exploration of whether or not behaviour change is more likely when a screening test 
focuses on maternal health threats.   
10.7.3 – THE CLINICAL UTILITY OF PRE-ECLAMPSIA SCREENING  
The lack of randomised control trial evidence about the usefulness of the screening test 
limits the ability of pregnant women to make an informed decision on whether or not to Page 249 of 316    Chapter 10: discussion and conclusions 
undertake it. While the research presented here suggests that the information of the 
screening test is useful for women, this may change if it is shown to not reduce the risks 
of pre-eclampsia or of unnecessary interventions, such as inductions of labour without 
improved outcomes.  Future research assessing the clinical utility of the screening test 
should compare various methods of monitoring following a high risk result, including a 
comparison of ultrasounds (which would have to be conducted within a hospital) and 
increased blood pressure monitoring (which could be conducted by the woman herself, 
or at local health centres). This would ensure minimal costs for maximum benefits to 
women and their families. 
There is a debate regarding the relative merits of prevention versus screening 
interventions in healthcare [74, 75]. Indeed, a health economics analysis undertaken as 
part of a HTA investigation into screening tests and potential treatments for pre-
eclampsia [76] discussed in chapter two of this thesis, suggested that prescribing all 
pregnant women with low-dose aspirin would have greater cost savings and health 
benefits than introduction of a screening programme. This may also apply to a healthy 
diet and/or exercise intervention, targeted at all women prior to conception or in early 
pregnancy, that would have a wider beneficial impact on health of mother and fetus than 
just reducing risk for pre-eclampsia. 
Such evidence could inform the development of decision aids or pre-test counselling for 
women to support informed decision-making prior to undertaking the screening test. 
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10.8   CONCLUSIONS  
For the majority of women, there is no evidence that this new prenatal screening test for 
pre-eclampsia will cause psychological harm. However, for a limited number of women 
there is some evidence that it could cause an increase in anxiety and stress. The majority 
of women appear to welcome the additional information it provides. It appears that 
reactions to prenatal screening tests are linked to illness representations of the health 
threat, with a perceived threat to the self resulting in a stronger sense of control, while a 
perceived threat to the fetus results in a greater dependence on health care providers. 
This hypothesis warrants further investigation as it could have an impact on how both 
screening and health promotion information are presented. Receiving a positive pre-
eclampsia screening result presents potential opportunities for health-promotion 
interventions. To make the most of these opportunities, it will be important for 
clinicians to understand how women perceive and respond to this screening test; the 
self-regulation model provides a useful framework in which to do this. This work 
provides a framework for assessing the psychological impacts of emerging prenatal 
screening tests that lack a diagnostic test or risk-reduction intervention. 
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Yes 
  (c) If relevant, consider translating estimates of relative risk 
into absolute risk for a meaningful time period 
N/A 
Other analyses  Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses 
Yes 
Discussion  Key results  Summarise key results with reference to study objectives  Yes 
Limitations  Discuss limitations of the study, taking into account sources 
of potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias 
No 
Interpretation  Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence 
Yes 
Generalisability  Discuss the generalisability (external validity) of the study 
results 
No 
Other 
information 
Funding  Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on 
which the present article is based 
Yes 
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APPENDIX 5 – SYSTEMATIC REVIEW PROTOCOL  
 
Assessing the impact of a first-trimester screening program for pre-eclampsia on 
women’s emotions, cognitions and health behaviors during pregnancy  
Systematic Review – Review Protocol 
Background 
Pre-eclampsia (PE) is the most prevalent of serious complications in pregnancy. It affects 
approximately 2% of pregnancies and causing over 50,000 deaths annually
1. The world 
health organisation acknowledges that a prediction of its onset will enable closer 
monitoring of those at risk
2, as well as identifying a cohort to enable exploratory study into 
the prevention and treatment of the disease. Poon et al
3 devised a new technology screening 
method predicting PE with a 5% false-positive rate, and this methodology has been 
launched within two London maternity units. Women booking for antenatal care at these 
units are offered screening during their 12 week ultrasound scan for a number of 
conditions, including PE. Those with a positive PE screen will be referred to a hypertension 
clinic to receive an increased level of monitoring, while those with a negative screen will be 
given low-risk prenatal care based on NICE guidelines.  
Currently there is no treatment for PE, anti-hypertensive can be used when blood pressure 
increases, but when a woman becomes very ill with the condition the only treatment option 
is delivery of the baby. The PE screen is distinctive in first-trimester prenatal screening 
because PE has the potential to harm both the mother and the fetus, as compared to 
conditions such as downs syndrome, which impacts the fetus only. Also, as there is no 
diagnostic test available, users of the screen need to carry the possibility of harm with them 
throughout the rest of their pregnancy.  
Giving women this knowledge may increase anxiety, or conversely, may empower her. 
Rich
4 argued that although knowing a risk for PE may cause anxiety, this is preferable to 
not knowing, and then being faced with an emergency clinical situation that they do not 
understand and that they have no control over.  
As the technology is new, it is currently unclear which theories (e.g. of risk, health 
behaviors, decision-making etc) are most useful for providing a framework for addressing 
these research questions.  
A preliminary review of the literature (including Cochrane database, DARE and the Health 
Technology Assessment Program and NICE) has identified no previous systematic review 
on this research topic, although there were relevant reviews on the psychological impact of 
screening for abnormalities in the fetus only
5,6, in the use of ultrasound technology as a 
screening tool 
7,
8 on the accuracy of antental screening for PE
9 and on screening in 
general
10,
11.  These reviews identified research themes, that formed the basis for developing 
the research questions of the current systematic review. 
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To investigate the emotional, cognitive and behavioural impact of prenatal screening for 
pre-eclampsia, a condition that (a) has health implications for the mother as well as the 
fetus and (b) is not treatable. 
Research Question: 
How does the impact of prenatal screening for pre-eclampsia differ from (a) prenatal 
screening that does not have health implications for the mother (e.g. Down syndrome and 
spina bifida) and (b) prenatal screening that has health implications for the mother and is 
treatable (e.g. HIV, diabetes)  
A PICOS breakdown of this question can be found in Appendix A and within the inclusion 
criteria. While synthesising the identified papers, it is expected that an appropriate 
theoretical frameworks to encapsulate this new study will be identified.  
Methodology 
 
Search Strategy 
 
Data will be sort using five different sources, listed below:  
 
Electronic Databases 
Eight databases will be used in total; seven following the method of the NICE guideline for 
antenatal care
12 which identifies the following databases:  
  PsychInfo. 
  MEDLINE (Ovid version for the period January 1966),  
  EMBASE (Ovid version from January 1980),  
  CINAHL (Cumulative Index to Nursing and Allied Health Literature),  
  The Cochrane Database of Systematic Reviews, up to Issue 3, 2003,  
  the British Nursing Index (BNI)  
  MIDIRS (Midwives Information and Resource Service). 
In addition the reviewers will search the ‘web of science’ database.  
 
Citation and Reference Tracking 
Once a study has been included into the review two further actions will be taken. Its 
bibliography will be reviewed for further relevant articles. Additionally a citation search 
will be performed to review any articles referencing it.  
 
Grey Literature 
Identification of ‘grey literature’ (conferences, abstracts, theses and unpublished trials) will 
be done by using specialist databases and by seeking advice from information scientists. 
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Hand Strategy  
On conclusion of the review the three journals that published the highest number of 
included studies will be identified, and their contents pages hand searched for any more 
relevant papers.  
 
Consultation with Experts 
The authors of the included studies will be approached and asked to identify any further 
articles that have not been captured.  
 
Inclusion and Exclusion Criterion  
Inclusion criteria: 
Based on the PICOS process, as detailed in 
13, and expanded within Appendix 1. 
 
Population: Pregnant women in early or late pregnancy undergoing prenatal screening 
Interventions: Prenatal screening with maternal health implications and/or for conditions 
with no current treatment options 
Comparator: Prenatal screening without maternal health implications or for treatable 
conditions 
Outcomes: Health-related behaviours (e.g. attendance to appointments), emotions (e.g. 
anxiety), cognitions (e.g. choices regarding place of birth), attachment to the 
pregnancy/fetus. 
Study Design: experimental, quasi-experimental, case-control, observational, systematic 
reviews, cohort, case studies and qualitative. As the screening technology is new, current 
forms of publication such as conference abstracts and dissertations will be included, as will 
published and unpublished journal articles and book chapters that meet the inclusion 
criteria. 
Exclusion criteria: 
As there is no funding available for translation, non-English articles will be noted but 
excluded.  
The first noted case of prenatal screening was in 1966
14. A margin of error is needed to 
ensure a search captures all relevant studies
15, therefore date limits will be set as a range of 
1965 to present.  
Opinion pieces and commentary will be excluded.  
 
Search Terms 
The reviewers will identify key words and pertinent MeSH (medical subject headings) and 
other subject headings using a variety of sources. These include examining the search 
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studies reported within them. Use of the in-built thesaurus for electronic databases and 
consultation with an Information Scientist will further refine the strategy, as will previously 
validated search filters appropriate to the area of study used by organizations such as The 
National Institute of Clinical Excellence (NICE) the Cochrane Database, HTA and DARE. 
(Shown in Appendix 2).  
The final search strategy will be performed using generic and specially developed filters, 
relevant terms and free-text terms. Boolean logic terms will also be applied to aid the 
process, and scoping searches will enable further refinement of the strategy. The final 
search strategy, including the particular truncations for the first five database interfaces, is 
detailed in Appendix 3. 
 
Quality assurance of search strategies 
To assess the validity of the search strategy ensure the accuracy of the search strategy three 
key studies identified prior to the search (
16,
17,
18) from expert consultation. These will be 
used to assess whether the strategy is sufficiently comprehensive. If they have not been 
identified, reasons for this will be ascertained and the strategy refined.  
 
Study Selection 
All studies identified will be entered into a bibliographic database (EndNote X3, 2009) and 
automatic software run to remove all duplicate entries. These will be examined for 
inclusion on three levels – Title, Abstract and Full-Text.  
The full text of selected papers will be read and included if the authors present new data on 
the psychological impact of a screening test, rather than, for example, a commentary 
following a study on the efficacy of the test. 
Guidelines for title, abstract and full text selection will be developed and piloted by 
independent coding. 10% of the titles, abstracts and full texts papers will be independently 
coded. If inter-rater agreement falls below 90%, the guidelines will be refined until 
acceptable reliability is achieved. Any disagreements will be discussed, and a consensus 
agreed. If consensus cannot be reached, a third researcher (SM) will be consulted. All 
disagreements will be recorded. A Kappa statistic will be calculated to measure agreement.  
 
Data Extraction 
A data extraction form has been designed to capture all the necessary information when 
reviewing the studies (Appendix 4). The data extraction form will be honed following 
piloting, with consultation from expert researchers.  
Quality Assessment of Included Studies 
The overall strength and quality of the body of evidence identified will be assessed by the 
use of the NICE methodology checklists, which can be viewed here:  
http://www.nice.org.uk/aboutnice/howwework/developingniceclinicalguidelines/clinicalgui
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The appropriate scale will be selected depending on the methodological approach used.  
An independent researcher will assess the quality of 25% of selected papers. Quality scores 
will be compared with the original and a comparison made. Any disagreements will be 
discussed, and a consensus agreed. If the two researchers achieve less than 90% consensus 
then all studies will be compared and a consensus agreed on all. If a consensus can not be 
achieved a third-party expert will be asked to make the final decision. Any conflicts will be 
discussed in the reviews final write up. 
 
Data Synthesis 
It is anticipated that the subject of this review will capture diverse studies, varying in 
methodologies and approaches, many of which will be qualitative in nature. Therefore a 
narrative synthesis approach will be conducted, as recommended by CRD’s Systematic 
Reviews - CRD’s guidance for undertaking reviews in health care
19 (Appendix 5). The 
narrative synthesis framework requires the use of appropriate tools for each of the different 
elements. The appropriate ones will be selected based on the type of evidence captured in 
this review. If data are captured that can be subjected to meta-analysis this will be done in 
consultation with a statistician.  
 
Dissemination 
The review will be submitted to a relevant peer-reviewed journal for publication and 
presented at academic conferences in the appropriate fields. Target audiences are 
obstetricians, fetal medicine experts, midwives, health psychologists, sociologists and 
genetic councillors. Page 267 of 316    Appendix 5 
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Appendix A: PICOS analysis of research question  
 
  A PICOS (Population, Interventions, Comparators, Outcomes, Study design) 
breakdown enables a reviewer to consider the components of a question
13. It facilitates a 
systematic analysis of the research question to ensure a focused approach to a review.   
 
How does the impact of prenatal screening for pre-eclampsia differ from prenatal screening 
that (a) does not have health implications for the mother (b) has health implications for the 
mother and is treatable? 
 
Populations -   
Pregnant women in early pregnancy undergoing screening 
Pregnant women in late pregnancy who experienced prenatal screening 
Postnatal exploration of the screening process 
 
Interventions/Treatments –  
Prenatal screening with maternal health implications;  
Prenatal screening for conditions with no current treatment options 
 
Comparator –  
Prenatal screening without maternal health implications;  
Screening for treatable conditions 
 
Outcomes –  
Health-related behaviours (improved diet, attendance to appointments, compliance to 
medical plans, decrease in alcohol, increase in exercise) 
Emotions (anxiety, depression, attachment) 
Cognitions (planned place of birth, analgesia intentions, breastfeeding intentions)   
 
Study Design –  
All experimental designs, including, but not restricted to, randomised control trials, 
observational studies, systematic reviews, patient issues studies, cohort studies, qualitative 
studies and case-control studies.     Page 270 of 316          Appendix 6 
APPENDIX 6 – SYSTEMATIC REVIEW SEARCH STRATEGY 
Population (15 terms) 
A
N
D
 
Intervention (11 terms) 
A
N
D
 
Outcome (36 terms) 
A
N
D
 
Comparator 
Antenatal* OR childbearing OR (early 
pregnancy) OR Gestation* OR Gravid* OR 
maternal-fe#tal OR parity OR parturition OR 
Pregnan* OR (pregnancy outcome) OR 
(pregnancy, high risk) OR (Pregnant Wom 
#n) OR Prenatal OR (wom #n of 
childbearing age) OR (pregnancy in 
adoles#ence) OR Perinatal OR Maternal OR 
labo#r 
 
 
 
 
 
 
 
 
(Restrict to title search) 
Screen* OR Test* OR (Mass 
screening) OR (High risk) 
OR (Large risk) OR 
(Increased risk) OR 
(Anonymous testing) OR 
(Neonatal screening) OR 
(Low* risk) OR (Decreased 
risk) OR (Small* risk) 
 
(access to information) OR afraid OR 
anger OR anxieties OR anxiety OR 
anxious OR attachment OR attitude* 
OR (behaviour change) OR 
bereavement OR cognitive OR cope 
OR coping OR compassion* OR 
concern* OR disappoint* OR distress 
OR discourse OR despair OR euphoria 
OR emotion* OR euphoric OR 
experience* OR empath* OR frustrat* 
OR fear* OR feeling* OR guilt* OR 
grief OR grieving OR hate OR hatred 
OR hostil* OR happi* OR happy OR 
honest* OR hope OR hoping OR issue* 
OR joy*  OR jealous* OR laugh* OR 
love OR loving OR lone* OR mourn* 
OR mood OR narrative OR nervous 
OR opinion* OR perceived OR 
perspective* OR perception* OR 
psycho* OR (psycho* adaptation) OR 
(psycho* adjustment) OR (right to 
choose) OR sadness OR (social 
perception) OR (social adjustment) OR 
stories OR (social values) OR story OR 
stress* OR satisfaction OR view OR 
worries OR worry OR worried 
 
Doesn’t have health 
implications for 
Mother 
(56 Terms) 
(Genetic test) OR (Genetic screen) OR (Congenital 
test) OR (Congenital screen) OR (Downs syndrome) 
OR (down syndrome) OR (Spina bifida) OR 
(Edward* syndrome) OR (syndrome) OR Trisomy 
OR (Trisomy 21) OR (Trisomy 18) OR (Trisomy 13) 
OR (Chromosomal disorder) OR (Mass Screening) 
OR (Nuchal Translucency Measurement) OR (Soft 
Marker) OR (Echogenic Bowel) OR (Echogenic 
Foci) OR (Short Femur) Or (Femur Length) OR 
(Dilated Renal Pelvis) OR (Renal Pelviectasis) OR 
(Choroid Plexus Cyst) OR (Nasal Bone) OR (Double 
Test) OR (Triple Test) OR (Quadruple Test) OR 
(Double Screen) OR (Triple Screen) OR (Quadruple 
Screen) OR (Combined Test) OR (Integrated Test) 
OR (Combined Screen) OR (Integrated Screen) OR 
(First Trimester Test) OR (Second Trimester Test) OR 
(First Trimester Screen) OR (Second Trimester 
Screen) OR (Chorionic Villi sampling) OR 
Amniocentesis OR amnio or CVS or (Pregnancy-
Associated Plasma Protein-A) OR (Alpha 
Fetoprotein) OR (Maternal Age) OR Ultrasound OR 
Ultrasonography OR (Fetal growth) OR IUGR OR 
(intrauterine growth restriction) OR (Termination of 
pregnancy) OR (High Risk) OR (Low Risk) 
 
OR 
Has health 
implications for the 
mother 
(18 Terms) 
(Diabetes mellitus) OR (Diabetes insipidus) OR 
Diabetes OR (Gestational diabetes) OR HIV OR 
(HIV in pregnancy) OR (Antenatal HIV screening) 
OR (Prenatal HIV screening) OR 
Heomoglobinopathy OR (sickle cell disease) OR  
(sickle cell trait) OR (Thalassemia trait) OR 
(Thalassemia disease) OR (Mass Screening) OR 
Anaemia OR Low iron OR (Iron supplements) OR 
Syphilis 
 
OR 
Relates specifically 
to pre-eclampsia 
(8 Terms) 
pre-eclampsia OR preeclampsia OR (pregnancy 
induced hypertension) OR pih OR pe OR Eclampsia 
OR Proteinurea OR Blood pressure 
Limit to Human and Female and English Language  
Not schizophrenia or alcohol$ or child$ or bipolar or efficacy in title Page 271 of 316    Appendix 7 
APPENDIX 7 – DATA EXTRACTION FORM 
Ref Number: 
 
 
 
Rev Date:    Reviewer:   
Title: 
 
 
 
 
Authors:   
Journal: 
 
 
 
 
Type of 
Publication:   
Published 
Date: 
 
 
 
 
Country of 
Origin 
 
  Source of 
Funding   
Inclusion 
and 
exclusion 
criteria 
 
 
 
 
Condition 
being 
screened for: 
 
 
 
 
Participant numbers and characteristics: 
Main 
hypothesis 
or research 
question: 
 
 
 
 
 
Total   
 
Group A 
 
 
 
 
Main Impact  Maternal  Fetal  Both 
Group B   
 
 
Group C   
 
 
Population: 
P
r
e
 
p
r
e
g
n
a
n
c
y
 
1
s
t
 
T
r
i
m
e
s
t
e
r
 
2
n
d
 
T
r
i
m
e
s
t
e
r
 
P
o
s
t
n
a
t
a
l
  Age 
 
 
 
Ethnicity 
 
 
 
Theory 
 
 
 
 
How 
Used? 
 
 
 
Psych  
impact Areas  Behaviours  Cognitions  Emotions 
 
 
Random 
Allocation 
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M
e
t
h
o
d
o
l
o
g
y
 
Case control Study   
Cohort Study   
Experimental   
Focus Groups   
Observations   
RCT   
Systematic Review   
Main 
outcome 
measure 
 
 
 
 
 
How 
measured? 
 
Method of 
analysis/ 
statistical 
technique 
 
 
 
 
 
 
R
e
s
u
l
t
s
 
a
n
d
 
C
o
n
c
l
u
s
i
o
n
s
 
 
 
 
 
 
 
 
 
 
Discusses 
clinical 
significance? 
 
 
 
 
Other 
Comments 
 
 
 
 
 
  Quality Assessment 
  Yes  No 
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APPENDIX 8 – REASONS FOR EXCLUSION 
Inclusion and Exclusion Key 
 
Included – Emotions  Included – Cognitions 
 
Excluded 
E1
   
Anxiety  C1  Desire to repeat screening  X1  Knowledge 
 
E2  Depression  C2  Maternal Responsibility  X2  Invasive testing 
E3  Worry  C3  Changed view of own health  X3  Diagnosis, not screening 
  Other  C4  Attachment to fetus  X4  Knowledge or Consent issues 
Included – Behaviours  C5  Changed view of fetus  X5  Acceptability and Uptake 
B1  Diet  C6  Risk Perceptions  X6  Confidentiality 
B2  Sexual Health  C7  Other  X7  Included in Green (2004) SR 
B3  Smoking      X8  Included in Garcia (2000) SR 
B4  Other      X9  Included in Baillie (1999) SR 
        X10  Other (specify) 
 
 
No.  Author  Title  Journal  Impact   Screen  Inc or 
Exc 
Code 
3  Abuelo DN, Hopmann 
MR, Barsel-Bowers G, 
Goldstein A 
Anxiety in women with low maternal serum alpha-fetoprotein 
screening results 
Prenatal Diagnosis 1991; 11: 
381-385 
F  DSS  X7 
4  Adams C, Parsons M   Prenatal testing  Birthings 1998; 12-17  F  DSS  X10 - 
CONF 
6  Al RA, Yalvac S, Altar 
OY, Dolen I 
 Perceived pain and anxiety before and after amniocentesis among 
pregnant Turkish women 
Clinical & Experimental 
Obstetrics & Gynecology 2009; 
36: 184-186 
F  INVASIV
E 
X2 
7  Api O, Demir HN, Api 
M et al 
 Anxiety scores before and after genetic sonogram  Archives of Gynecology & 
Obstetrics 2009; 280: 553-558 
F  USS  E1 
8  Baillie C, Hewison J, 
Mason G 
 Should ultrasound scanning in pregnancy be routine?   In Journal of Reproductive and 
Infant Psychology, Edition 
1999; 149-157 
F  USS  E1/2/3; 
B3; 
C1/2/3/4 
9  Ball J, Van Riper M, 
Engstrom J 
 Incidental finding of ultrasound markers for Down syndrome in 
the second trimester of pregnancy: a case study 
 J Midwifery & Women's 
Health 2005; 50: 243-245 
F  USS  X2 
10  Bartha JL, Martinez-
del-Fresno P, Romero-
Carmona R et al 
Maternal anxiety and fetal behavior at 15 weeks' gestation   Ultrasound in Obstetrics & 
Gynecology 2003; 22: 57-62 
F  AMNIO  X2 
12  Bekker HL, Hewison J, 
Thornton JG 
 Applying decision analysis to facilitate informed decision making 
about prenatal diagnosis for Down syndrome: a randomised 
controlled trial 
 Prenatal Diagnosis 2004; 24: 
265-275 
F  DSS  X5 
13  Bennett MJ, Gau GS, 
Gau DW 
 Women's attitudes to screening for neural tube defects   British Journal of Obstetrics & 
Gynaecology 1980; 87: 370-
371 
F  NTD  X5 
15  Berne-Fromell K, 
Kjessler B 
 Anxiety concerning fetal malformations in pregnant women 
exposed or not exposed to an antenatal serum alpha-fetoprotein 
screening program 
 Gynecologic & Obstetric 
Investigation 1984; 17: 36-39 
F  DSS  E1 
17  Boukydis CFZ, 
Treadwell MC, 
Delaney-Black V et al 
 Women's responses to ultrasound examinations during routine 
screens in an obstetric clinic 
 Journal of Ultrasound in 
Medicine 2006; 25: 721-728 
F  USS  E1/E2/ 
C4/C1 
18  Brajenovic-Milic B, 
Babic I, Ristic S et al 
 Pregnant women's attitudes toward amniocentesis before 
receiving Down syndrome screening results 
Womens Health Issues 2008; 
18: 79-84 
F  INVASIV
E 
X2 
19  Bricker L, Garcia J, 
Henderson J, et al 
 Ultrasound screening in pregnancy: a systematic review of the 
clinical effectiveness, cost-effectiveness and women's views 
Summary 
British Journal of Clinical 
Governance 2001; 6: 51-54 
F  USS  E B C 
20  Brisch KH, Munz D, 
Bemmerer-Mayer K, et 
al 
 Ultrasound scanning for diagnosis of foetal abnormality and 
maternal anxieties in a longitudinal perspective 
 Journal of Reproductive and 
Infant Psychology 2002; 20: 
223-235 
F  USS  E1 
21  Brisch KH, Munz D, 
Kachele H et al 
 Effects of Previous Pregnancy Loss on Level of Maternal Anxiety 
after Prenatal Ultrasound Screening for Fetal Malformation 
 Journal of Loss and Trauma 
2005; 10: 131-153 
F  USS  E1 
23  Burke BM, Kolker A   Clients undergoing chorionic villus sampling versus 
amniocentesis: contrasting attitudes toward pregnancy 
 Health Care for Women 
International 1993; 14: 193-200 
F  INVASIV
E 
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No.  Author  Title  Journal  Impact   Screen  Inc or 
Exc 
Code 
25  Burton B, Dillard R, 
Clark E 
 Maternal serum alpha-fetoprotein screening: the effect of 
participation on anxiety and attitude toward pregnancy in women 
with normal results 
 American Journal of Obstetrics 
& Gynecology 1985; 152: 540-
543 
F  DSS  E1/E2 
24  Burton B, Dillard R, 
Clark E 
 The psychological impact of false positive elevations of maternal 
serum alpha-fetoprotein 
 American Journal of Obstetrics 
& Gynecology 1985; 151: 77-
82 
F  DSS  E1/E2 
26  Carolan M, Hodnett E   Discovery of soft markers on fetal ultrasound: maternal 
implications 
 Midwifery 2009; 25: 654-664  F  USS  E1 
28  Cash R, Manogaran M, 
Sroka H, Okun N 
 An assessment of women's knowledge of and views on the 
reporting of ultrasound soft markers during the routine anatomy 
ultrasound examination 
 Journal of Obstetrics & 
Gynaecology Canada: JOGC 
2010; 32: 120-125 
F  USS  X5 
29  Caughey AB, 
Washington AE, 
Kuppermann M 
 Perceived risk of prenatal diagnostic procedure-related 
miscarriage and Down syndrome among pregnant women 
 American Journal of Obstetrics 
& Gynecology 2008; 198: 333 
e331-338 
F  DSS  C6 
30  Cederholm M, Sjoden 
PO, Axelsson O 
 Psychological distress before and after prenatal invasive 
karyotyping 
 Acta Obstetricia et 
Gynecologica Scandinavica 
2001; 80: 539-545 
F  INVASIV
E 
X2 
2  Cederholm, M  Women's knowledge, concerns and psychological reactions before 
undergoing an invasive procedure for prenatal karyotyping 
Ultrasound in Obstetrics & 
Gynecology 1999; 14: 267-272 
F  INVASIV
E 
X2 
31  Chan LW, Chan OK, 
Chau MCM et al 
 Expectation and knowledge of pregnant women undergoing first 
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CONFIDENTIALITY AGREEMENT 
 
Security & Privacy 
  
Data Protection  Any information which you volunteer will be treated with 
the highest standard of security and confidentiality, strictly in accordance with 
the Data Protection Acts, 1988 and 2003. 
  
Confidentiality 
The nature of the work performed and any information transmitted to UK 
Transcription by the Client shall be confidential. We shall not without the prior 
consent of client, divulge or otherwise disclose such information to any person 
other than authorised employees or authorised subcontractors of UK 
Transcription whose job performance requires such acts. 
  
Website Security 
This website is 128 bit SSL secured, and all file transfers are encrypted. All files 
are permanently destroyed after 10 days. Transcripts are securely stored 
online for 60 days. Only authorised key staff have access to the server. This 
website is also subject to a quarterly security audit by an external security 
firm. 
  
Office Location 
The UK Transcription office is located in central Brighton, just a couple of 
minutes from Brighton Railway Station. . The office is housed in a self-
contained, fully registered, comprehensively insured commercial property, 
secured with panic buttons and an industrial grade alarm system.  
  
Transcript Delivery 
Various security controls can be applied on request, such as password 
protection, encryption and secure downloads. However, we find that most 
clients prefer receiving transcripts via unencrypted email attachment, and as 
such this is the default delivery method. Additional security is supplied at no 
extra cost on request. 
  
Non-Disclosure 
All staff and typists are subject to a legally binding NDA. 
Email support@uktranscription.com for info or a draft copy of our standard 
confidentiality agreement. We are happy to sign an agreement of your own 
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APPENDIX 13 - STAGES OF THE FRAMEWORK PROCESS 
This appendix illustrates stages two (coding), three (charting) and four (indexing) of 
the framework process. For the purposes of brevity, only one example is given., that 
of HR1 
(I) CODING 
Following the familiarisation process the transcripts were coded using NVIVO. The 
coding process in NVIVO involves selecting the relevant text, and allocating it to the 
correct code. Two  independent researchers developed the coding matrix together, 
then independently coded each transcript. NVIVO colour codes the transcripts to 
facilitate visualisation of codes. A section of transcript can be attributed to more than 
one code. Figure 1 shows an excerpt from HR7’s transcript, with an examples of some 
codes: Consequences (green highlights), Information seeking (red highlights), coping 
strategies (yellow highlights), Perception of risk (blue highlights) and behaviour 
changes (purple highlights).  
(II) SUMMATION 
Following the coding process, a matrix was developed. The columns for the matrix 
were the codes from the coding matrix, and the rows were the individual participants. 
NVIVO, which is optimised for the Framework approach, automatically populates the 
matrix with allocated codes. A section of the example from above is given in Table 1 
and Table 2, with Table 1 showing the quotes and Table 2 the summaries. 
(III) CHARTING 
Following the indexing process, a second matrix was formed which consisted of 
headings and subheadings. At this stage the titles of the coding framework were 
amended. The matrix was then summarised, to include a statement about each code, 
and quotations were pulled from the first matrices to support the statement. Data 
related to participants were entered along the rows and themes were entered in 
columns. Table two includes an excerpt for the final summation for HR8, with 
supportive quotes (from the whole transcript, not just the excerpt in Figure 1). To aid 
comparison, an additional example from HR1 is also included.  
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TABLE 6 - EXCERPT FROM THE INDEXING MATRIX FOR HR7 
 
 
C : behaviour change  H : Consequences  M : Perception of risk  T : Seeking further information  W : Threat to mother or fetus 
5 : HR 7 
 Ithink for me, it’s unusual for me because I 
think normally I’d want to be like all over it 
and working out exactly what was what.  And 
knowing, I think knowing more about it is a 
more normal reaction for me.  And instead 
I’m sort of quite happy going with what they 
say and taking, taking their advice on board 
and just kind of, well they didn’t even really 
give me any advice but just taking the fact 
that they’re happy as read and just going 
with it. 
 
Yes, well I still have, no I think quite, yes 
quite successfully.  I think because it’s in my 
head that my blood pressure was high 
because I was worried about stuff.  I’ve kind 
of taken the view that well it’s better not to 
worry about it then.  And I suppose that is 
because it’s not just me now it’s me and a 
baby.  So it’s kind of, I’m trying to be, trying 
not to worry about things so that it doesn’t 
hurt it in a way. 
 
Although actually I don’t know whether the, 
kind of the frequency of the scans and 
check-up make me a little bit more relaxed 
about like I think I was probably like a little bit 
too strict with myself in terms of “Well I’m not 
going to drink tea and I’m not going to…”  
And then one of the midwives said “Oh would 
you like a cup of tea?”  So I thought “Oh well 
this is fine then I can have a cup of tea, that’s 
okay.” 
Oh it can affect the baby’s sort of growth and size and 
things.”  And I guess was quite factual about it but 
couldn’t really say “It’s nothing to worry about, don’t 
worry.”  Because that wouldn’t, I don’t know I guess she 
couldn’t really say that without having kind of seen me 
or been kind of privy to the scan. 
 
So Googling sort of said, I suppose the thing that most 
concerned me was well there’s no cure for it, you can’t 
cure it so if you get it then you have to deliver the baby.  
And then you think if you deliver the baby before it’s a 
viable baby then obviously you lose the baby and so 
that was worrying to read.  
 
Like swelling and oh maybe I don’t know like, I feel like I 
did know this and now I’ve just not really thought about 
it for a while.  Maybe like dizziness but then I’m not sure 
if that’s now low blood pressure I’m getting confused. 
 
Like I’m kind of thinking in my head “Well I only need to 
get through another month and then the baby’s viable 
anyway.”  So if I get it, it wouldn’t be ideal but at least I 
wouldn’t lose the baby. 
 
Well I think it’s some 
crazy small percentage in 
a way like sort of eight out 
of…  I can’t remember the 
odds now but I remember 
thinking at the time well it 
doesn’t sound particularly 
bad.  
 
But I don’t really think, 
like now I don’t really 
think it’s kind of higher 
than 50% or something.  
It’s kind of much lower 
than that I think. 
 
Which is why I think I kind 
of feel like I am a bit of a 
fraud because perhaps 
the only reason why it 
was high at 8 weeks and 
12 weeks was because I 
was quite stressed out 
anyway about telling 
work.  And yes just about 
telling work really. 
 
 
did a bit of kind of Googling and read the 
bit in my book.  But it was good not 
having very long to wait really in between 
the 12 week scan and then coming back 
on the Friday. 
 
Yes I suppose that was rather scarier 
than…  But then you, I guess you always 
look at Google and you kind of think “Well 
if I Google it, you caveat that with the fact 
that it’s likely to be slightly dramatic.”  So 
Googling sort of said, I suppose the thing 
that most concerned me was well there’s 
no cure for it, you can’t cure it so if you 
get it then you have to deliver the baby. 
 
I think Hugo probably did more Googling 
than I did.  I think I just kind of relied on 
the chapter in my, oh it wasn’t even a 
chapter it was kind of like a little box.  And 
thought “Well we can ask on Friday.” 
 
 But then I do quite, I mean it is a bit odd 
that I don’t really know the answers 
because I do quite like to be informed 
so… 
 
No, no because it has pretty 
serious impact on me as well.  But 
I don’t know I’m kind of thinking 
more of the baby than me.  No 
because it isn’t the point that it 
affects the mother which is why 
there isn’t a cure for it.  So you 
know everybody gets distressed 
and you have to just do something 
about it. 
 
I guess no, well not really because 
the thing is if I’m at risk then the 
baby’s at risk so it’s kind of like well 
if I’m not going to be very well then 
neither will the baby so I kind of 
see the two of us as a one thing at 
the moment anyway.  Yes I don’t 
think, I don’t think I’m prioritising it 
it’s just you do tend to kind of think 
about the effect that it will have on 
the baby more, I think I think about 
that more than me only in the 
sense that I know at the moment if 
I got it tomorrow then it wouldn’t, 
well I don’t think we’d have a baby 
if it was really serious then we 
would lose the baby.  But I don’t 
really feel like that’s likely. 
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TABLE 7 - EXCEPT FROM THE CHARTING PROCESS FOR HR7 AND HR1 
 
A : Cause  B : Consequences  C : Control - Cure  D : Evidence of confusion between 
representation and info  E : Identity  F : Perception of risk 
10 : HR 1 
Feels lifestyle a key 
contributing factor to 
hypertension - discusses 
stress at work and exercise. 
 
PE caused by a combination 
of luck, genetics and 
lifestyle. 
 
Some evidence of fatalism 
Family friend had severe 
PE - ‘touch and go’. 
 
More concerned with risks 
to mother than fetus. 
 
Knowledge of symptoms 
such as headaches, 
flashing lights, swelling. 
 
She is surprised by how 
concerned with the 
screening result she was.  
Feels not much she can do to reduce 
risk, but is making behavioural changes 
anyway. Addressing work pressures 
and increasing exercise, as a direct 
result of screen result 
Strong sense of lack of control - almost 
fatalistic - does not see a reason for 
high risk result, so feels ‘hidden causes’ 
- blood flow, arteries, that she has no 
control over. Feels ‘in the hands of the 
professionals’.  
Also discusses the affect the pregnancy 
has had on her body already - difficulty 
walking up stairs 
Pleased with attending the clinic due to 
additional scans - feels ‘getting checked 
up on’ 
Confused as blood pressure ‘was ok’, 
had always had good blood pressure, 
so why was result high? How did scan 
show risk for PE? 
Personal research did not help 
coherence - feels not in a ‘risk’ category 
-identifies as twins, obese. 
Never been seriously ill before, never 
had a hospital admission.  
 
“it just seems I think its simply that I 
cant work out why I am so therefore my 
gut says if I don't fall into all of the high 
risk categories and the blood pressure 
is supposed to be ok, and the second 
scan blood flow is ok, there is nothing 
indicating at the moment that I should 
be worried” 
Screening test: 
blood pressure 
readings, ‘blood 
flow’, arteries - one 
was fine, the other 
wasn't.   
 
Condition: high 
blood pressure, 
effects mother and 
baby, headaches, 
swelling.  
Found it difficult to understand numbers 
without a frame of reference. Compares with 
DS risk, where was told ‘really really low 
risk’ whereas no comparisons made for PE.  
 
Confused over ‘early’ versus ‘overall’ risk. 
 
Does not feel at risk - ? typo when inputting 
results. But conflicted - ‘I maybe being 
stupid’. Cannot see any reason why she is 
at risk.  
If she does get PE, it will be ‘mild’, not 
‘severe’. 
3 : HR 7 
Felt the pressure of the USS 
increased blood pressure - 
felt 'bombarded' with 
questions, 'pushed BP up'. 
Also was concerned as had 
taken time off work for scan 
but had not told employers 
about pregnancy yet. Feels 
these stessors may have 
contributed to higher BP, 
thus screen result- feels BP 
was 'artificially high' 
Does not feel responsbile - 
has a 'good lifestlye' is a 
'good age' to be pregnant, 
not sure why has this result. 
Suggests genetic link- 
unsure why high risk when 
mother didnt have it. Also 
biological causes - due to the 
way the placenta attaches. 
Discusses consequences 
to the fetus - growth 
restriction. Notes that 
there is no cure without 
delivery, concerned about 
delivering prior to viability, 
rather than concerns for 
self or pre-term birth 
generally. Feels any risk 
to her directly relates to 
risk to baby - if she is 
unwell, so is fetus. 
Conscious that PE may 
cause her to lose baby 
Feels would be dismissive 
of soft-symptoms 
(swelling) as does not 
want to worry. Did not 
recall indicators such as 
headache, epigastric pain 
etc.  
Has affected the choices 
she is allowed to make.  
Expresses a lack of control - no cure, 
nothing she can do or could have done 
to change result. But then discusses 
the stress of work, and potentially 
reducing that stress - although no steps 
taken to do so.  
Mentions potential benifits of asprin, but 
no desire to take. Does not feel she will 
know she has PE, and is 'putting my 
faith in the hypertension team to pick it 
up every month rather than me' - 
control to doctors, not to self. Has 
'stopped worrying about it' as the HTC 
is monitoring. She feels this is unusal 
for herself, as she would generally take 
control, ask more questions, challenge.  
Shouldnt be at risk as her mum did not 
get it. Links stress regaurding telling 
work to result, and now work know, she 
is no longer at risk.  
 
"I think that increased my stress levels 
and probably meant that my blood 
pressure was artificially high, it probably 
wasn’t a true reflection necessarily of 
what was actually going on." 
Screening 
test:'Blood flow', 
blood pressure  
Condition:high blood 
pressure with 
protein urea, some 
symptom knowledge 
Feels confused about risk status - conflict 
between not feeling at risk - no family 
history - and the result she has been given. 
A risk is not a certainty. Identifies her risk as 
'some crazy small percentage' Feels a fraud 
for attending HTC, stongly feels results 
caused by stress of not telling work, and 
now that is resolved there are no risk 
factors. Although still feels between '10 and 
20, 25%' chance of developing it, and a 
conflict - "But a little bit of me thinks “Yes I 
must be high risk because they’ve said I 
am.” " Page 292 of 316                Appendix 14 
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APPENDIX 16 – COPY OF INTRODUCTION TEXT USED IN 
DCE 
 
Introduction – information about pre-eclampsia 
Below is some information regarding pre-eclampsia that you may wish to read prior to 
completing this questionnaire.  
 
What is pre-eclampsia? 
It is an illness you can get only during pregnancy or straight after your baby is born. It can 
affect you and your unborn baby. Pre-eclampsia used to be known as 'toxaemia'. 
When does it happen? 
Most women don't get pre-eclampsia till the last few weeks of pregnancy, but it can start as 
early as 20 weeks or (very rarely) even earlier. It is also possible for it to develop during labour 
or soon after the baby is born. 
What happens to you? 
Pre-eclampsia involves changes in blood vessels all over your body. As a result blood pressure 
rises and protein from the blood leaks into the urine. Some swelling is common in normal 
pregnancy especially in the ankles but in pre-eclampsia water can leak out of the blood vessels 
and cause sudden swelling (oedema) especially in the face and hands. Most women with pre-
eclampsia are mildly affected, however some women become seriously ill with extra problems 
in the liver, brain, lungs or blood clotting system. Pre-eclampsia can get worse very quickly - 
that's why you need to attend all antenatal check-ups. 
What happens to the baby? 
Your baby may be growing too slowly, because not enough blood is getting to the placenta. This 
can lead to problems with your baby’s health.  
What is the cause? 
Pre-eclampsia is caused by problems in the placenta. The placenta is the ‘special’ pregnancy 
organ that brings the baby food and oxygen from your blood. In pre-eclampsia the placenta can't 
get as much blood from you as it needs and this affects you and your baby in different ways. 
What is the treatment? 
Because the placenta causes pre-eclampsia, it doesn't get better until sometime after delivery. 
Many women with pre-eclampsia have their babies early. The doctors and midwives monitor 
you and your baby very carefully and they may decide it is too risky to continue the pregnancy. 
While you remain pregnant, your doctor may give you drugs that control blood pressure without 
harming your baby.  
Can pre-eclampsia be prevented? 
There is no reliable way to do this, although research is on going on ways to reduce risks and/or 
treat the condition once it has developed.  
Can pre-eclampsia be predicted? Page 296 of 316    Appendix 16            Appendix 14 
The schedule of appointments that pregnant women have is calculated to best detect pre-
eclampsia as it develops. This is assessed regularly, and adjusted when new evidence comes to 
light. However, it has been felt for a long time that it would be useful to predict the pregnancies 
that are most likely to be affected by pre-eclampsia, before it actually develops. 
There are two main ways of doing this - certain groups of women are more likely to develop 
pre-eclampsia (for example, if a relative developed pre-eclampsia during one of their 
pregnancies). Questions can be asked during initial appointments with a midwife or doctor so a 
closer eye can be given to those women. This is not a formal predictive test, and any follow-up 
checks would be agreed with women and her care provider. 
Alternatively, new screening tests have been developed that can identify women that have a 
higher chance of developing pre-eclampsia. These tests look at a combination of hormones in 
the woman's blood, measurements taken from ultrasound scans, alongside other factors (for 
example, the woman's weight and age), to calculate a formal risk score, which can be expressed 
numerically (for example, a 1 in 100 change of developing pre-eclampsia). Those women who 
are identified as most likely to develop pre-eclampsia would have more appointments in their 
pregnancy to monitor the health of the mother and baby.   
How accurate are these new screening tests? 
It is important to remember that no screening test is 100% accurate. Therefore, along with 
correctly identifying those women that go on to develop pre-eclampsia, the screening test would 
incorrectly identify women who would not develop it. Similarly, some women who were told 
they would not go on to develop pre-eclampsia would develop the condition. The accuracy of 
the pre-eclampsia screening tests are similar to other prenatal screening tests that you are 
offered during your pregnancy.   
Is there an advantage to having a formal screening test? 
We do not have an answer to that question yet. There is not yet evidence to say that knowing 
you are at risk of pre-eclampsia before it develops causes any benefits, or any disadvantages, 
although many people have put forward points on both sides. As there is currently no reliable 
way of reducing the risk once we have discovered it, a screening test would provide 
information, and possibly increase the amount of monitoring, but would not result in a 
treatment. 
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APPENDIX 17A – DCE QUESTIONNAIRE – SPECIFICITY CONDITION 
 
   
 
 
UCL Hospitals is an NHS Foundation Trust incorporating the Eastman Dental Hospital, Elizabeth 
Garrett Anderson & Obstetric Hospital, The Heart Hospital, Hospital for Tropical Diseases, The 
Middlesex Hospital, National Hospital for Neurology & Neurosurgery, The Royal London 
Homoeopathic Hospital and University College Hospital. 
 
Integrated Antenatal Services 
 Elizabeth Garrett Anderson Wing 
University College Hospital 
235 Euston Road 
NW1 2BU 
 
Telephone: 020 7380 9400 
Direct Line: 0207 380 9566 
Fax:  0207 380 9941 
Web-site: www.uclh.nhs.uk 
 
Form version: 2.00 (31
st May 2013) 
Project ID number:   
Patient Identification Number for this study: _____________     
    Please 
initial 
 
1.  I confirm that I have read and understood the information leaflet dated May 2013 (v 2.0) for the 
above study and have had the opportunity to ask questions. 
 
 
 
2.  I confirm that I have had sufficient time to consider whether or not want to be included in the 
study 
 
 
3.  I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
 
4.  I understand that although I do not have to answer all of the questions included within the 
survey, failure to do so may result in my responses not being included within the analysis 
 
 
 
 
   
 
 
 
 
 
_____________________ 
 
__________________ 
 
__________________________________  
Name  Date  Signature     
 
 
_____________________ 
 
 
__________________ 
 
 
__________________________________  
Researcher’s Name 
(to be contacted if there are any 
problems) 
Date  Signature     
 
 
One form for patient, one for study documentation  
CONSENT FORM – Discrete Choice Survey 
 
Title of project: Assessing the acceptability of first trimester pre-eclampsia screening tests 
Name of Principal Investigators :   James Harris – Research Midwife 
Belinda Green – Consultant Midwife  
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(Copy of text from Appendix 16 inserted here) 
 
Section A – Choice Scenarios  
 
Below are 8 separate choice scenarios. Each choice involves two different screening tests that 
could tell you (or your client, for health professionals) if you are at an increased risk of 
developing pre-eclampsia during this pregnancy. We would like you to choose between test A or 
test B. The tests differ in their accuracy, the level of information they provide, how the test is 
calculated, and the follow up that occurs after a high risk result is given.  
 
Currently there are no agreed ways in which to decrease a risk for pre-eclampsia once it has 
been identified. Researchers continue to assess various medications, dietary and lifestyle 
changes that may reduce a risk once it is identified. However, as this work is ongoing, please 
assume that by having the test the only benefit would be in knowing the risk of pre-eclampsia, 
rather than reducing that risk. 
 
While an increase in monitoring that occurred as a result of a high-risk result may detect pre-
eclampsia earlier, and may therefore reduce the harm that pre-eclampsia causes, this has yet to 
be assessed.  
 
Q1 – Please consider each choice separately and tick the box to show which option you would prefer – 
Test A or Test B. 
 
  Test A  Test B 
Accuracy  Test identifies 50% of pregnancies affected by 
pre-eclampsia 
Test identifies 75% of pregnancies affected by 
pre-eclampsia, 95% of the most dangerous 
Level of information  Placed in ‘high risk’ or ‘low risk’ group  Risk given in numerical form (1 in 30, or 30% 
chance of developing pre-eclampsia) 
Testing procedure  Medical history assessment 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so no 
additional needles or ultrasounds needed), 
weight, blood pressure measurements, medical 
history assessment 
Follow up  Additional appointments as planned by women 
and health professional 
Pre-arranged schedule of additional monitoring 
for blood pressure checks, blood tests and 
ultrasound scans 
 
Test A    Test B   
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Q2 – Please consider each choice separately and tick the box to show which option you would prefer – 
Test A or Test B. 
 
  Test A  Test B 
Accuracy  Test identifies 50% of pregnancies affected by 
pre-eclampsia 
Test identifies 75% of pregnancies affected by 
pre-eclampsia, 95% of the most dangerous 
Level of information  Placed in ‘high risk’ or ‘low risk’ group  Risk given in numerical form (1 in 30, or 30% 
chance of developing pre-eclampsia) 
Testing procedure 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so no 
additional needles or ultrasounds needed), 
weight, blood pressure measurements, medical 
history assessment 
Medical history assessment 
Follow up 
Pre-arranged schedule of additional monitoring 
for blood pressure checks, blood tests and 
ultrasound scans 
Additional appointments as planned by women 
and health professional 
 
Test A    Test B   
 
Q3 – Please consider each choice separately and tick the box to show which option you would prefer – 
Test A or Test B. 
 
 
 
Test A  Test B 
Accuracy  Test identifies 50% of pregnancies affected by 
pre-eclampsia 
Test identifies 75% of pregnancies affected by 
pre-eclampsia, 95% of the most dangerous 
Level of information  Risk given in numerical form (1 in 30, or 30% 
chance of developing pre-eclampsia)  Placed in ‘high risk’ or ‘low risk’ group 
Testing procedure  Medical history assessment 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so no 
additional needles or ultrasounds needed), 
weight, blood pressure measurements, medical 
history assessment 
Follow up 
Pre-arranged schedule of additional monitoring 
for blood pressure checks, blood tests and 
ultrasound scans 
Additional appointments as planned by women 
and health professional 
 
Test A    Test B   
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Q4 – Please consider each choice separately and tick the box to show which option you would prefer – 
Test A or Test B. 
 
  Test A  Test B 
Accuracy  Test identifies 50% of pregnancies affected by 
pre-eclampsia 
Test identifies 75% of pregnancies affected by 
pre-eclampsia, 95% of the most dangerous 
Level of information  Risk given in numerical form (1 in 30, or 30% 
chance of developing pre-eclampsia)  Placed in ‘high risk’ or ‘low risk’ group 
Testing procedure  Medical history assessment 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so no 
additional needles or ultrasounds needed), 
weight, blood pressure measurements, medical 
history assessment  
Follow up  Additional appointments as planned by women 
and health professional 
Pre-arranged schedule of additional monitoring 
for blood pressure checks, blood tests and 
ultrasound scans 
 
Test A    Test B   
 
Q5 – Please consider each choice separately and tick the box to show which option you would prefer – 
Test A or Test B. 
 
  Test A  Test B 
Accuracy  Test identifies 75% of pregnancies affected by 
pre-eclampsia, 95% of the most dangerous 
Test identifies 50% of pregnancies affected by 
pre-eclampsia 
Level of information  Placed in ‘high risk’ or ‘low risk’ group  Risk given in numerical form (1 in 30, or 30% 
chance of developing pre-eclampsia) 
Testing procedure  Medical history assessment 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so no 
additional needles or ultrasounds needed), 
weight, blood pressure measurements, medical 
history assessment 
Follow up 
Pre-arranged schedule of additional monitoring 
for blood pressure checks, blood tests and 
ultrasound scans 
Additional appointments as planned by women 
and health professional 
 
Test A    Test B   
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Q6 – Please consider each choice separately and tick the box to show which option you would prefer – 
Test A or Test B. 
 
  Test A  Test B 
Accuracy  Test identifies 75% of pregnancies affected by 
pre-eclampsia, 95% of the most dangerous 
Test identifies 50% of pregnancies affected by 
pre-eclampsia 
Level of information  Placed in ‘high risk’ or ‘low risk’ group  Risk given in numerical form (1 in 30, or 30% 
chance of developing pre-eclampsia) 
Testing procedure 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so no 
additional needles or ultrasounds needed), 
weight, blood pressure measurements, medical 
history assessment 
Medical history assessment 
Follow up  Additional appointments as planned by women 
and health professional 
Pre-arranged schedule of additional monitoring 
for blood pressure checks, blood tests and 
ultrasound scans 
 
Test A    Test B   
 
Q7 – Please consider each choice separately and tick the box to show which option you would prefer – 
Test A or Test B. 
 
  Test A  Test B 
Accuracy  Test identifies 75% of pregnancies affected by 
pre-eclampsia, 95% of the most dangerous 
Test identifies 50% of pregnancies affected by 
pre-eclampsia 
Level of information  Risk given in numerical form (1 in 30, or 30% 
chance of developing pre-eclampsia)  Placed in ‘high risk’ or ‘low risk’ group 
Testing procedure  Medical history assessment 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so no 
additional needles or ultrasounds needed), 
weight, blood pressure measurements, medical 
history assessment 
Follow up  Additional appointments as planned by women 
and health professional 
Pre-arranged schedule of additional monitoring 
for blood pressure checks, blood tests and 
ultrasound scans 
 
Test A    Test B   
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Q8 – Please consider each choice separately and tick the box to show which option you would prefer – 
Test A or Test B. 
 
  Test A  Test B 
Accuracy  Test identifies 75% of pregnancies affected by 
pre-eclampsia, 95% of the most dangerous 
Test identifies 50% of pregnancies affected by 
pre-eclampsia 
Level of information  Risk given in numerical form (1 in 30, or 30% 
chance of developing pre-eclampsia)  Placed in ‘high risk’ or ‘low risk’ group 
Testing procedure 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so no 
additional needles or ultrasounds needed), 
weight, blood pressure measurements, medical 
history assessment 
Medical history assessment 
Follow up 
Pre-arranged schedule of additional monitoring 
for blood pressure checks, blood tests and 
ultrasound scans 
Additional appointments as planned by women 
and health professional 
 
Test A    Test B   
 
 
 
 
 
Q 9 – How sure are you about the choices you have made regarding which screening tests 
you would choose? Please circle one number between 1 and 10, where 1 indicates ‘very 
unsure’ and 10 indicates ‘very sure’. 
 
1  2  3  4  5  6  7  8  9  10 
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Q 10 - Please read and respond to the following statement: 
 
“Although there is nothing they can do to reduce my risks for pre-
eclampsiaia, I would rather have a test for it.” 
 
Strongly Disagree  Disagree  Agree  Strongly Agree 
 
If you ticked strongly agree or agree, please indicate which statement best matches why you 
would have a pre-eclampsia screening test 
 
It is better to know than to be surprised 
 
 
Because I feel there would be things I can do to lower my risk 
 
 
I will do the tests my doctors or midwives suggest 
 
 
Other (please specify)  
_______________________________________________________________________ 
 
 
Q 11 - Please read and respond to the following statement: 
 
“If there is nothing they can do to reduce my risk for pre-clampsia, I 
would rather not have a screening test for it.” 
 
Strongly Disagree  Disagree  Agree  Strongly Agree 
 
If you ticked strongly agree or agree, please indicate which statement best matches why you 
would have a pre-eclampsia screening test 
 
Knowing would make me anxious 
 
 
Unless there is an actual problem, I do not want extra appointments 
 
 
I do not like screening tests 
 
 
Other (please specify)  
_______________________________________________________________________ 
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Q 12 - A number of statements which people use to describe themselves are given below. Read 
each statement and then circle the most appropriate number to the right of the statement to 
indicate how you feel right now, at this moment. There are no right or wrong answers. Do not 
spend too much time on any one statement, but give the answer which seems to describe your 
present feelings best. 
 
  Not at All  Somewhat  Moderately  Very Much 
I feel calm  1  2  3  4 
I am tense  1  2  3  4 
I feel upset  1  2  3  4 
I am relaxed  1  2  3  4 
I feel content  1  2  3  4 
I am worried  1  2  3  4 
 
Q 13 – The following questions ask you to rate your current intentions for this pregnancy 
related to labour and the immediate period after having your baby. There are no right or wrong 
answers. We are only seeking your opinion. On each of the following scales, please put a 
vertical mark through the line to indicate your assessment of risk for each item.  
 
(1) The risk for myself during this pregnancy 
 
 
(2) The risk for my unborn baby during this pregnancy 
 
 
(3) My risk of haemorrhaging (losing too much blood) during this pregnancy 
 
 
(4) My risk of having a caesarean section 
 
 
(5) My risk of dying during this pregnancy Page 305 of 316    Appendix 16            Appendix 14 
 
 
(6) My baby’s risk of being born prematurely 
 
 
(7) My baby’s risk of having a birth defect 
 
 
(8) My baby’s risk of needing to go to the neonatal intensive care unit 
 
 
(9) My baby’s risk of dying during this pregnancy 
 
 
 
Some questions about you. 
 
Q14 – What is your gender? 
Female    Male   
 
Q 15 – Are you currently pregnant? 
Yes    No   
 
Q15 – What year were you born? 
_________________________   
Q16 - Please indicate your marital status 
Married/Civil partner    Living with partner   
Partner, not living together    Separated / divorced   
Widowed    Single   
 
Q17 - What is the highest level of education you have completed? Page 306 of 316    Appendix 16            Appendix 14 
No qualifications    GCSE or equivalent   
A level or equivalent    First degree (BSc, BA etc)   
Masters degree    PhD   
 
Q18 - What is your race? 
Asian – Bangladeshi 
 
  Black – African    White – British   
Asian – Indian 
 
  Black – Caribbean    White – Irish   
Asian – Pakistani 
 
  Black – other 
__________________ 
  White – other 
____________________ 
 
Asian – Other 
_________________ 
         
    Mixed 
__________________ 
  Other 
___________________ 
 
 
Q19 - Do you have children? 
Yes    No   
 
 
If yes, did you or your partner develop pre-eclampsia in a previous pregnancy? 
Yes    Maybe    No   
 
 
Q20 - Are you a healthcare professional involved in providing care for pregnant 
women? 
Yes    No   
 
If yes, please advice your profession 
Midwife    Obstetrician   
Nurse    General practitioner   
Other profession (please specify)    Doctor – other (please specify)   
 
Q21 - To help us compare your responses to those from different areas, it is useful for us 
to know your postcode 
Postcode    Rather not say   
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APPENDIX 17B - DCE QUESTIONNAIRE – POPULATION PREVALENCE 
CONDITION  
 
   
 
 
UCL Hospitals is an NHS Foundation Trust incorporating the Eastman Dental Hospital, Elizabeth 
Garrett Anderson & Obstetric Hospital, The Heart Hospital, Hospital for Tropical Diseases, The 
Middlesex Hospital, National Hospital for Neurology & Neurosurgery, The Royal London 
Homoeopathic Hospital and University College Hospital. 
 
Integrated Antenatal Services 
 Elizabeth Garrett Anderson Wing 
University College Hospital 
235 Euston Road 
NW1 2BU 
 
Telephone: 020 7380 9400 
Direct Line: 0207 380 9566 
Fax:  0207 380 9941 
Web-site: www.uclh.nhs.uk 
 
Form version: 2.00 (31
st May 2013) 
Project ID number:   
Patient Identification Number for this study: _____________     
    Please 
initial 
 
1.  I confirm that I have read and understood the information leaflet dated May 2013 (v 2.0) for the 
above study and have had the opportunity to ask questions. 
 
 
 
2.  I confirm that I have had sufficient time to consider whether or not want to be included in the 
study 
 
 
3.  I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
 
4.  I understand that although I do not have to answer all of the questions included within the 
survey, failure to do so may result in my responses not being included within the analysis 
 
 
 
 
   
 
 
 
 
 
_____________________ 
 
__________________ 
 
__________________________________  
Name  Date  Signature     
 
 
_____________________ 
 
 
__________________ 
 
 
__________________________________  
Researcher’s Name 
(to be contacted if there are any 
problems) 
Date  Signature     
 
 
One form for patient, one for study documentation  
CONSENT FORM – Discrete Choice Survey 
 
Title of project: Assessing the acceptability of first trimester pre-eclampsia screening tests 
Name of Principal Investigators :   James Harris – Research Midwife 
Belinda Green – Consultant Midwife  
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(Copy of text from Appendix 16 inserted here) 
Section A – Choice Scenarios  
 
Below are 8 separate choice scenarios. Each choice involves two different screening tests that 
could tell you (or your client, for health professionals) if you are at an increased risk of 
developing pre-eclampsia during this pregnancy. We would like you to choose between test A or 
test B. The tests differ in their accuracy, the level of information they provide, how the test is 
calculated, and the follow up that occurs after a high risk result is given.  
 
Currently there are no agreed ways in which to decrease a risk for pre-eclampsia once it has 
been identified. Researchers continue to assess various medications, dietary and lifestyle 
changes that may reduce a risk once it is identified. However, as this work is ongoing, please 
assume that by having the test the only benefit would be in knowing the risk of pre-eclampsia, 
rather than reducing that risk. 
 
While an increase in monitoring that occurred as a result of a high-risk result may detect pre-
eclampsia earlier, and may therefore reduce the harm that pre-eclampsia causes, this has yet to 
be assessed.  
 
Q1 – Please consider each choice separately and tick the box to show which option you would prefer – 
Test A or Test B. 
 
  Test A 
 
Test B 
Accuracy  5% of those identified as high risk go on to 
develop pre-eclampsia 
25% of those identified as high risk go on to 
develop pre-eclampsia 
Level of information  Placed in ‘high risk’ or ‘low risk’ group  Risk given in numerical form (1 in 30, or 30% 
chance of developing pre-eclampsia) 
Testing procedure  Medical history assessment 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so no 
additional needles or ultrasounds needed), 
weight, blood pressure measurements, medical 
history assessment 
Follow up  Additional appointments as planned by women 
and health professional 
Pre-arranged schedule of additional monitoring 
for blood pressure checks, blood tests and 
ultrasound scans 
     
Test A    Test B   
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Q2 – Please consider each choice separately and tick the box to show which option you would prefer – 
Test A or Test B. 
 
  Test A 
 
Test B 
Accuracy  5% of those identified as high risk go on to 
develop pre-eclampsia 
25% of those identified as high risk go on to 
develop pre-eclampsia 
Level of information  Placed in ‘high risk’ or ‘low risk’ group  Risk given in numerical form (1 in 30, or 30% 
chance of developing pre-eclampsia) 
Testing procedure 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so no 
additional needles or ultrasounds needed), 
weight, blood pressure measurements, medical 
history assessment 
Medical history assessment 
Follow up 
Pre-arranged schedule of additional monitoring 
for blood pressure checks, blood tests and 
ultrasound scans 
Additional appointments as planned by women 
and health professional 
 
Test A    Test B   
 
Q3 – Please consider each choice separately and tick the box to show which option you would prefer – 
Test A or Test B. 
 
  Test A 
 
Test B 
Accuracy  5% of those identified as high risk go on to 
develop pre-eclampsia 
25% of those identified as high risk go on to 
develop pre-eclampsia 
Level of information  Risk given in numerical form (1 in 30, or 30% 
chance of developing pre-eclampsia)  Placed in ‘high risk’ or ‘low risk’ group 
Testing procedure  Medical history assessment 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so no 
additional needles or ultrasounds needed), 
weight, blood pressure measurements, medical 
history assessment 
Follow up 
Pre-arranged schedule of additional monitoring 
for blood pressure checks, blood tests and 
ultrasound scans 
Additional appointments as planned by women 
and health professional 
 
Test A    Test B   
 
Q4 – Please consider each choice separately and tick the box to show which option you would prefer – 
Test A or Test B. 
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  Test A  Test B 
Accuracy  5% of those identified as high risk go on to 
develop pre-eclampsia 
25% of those identified as high risk go on to 
develop pre-eclampsia 
Level of information  Risk given in numerical form (1 in 30, or 30% 
chance of developing pre-eclampsia)  Placed in ‘high risk’ or ‘low risk’ group 
Testing procedure  Medical history assessment 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so no 
additional needles or ultrasounds needed), 
weight, blood pressure measurements, medical 
history assessment  
Follow up  Additional appointments as planned by women 
and health professional 
Pre-arranged schedule of additional monitoring 
for blood pressure checks, blood tests and 
ultrasound scans 
 
Test A    Test B   
 
Q5 – Please consider each choice separately and tick the box to show which option you would prefer – 
Test A or Test B. 
 
  Test A 
 
Test B 
Accuracy  25% of those identified as high risk go on to 
develop pre-eclampsia 
5% of those identified as high risk go on to 
develop pre-eclampsia 
Level of information  Placed in ‘high risk’ or ‘low risk’ group  Risk given in numerical form (1 in 30, or 30% 
chance of developing pre-eclampsia) 
Testing procedure  Medical history assessment 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so no 
additional needles or ultrasounds needed), 
weight, blood pressure measurements, medical 
history assessment 
Follow up 
Pre-arranged schedule of additional monitoring 
for blood pressure checks, blood tests and 
ultrasound scans 
Additional appointments as planned by women 
and health professional 
 
Test A    Test B   
 
Q6 – Please consider each choice separately and tick the box to show which option you would prefer – 
Test A or Test B. 
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  Test A 
 
Test B 
Accuracy  25% of those identified as high risk go on to 
develop pre-eclampsia  
5% of those identified as high risk go on to 
develop pre-eclampsia 
Level of information  Placed in ‘high risk’ or ‘low risk’ group  Risk given in numerical form (1 in 30, or 30% 
chance of developing pre-eclampsia) 
Testing procedure 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so no 
additional needles or ultrasounds needed), 
weight, blood pressure measurements, medical 
history assessment 
Medical history assessment 
Follow up  Additional appointments as planned by women 
and health professional 
Pre-arranged schedule of additional monitoring 
for blood pressure checks, blood tests and 
ultrasound scans 
     
Test A    Test B   
 
Q7 – Please consider each choice separately and tick the box to show which option you would prefer – 
Test A or Test B. 
 
  Test A  Test B 
Accuracy  25% of those identified as high risk go on to 
develop pre-eclampsia 
5% of those identified as high risk go on to 
develop pre-eclampsia 
Level of information  Risk given in numerical form (1 in 30, or 30% 
chance of developing pre-eclampsia)  Placed in ‘high risk’ or ‘low risk’ group 
Testing procedure  Medical history assessment 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so no 
additional needles or ultrasounds needed), 
weight, blood pressure measurements, medical 
history assessment 
Follow up  Additional appointments as planned by women 
and health professional 
Pre-arranged schedule of additional monitoring 
for blood pressure checks, blood tests and 
ultrasound scans 
 
Test A    Test B   
 
 
Q8 – Please consider each choice separately and tick the box to show which option you would prefer – 
Test A or Test B. 
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  Test A 
 
Test B 
Accuracy  25% of those identified as high risk go on to 
develop pre-eclampsia 
5% of those identified as high risk go on to 
develop pre-eclampsia 
Level of information  Risk given in numerical form (1 in 30, or 30% 
chance of developing pre-eclampsia)  Placed in ‘high risk’ or ‘low risk’ group 
Testing procedure 
Blood tests and ultrasound measurements 
(taken at the same time as routine tests, so no 
additional needles or ultrasounds needed), 
weight, blood pressure measurements, medical 
history assessment 
Medical history assessment 
Follow up 
Pre-arranged schedule of additional monitoring 
for blood pressure checks, blood tests and 
ultrasound scans 
Additional appointments as planned by women 
and health professional 
 
Test A    Test B   
 
 
 
Q 9 – How sure are you about the choices you have made regarding which screening tests 
you would choose? Please circle one number between 1 and 10, where 1 indicates ‘very 
unsure’ and 10 indicates ‘very sure’. 
 
1  2  3  4  5  6  7  8  9  10 
 
 
 
Q 10 - Please read and respond to the following statement: 
 
“Although there is nothing they can do to reduce my risks for pre-
eclampsiaia, I would rather have a test for it.” 
 
Strongly Disagree  Disagree  Agree  Strongly Agree 
 
If you ticked strongly agree or agree, please indicate which statement best matches why you 
would have a pre-eclampsia screening test 
 
It is better to know than to be surprised 
 
 
Because I feel there would be things I can do to lower my risk 
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I will do the tests my doctors or midwives suggest 
 
 
Other (please specify)  
___________________________________________________________________ 
 
 
 
 
 
 
 
Q 11 - Please read and respond to the following statement: 
 
“If there is nothing they can do to reduce my risk for pre-clampsia, I 
would rather not have a screening test for it.” 
 
Strongly Disagree  Disagree  Agree  Strongly Agree 
 
If you ticked strongly agree or agree, please indicate which statement best matches why you 
would have a pre-eclampsia screening test 
 
Knowing would make me anxious 
 
 
Unless there is an actual problem, I do not want extra appointments 
 
 
I do not like screening tests 
 
 
Other (please specify)  
___________________________________________________________________ 
 
 
 
 
 
Q 12 - A number of statements which people use to describe themselves are given below. Read 
each statement and then circle the most appropriate number to the right of the statement to 
indicate how you feel right now, at this moment. There are no right or wrong answers. Do not 
spend too much time on any one statement, but give the answer which seems to describe your 
present feelings best. 
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  Not at All  Somewhat  Moderately  Very Much 
I feel calm  1  2  3  4 
I am tense  1  2  3  4 
I feel upset  1  2  3  4 
I am relaxed  1  2  3  4 
I feel content  1  2  3  4 
I am worried  1  2  3  4 
 
 
Q 13 – The following questions ask you to rate your current intentions for this pregnancy 
related to labour and the immediate period after having your baby. There are no right or wrong 
answers. We are only seeking your opinion. On each of the following scales, please put a 
vertical mark through the line to indicate your assessment of risk for each item.  
 
(1) The risk for myself during this pregnancy 
 
 
(2) The risk for my unborn baby during this pregnancy 
 
 
(3) My risk of haemorrhaging (losing too much blood) during this pregnancy 
 
 
(4) My risk of having a caesarean section 
 
 
(5) My risk of dying during this pregnancy 
 
 
(6) My baby’s risk of being born prematurely 
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(7) My baby’s risk of having a birth defect 
 
 
(8) My baby’s risk of needing to go to the neonatal intensive care unit 
 
 
(9) My baby’s risk of dying during this pregnancy 
 
 
 
Some questions about you. 
 
Q14 – What is your gender? 
Female    Male   
 
Q 15 – Are you currently pregnant? 
Yes    No   
 
Q15 – What year were you born? 
_________________________   
Q16 - Please indicate your marital status 
Married/Civil partner    Living with partner   
Partner, not living together    Separated / divorced   
Widowed    Single   
 
Q17 - What is the highest level of education you have completed? 
No qualifications    GCSE or equivalent   
A level or equivalent    First degree (BSc, BA etc)   
Masters degree    PhD   
 
Q18 - What is your race? 
Asian – Bangladeshi 
 
  Black – African    White – British   Page 316 of 316    Appendix 16            Appendix 14 
Asian – Indian 
 
  Black – Caribbean    White – Irish   
Asian – Pakistani 
 
  Black – other 
________________ 
  White – other 
________________ 
 
Asian – Other 
__________________ 
         
    Mixed 
________________ 
  Other 
_________________ 
 
 
 
Q19 - Do you have children? 
Yes    No   
 
 
If yes, did you or your partner develop pre-eclampsia in a previous pregnancy? 
Yes    Maybe    No   
 
 
Q20 - Are you a healthcare professional involved in providing care for pregnant 
women? 
Yes    No   
 
If yes, please advice your profession 
Midwife    Obstetrician   
Nurse    General practitioner   
Other profession (please specify)    Doctor – other (please specify)   
 
Q21 - To help us compare your responses to those from different areas, it is useful for us 
to know your postcode 
Postcode    Rather not say   
 
 
 
 
 
 
 